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SUMMRY
The thesis consists of three parts:
I. Review of the relevant Literature on -
(a) Transmethylation and Schizophrenia
(b) Biological Methylation
II. Human Studies: The effect of L-methionine feeding (without
MOl) on chronic schizophrenics.
Clinical
1. In a double blind cross over study of L-methionine against
glycine (placebo) without MO-ihhibitors L-methionine produced a
schizophreniform psychosis in nine out of sixteen schizophrenics.
The psychosis was different clinically from a toxic psychosis which
preceded it in two cases. Thus, chronic schizophrenics could be
divided into two groups, "reactors" and "non-reactors" to L-
methionine. However, no predictions could be made on clinical
'grounds as to whether a particular schizophrenic would react or not.
2o Following recovery from the immediate effects of L-methionine
there was no significant change in the mental state and behaviour
of any of the patients. L-methionine was neither harmful nor
therapeutically beneficial.
Biochemical
1. A method for the determination of HMP& (4-hydroxy, 3-methoxy
phenyl glycol), the major O-methylated catabolite of noradrenaline
centrally, in urine was developed. HMPG- and VMA (4-hydroxy,
3-methoxy mandelic acid), the major O-methylated cataholite of M
in the body, were estimated every other day in 24 hour urines of
six male chronic schizophrenics over the twelve week period of the
L-methionine study. The results showed that L-methionine did not
produce a statistically significant increase in the urinary levels
of either HMPG or VMA.
2. The 24 hour urinary levels of HMPG- in the six chronic schizo¬
phrenics were compared with those from five normal volunteers and
five acute schizophrenics. The levels in the acute schizophrenics
were statistically higher than those in the chronic schizophrenics
and normals; however, no statistically significant difference was
found between the latter two groups.
Ill. Animal Studies
1. L-Methionine - a methyl donor for O-methylation of catecholamine
catabolites, in vivo:
C ^"-methyl L-methionine was injected intravenously into two groups
of rats. One group was killed two hours after the injection and
their brains assayed, while in the other group 24 hour urine was
collected for assay. Some of the radioactivity detected both
in brain and urine was identified, using different chromatographic
procedures, as O-methylated catabolites of NA (noradrenaline) and
dopamine. This may suggest that, in vivo, O-methylated catabolites
derive their methyl groups from L-methionine.
2« The effect of L-methionine loading on noradrenaline catabolism
in rat brain:
One group of rats was fed for four days and then injected intra-
peritoneally with L-methionine while another control group was
treated similarly using glycine instead. Both groups were injected
14
intraventricularly with C -MA three hours after the intraperitoneal
injection and killed one hour after the intraventricular injection.
Brain assay for NA cataholites showed that L-methionine loading did
not increase the levels of the O-methylated NA cataholites as com¬
pared to the non-O-methylated ones. The results showed similar
percentages of the cataholites in hoth groups, except for DHMA
(dihydroxy mandelic acid). The percentage of that cataholite was
lower in the L-methionine group. However, it is doubtful whether
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Abbreviations and terms used frequently in the text
L - Levo isomer
D - Dextro isomer
DL - Both isomers
C^1" - Carbon radioisotope
3
H - Tritium radioisotope
C^-methyl - L-methionine - the active methyl group is C*^ labelled.
MAO - Mono amine oxidase
MAOI - Mono amine oxidase inhibitor
COMT « Catechol 0-methyl transferase
NA - Noradrenaline - norepinephrine
Epinephrine - Adrenaline
0-methyl - Methoxy group (CH^O-)
N-methyl - Methyl group on nitrogen (CH^N-)
NM - Normetanephrine
M - Metanephrine
MTYR - 3-niethoxy tyramine - 3-methoxy dopamine
HVA - Homovanillic acid, 3-methoxy, 4-hydroxy phenylacetic acid
VMA - Vanylmandelic acid, 3-methoxy, 4-hydroxy mandelic acid
DHMA - Dihydroxy mandelic acid
DOPAC - Dihydroxy phenylacetic acid
HMPT - 4-hydroxy, 3-methoxy phenyl ethanol
HMPG- - 4-hydroxy, 3-methoxy phenyl glycol
DHPC - Dihydroxy phenyl glycol
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INTRODUCTION
For the past fifty years research workers have sought for some
hioohemical or biological dysfunction (or "lesion") in schizophrenia,
without, until recently, any very encouraging results. Although it
is generally agreed that the aetiology of the neuroses may lie in
psychological and environmental factors, it has been widely held
that schizophrenia and manic-depressive psychoses are associated
with some error of metabolism; however, this is not to deny the
subordinate importance of psychological factors which may well modify
the development of the underlying biochemical abnormality.
In the past, biochemical research work on schizophrenia had been
carried out on purely empirical lines. Generally there was a dearth
of specific hypotheses and people merely applied the biochemical
procedures that were available to them at the time.
Such research included studies of adrenocortical and liver
functions, blood glucose and, latterly, serum aldolase and kinase,
etc., without showing any conclusive and reproducible findings.
During the last decade there has been a change in research strategies
in the way of construction of several specific biochemical hypo¬
theses; these include the mescaline hypothesis, the autoimmune
theory, the abnormal phenylalanine metabolism hypothesis, the
abnormal tryptophane metabolism hypothesis, the psychotomimetic
indole hypothesis and the kynurenin hypothesis. However, most of
the above hypotheses have failed to gain widespread support, due
either to the incompetence or limitations of biochemical methodology,
and/or to failure of replication by other workers.
- 2 -
An hypothesis that attracted some interest among research wor¬
kers was the "Mescaline Theory"; this suggested that schizophrenia
was a disorder involving the process of methylation in the body.
In 1952 when Osmond, Harley-Mason and Smythies put forward this
hypothesis, they focused attention only on disorders of methylation
involving the catecholamines. This approach was limited because
mescaline (an hallucinogen) has a related chemical structure to
noradrenaline. In the course of time research work became more
sophisticated and knowledge accrued especially in the area of amine
metabolism in brain and periphery. Thus both 0 and N methylation
of catechol and indole amines were confirmed as an important step in
their catabolism, etc. These findings gave additional tentative
support to the mescaline theory which by then was better known as
the "Transmethylation Theory" of schizophrenia. The assumed
importance of transmethylation was tested in a number of ways.
The present investigation is an extension of this work and in
some respects is complementary; it consists of:-
1. A review of the relevant literature, both historical and more
recent, which relates to the transmethylation theory and the role
of L-methionine in catecholamine metabolism.
2. A detailed clinical study of the effects of L-methionine without
MAD inhibitors on schizophrenic patients with two main objectives:
(a) To assess and characterize the so-called "Methionine
Reaction" with special reference to its specificity.
(b) To evaluate the alleged therapeutic benefits of
L-methionine in schizophrenia.
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3. A 'biochemical study of the effects of L-methionine on catechol¬
amine metabolism in schizophrenics, specifically a longitudinal
study of the levels of normally occurring O-methylated catecholamine
catabolites in the urine, with special emphasis on any changes in
these during L-methionine administration.
4. Animal experiments designed to show in vivo:
(i) that there is a transfer of methyl groups from L-methionine
to the various O-methylated catecholamine catabolites.
(ii) whether L-methionine loading increases the brain levels
of catechol-O-methylated catabolites.
SECTION I
REVIEW OF THE LITERATURE
Transmethylation and Schizophrenia
Historical Background; Since the 19th century it has "been held
that model psychoses (schizophreniform psychoses produced hy toxic
substances) might give clues to the mechanism of the naturally
occurring psychoses. Moreau de Tour (1845) published a monograph
on the subject: "Du Hachich et de L'Alienation Kentale. Etudes
psychologiques". Prentiss and Morgan, as long ago as 1895,
pointed out that mescaline could induce a "toxic psychosis"•
Beringer (1927) reviewed the literature and published a mono¬
graph, "Der Meskalinrausch", in which he compared mescaline
intoxication with schizophrenia, stating that a study of the
effect of mescaline in non-schizophrenics might help in under¬
standing disturbances in intermediary metabolism as a cause of
schizophrenia. However, his report was limited to clinical
interests and did not mention the similarity in chemical structure
of mescaline (which was identified by Spaeth in 1918) and nor¬
adrenaline.
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De Jong (1930 and 1943) in Holland was interested in the symp¬
toms of catatonia. He completed a series of animal experiments
and showed that several compounds, especially bulbocapnine, were
capable of producing "experimental catatonia". He did not con¬
sider the states identical, but pointed out that the resemblance
of experimental catatonia to schizophrenic catatonia might be
important in understanding the aetiology of the latter. In 1931
he showed that experimental catatonia in different animal species
could be produced by mescaline. He realised the similarity of
chemical structure between mescaline and adrenaline and went
further to show that adrenaline and also acetylcholine could
both produce a "catatonic syndrome". Noteboom (1934) then
investigated a series of mescaline and adrenaline derivatives
including 3,4 dimethoxy-phenylethylamine (DMPEA) which produced
"catatonia".
However, subsequently interest waned, especially among psy¬
chiatrists. This was probably due to the difficulty in the
interpretation of the "catatonic state" in animals, the non-
specificity and variability of the human catatonic syndrome and
the unavailability of biochemical techniques to assess brain
metabolism. Mayer-Gross (1931) discussed model psychoses and
again drew attention to the similarity of chemical structure
between mescaline and adrenaline.
The Mescaline Theory; Osmond and Smythies (1952) together with the
chemist, Harley-Mason, advanced their hypothesis that schizophrenia
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might "be caused by a metabolic aberration in which mescaline-like
metabolites of adrenaline could be formed in the body and thus
produce somewhat similar psychological phenomenae as mescaline
itself. At the time, little was known about the metabolism of
adrenaline although a note by Harley-Mason was included that stated
in part:
"It is extremely probable that the final stage in the biogenesis
of adrenaline is a transmethylation of noradrenaline, the methyl
group arising from methionine or choline. It is just possible
that a pathological disordering of its transmethylation mechan¬
ism might lead to methylation of one or both of its phenolic
hydroxyl groups instead of its amino group ... Methylation
of phenolic hydroxyl groups in the animal body is of rare occur¬
rence but a significant case has been reported recently ...
It is particularly interesting to note that out of a series of
phenylethylamine derivatives tested by Noteboom, 3,4 dimethoxy-
phenylethylamine was the most potent in producing catatonia in
animals".
Osmond, Harley-Mason and Smythies suggested that the phenolic
hydroxyl groups of adrenaline might be methylated so that a mescaline--
like structure was formed and they considered that 3,4 dimethoxy-
phenylethylamine might be the substance involved. This hypothesis
concerning "excess methylation" has since been useful in directing
research on schizophrenia. In the light of the above remarks it is
perhaps surprising that nobody studied the psychological effects of
DMPEA in man before Hollister and Friedhoff (1966) who found it to
be practically inactive.
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O-Methylation of Catecholamines - the "Pink Spot": Armstrong et al
(1957) showed that 3-methoxy-A-hydroxymandelic acid (VMA) was the
main metabolite of noradrenaline and Axelrod et al (1959a) showed
that O-methylation of noradrenaline and adrenaline was a major step
in their degradation, although this was either preceded or followed
by deamination. Later, other metabolites were detected (see review
by Axelrod (1959)) and used as research "tools" in schizophrenia.
Bergsman (1959) showed that there were no differences between
schizophrenic and normal persons in the excretion of adrenaline and
noradrenaline in the urine. Also Mann and La Brosse (1959) and
Pind and Faurbye (1961) found that both schizophrenics and normals
excreted equal amounts of vanylmandelic acid (VMA). Furthermore,
La Brosse et al (1963), who infused tritium labelled adrenaline
intravenously in twelve schizophrenic and twelve normal control
persons, found no difference between the two groups in the level of
adrenaline and noradrenaline in blood, taken at consecutive hourly
intervals following the infusion. The two groups also excreted the
same urinary amounts of the various catechol metabolites. There was,
therefore, no evidence to indicate any abnormalities of catecholamine
metabolism in schizophrenics until Friedhoff and Van Winkle (1962,1962 a)
announced that they had identified 3,4 dimethoxy-phenylethylamine
(DMPEA) in the urine of schizophrenics but not in the urine of normal
controls. They also infused tritium labelled dopamine (the presumed
precursor of DMPEA) in five schizophrenics, then collected their
urine for the next three hours, and claimed that DMPEA, 3-methoxy,
4-hydroxyphenylethylamine, 3,4-dimethoxyphenylacetic acid and 3-
methoxy-4-hydroxyphenylacetic acid were isolated (Friedhoff and
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Van Winkel, 1963).- Moreover, they reported that liver tissue from
a schizophrenic patient could convert dopamine to DMPEA in vitro.
This work, however, was not confirmed by Wagner et al (1966) or
Faurbye and Pind (I967) who, in addition, were unable to either iso¬
late DMPEA from the urine of schizophrenics, or find any difference
in labelled dopamine metabolites between normals and schizophrenics
after the infusion of labelled dopamine. They also showed that
liver tissue from both schizophrenics and normals did not convert
dopamine to DMPEA. Friedhoff and Furiya (1967) stated that they
continued to find DMPEA only in urine from schizophrenics.
Bourdillon et al (1965) reported that 60 per cent of schizophrenics
excreted the abnormal metabolite, the "Pink Spot", while only one out
of 300 normals and non-schizophrenic psychiatric patients excreted
it. Furthermore, they found that 80 per cent of patients diagnosed
as "non-paranoid" or "Schneider-positive" excreted the compounds
whilst only 10 per cent of those diagnosed as "paranoid" or
"Schneider-negative" did so. These results were confirmed by Euehl
et al (1964) in the USA and by Sen and Mc&eer (1964) in Canada,
while Takesada et al (1963) in Japan and Studnitz and Nyman (1965)
in Sweden stated on the other hand that they found the compound in
the urine from both normal and schizophrenic persons. The latter
finding was confirmed by Creveling and Daly (1967), who positively
identified small amounts of DMPEA in urine using mass spectrometry,
and Kuehl et al (1966), who identified the acid metabolite in
larger amounts; however, there was no difference between normals
and schizophrenics. On the other hand, Perry et al (1964) in
Canada and Faurbye and Pind (1964, 1966, 1967a) in Denmark reported
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that they were unable to demonstrate EMPEA either in the urine of
schizophrenic or in the urine of normal persons. Williams et al
(1966), Boulton and Felton (1966), Bell and Somerville (1966), Nunn
and Wheeler (1966), using other analytical methods, also questioned
the occurrence of DMPEA in the urine of schizophrenics.
The discrepancy in these findings was perhaps due to (i) the
different analytical procedures used by the various workers in iso¬
lating and identifying the "Pink Spot" and (ii) several substances,
such as p-tyramine (Boulton et al, 1967); bacterial intestinal
products and dietary factors (Perry et al, 1966); drug metabolites
(Faurbye and Pind, 1966, 1967) which might have interfered with the
identification of DMPEA. Finally, Watt et al (1969) pointed out
that the appearance or non-appearance of the "Pink Spot" was depen¬
dent on such factors as urine volume and pH; these had been neglec¬
ted by previous workers. Watt et al demonstrated that the substance
responsible for the "Pink Spot" was n-acetyl cadaverine, presumably
derived from gut bacteria and that schizophrenics did not differ
from normals in their excretion of it. At present Friedhoff and
Van Winkle are the only remaining workers who maintain that DMPEA
is the substance responsible for the so-called "Pink Spot".
Even if DMPEA should be excreted by schizophrenics, presumably
it plays no role in the aetiology of that disorder since Hollister
and Friedhoff (1966), who gave either DMPEA (500-1000 mgm orally) or
mescaline or placebo "blind" to thirteen volunteers, seven of whom
previously suffered from a "schizophrenic reaction", found that only
mescaline produced psychotic symptoms. Likewise, Shulgin et al
(1966), who gave DMPEA to normal persons, could not detect any
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psychotic symptoms in any of them. The only remaining role for
this substance in schizophrenia is the remote possibility that it
may be toxic to schizophrenics who may be unable to demethylate it
properly (vide infra).
N and 0 Methylation of Catechol and Indole Amines: During the late
fifties and early sixties, new methylating enzymes were being dis¬
covered by different research workers. Phenylethanolamine N-methyl
transferase (Keller et al, 1950 and Axelrod, 1962a), which converts
noradrenaline to adrenaline in liver, adrenal medulla and brain
(Barchas et al, 1969; Ciaranello et al, 1969), and hydroxyindole
0-methyl transferase (Lerner et al, 1959; Axelrod and Weissbaoh,
I960), which converts N-acetylserotonin to melatonin, being (in the
present context) among the most significant. Both require S-
adenosyl methionine as a methyl donor and are substrate specific.
Perhaps the third and most interesting N-metbylating enzyme which
is less substrate specific was isolated from rabbit lung by Axelrod
(1961, 1962b). In vitro, it could N-methylate tryptamine and
serotonin to the psychotomimetic derivatives N, N-dimethyltiyptamine
and bufotenine respectively. The enzyme could also N-methylate
B-phenylethylamine, tyramine, dopamine, normetanephrine, metanephrine
and a variety of exogenous compounds such as mescaline, amphetamine,
etc. Although this enzyme has not yet been found in man, it
generated theories relating to the possible functional significance
of these compounds in the pathogenesis of schizophrenia.
The Trans-Methylation Theory; The discovery that methylation was an
important step in the catabolism of catechol and indole amines
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broadened the vistas of the "mescaline theory" which then became
better known as the "Trans-Methylation Theory" of schizophrenia.
The new concept simply implied the possibility that schizophrenia
was due either to an aberration of methylation in the body or a
defect in demethylation. Indole metabolites, as well as catechol
metabolites, were incriminated. The interest in the former was
engendered by the discovery of many psychotomimetic methylated
indole derivatives such as N, N-dimethyltryptamine, psilocin and
psilocybin.
Bufotenine (N, N-dimethylserotonin) was first claimed by Fabing
and Hawkins (1956) to have psychotomimetic properties. This, how¬
ever, was later denied (Holmstead, 1967; Turner and Merles, 1959)•
Like the "Pink Spot", bufotenine was suspected by some authors
(Bumpus, 1958; Fischer et al, 1961; Brune et al, 1963) to occur in
urines of schizophrenics, but denied by others (Siegel, 1965;
Runge et al, 1966; Sprince et al, 1963). Tanimurkai et al (1967,
1970) claimed to have developed a more sensitive method to detect
small amounts of bufotenine and DMT (N, N-dimethyltryptamine) in
urine and with their method analysed the urine of four chronic
schizophrenic patients on a controlled diet which excluded all pre¬
formed catechol and indole amines. They discontinued all other
medications and gave their subjects monoamine oxidase inhibitors
(MAO-inhibitors) and L-cystein. The authors reported that excretior.
of bufotenine was less (l mg/24 hrs) in the absence of MAO blockade
than with it (2-5 mg/24 hrs). On the other hand DMT could be
detected in small amounts only after MAO blockade. This was regard¬
less of the presence or absence of L-cystein. They were also able
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to correlate the levels of urinary bufotenine and DMT with the
clinical condition of the patients, finding that during an active
psychotic state both compounds were excreted in larger amounts in
the urine. However, although the controlled diet excluded preformed
-
catechols, it contained preformed N-methylated amines present in
plant food, and unavoidably tiyptamine which cannot be completely
eliminated from the diet.
Mclsaac (1961) pointed to the similarity in chemical structure
of melatonin (a pineal hormone) and harmine (a hallucinogenic drug).
He suggested that melatonin might be involved in schizophrenia.
However, this idea lacked experimental support until G-reiner and
Nicholson (1965) reported that melanin was deposited to excess in
certain post-mortem tissues derived from schizophrenic patients.
In humans, melatonin inhibits melanin production and, therefore,
decreases pigmentation. On these grounds the authors hypothesised
that the normal route of synthesis of melatonin from serotonin was
blocked owing to the congenital absence of a certain enzyme (an 0-
methyltransferase) and instead of melatonin, hallucinogenic compounds
like harmine were produced. However, this hypothesis did not take
account of the possibility (i) that the excess melanin might have,
been due to an abnormality of adrenaline metabolism, since melanin
can also be formed from tyrosin, and (ii) that an abnormality of
0-methyl transferase itself might have been the primary cause and
the excess melanin (due to decreased melatonin) might have been
secondary. Although the Greiner-Nicholson theory lacked cohesion,
since harmine itself is an 0-methylated compound, excess pigmentation
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in schizophrenic patients had been reported by Shattock (1950).
Harsden (1965)» on the other hand, argued that the apparent increased
melanosis in schizophrenic patients might reflect some disorder in
dopamine and noradrenaline metabolism in the brain. His hypothesis
stated that during the process of embryonic cerebral development,
catecholamine synthesis might be diminished in the brain stem nuclei,
and tyrosine metabolism might be diverted towards the formation of
neuro-melanin rather than catecholamines.
Although DMT and bufotenine were claimed to be present in schizo¬
phrenic patients, and were reported to increase just prior to exacer¬
bation of psychotic symptoms, this work needs further confirmation.
These observations are important since Morgan and Mandell (1969)
reported the presence, in rabbit brain, of an N-methyl transferase
capable of converting tryptamine to the hallucinogenic compound DMT.
Attempts to influence Methylation Reactions in Schizophrenia:
Hoffer et al (1957) administered niacin and niacinamine (both methyl
acceptors) to schizophrenics and reported varying degrees of improve¬
ment in their clinical states; these findings have not been independ¬
ently confirmed to date.
Cantoni (1953) showed that L-methionine, the essential precursor
of S-adenosylmethionine, transferred its methyl group to acceptor
compounds in the process of transmethylation. Furthermore,
Baldessarini and Kopin (1963) reported that feeding L-methionine (which
is biologically more active than the D-form which is readily meta¬
bolised in the liver; Harper et al, 1970) to rats produced a sig¬
nificant increase in S-adenosylmethionine in liver and brain. In an
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attempt to study the effects of raising "brain amines in the "brain,
Pollin et al (1961) investigated the effects of oral administration
of a series of amino acids and other compounds on chronic schizo¬
phrenic patients, pre-treated with the MAO-inhibitor iproniazid.
The latter was given since animal experiments had shown that MAO-
inhibitors increased (i) the brain content of amines by blocking
deamination, the alternative catabolic step in amine catabolism,
and (ii) increased the rate of methylation in the body (Baldessarini,
1967). Thus MO inhibitors had the dual function of firstly protec¬
ting any methylated metabolites from degradation by deamination and
secondly, increasing the rate of O-methylation of amines. They
found that "marked psychotic" changes occurred with L-methionine
(20 g/day) in four out of nine patients. The psychotic reaction
disappeared abruptly upon withdrawal of L-methionine and in some
cases unexpected clinical improvement was reported; this persisted
for weeks or months. The authors could not, however, be certain
whether the psychotic reaction was a "flare up of the schizophrenic
symptoms" or merely a "toxic delirium". In contrast, loading with
tryptophane produced a mild psychic reaction in seven of nine patients,
mainly characterized by stimulation, euphoria and, at times, elation.
Loading with glycine, phenylalanine, glutamine, histidine, tyrosine,
5-hydroxytryptophane, dopa, ammonium chloride and placebo did not
induce any reaction during the continued treatment with the MAO
inhibitor. These findings focused research interest on L-methionine
and tryptophane.
Brune and Himwich (1962a) gave L-methionine and an MO-inhibitor
(isocarboxazid) to nine schizophrenic patients. They observed a
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psychotic syndrome in seven patients which they considered as heing a
combination of (i) non-specific toxicity plus (ii) a recurrence and
exacerbation of previous schizophrenic symptoms. Park et al (1965)
gave seventeen schizophrenics L-methionine or glycine (an amino acid
without methyl donating properties) and isocarboxazid; two became
overtly more psychotic while a third reacted less strikingly to L-
methionine. From this study and their review of the literature, the
authors concluded that it was impossible to differentiate between non¬
specific toxic reactions and accentuation of the schizophrenic symp¬
toms proper. The effect of L-methionine and MD-inhibitors on
schizophrenic patients was also confirmed by Kakimoto et al (1967)
who reported the same clinical effects, but again were unable to
elucidate the nature of the reaction. They measured normetanephrine
(MM) and metanephrine (M) in the urine of their schizophrenics and
found no increase in the levels of these O-methylated metabolites of
noradrenaline and adrenaline on L-methionine loading.
On the other hand, Alexander et al (1963) gave L-methionine
(20 g/day) or L-tryptophane (15 g/day) with or without tranylcypromine
to six schizophrenics and two non-schizophrenio3. The combination of
L-methionine and tranylcypromine produced a psychotic reaction in five
of the six schizophrenics but only behavioural changes in the non-
schizophrenics (insomnia, alertness, fear and agitation). L-
methionine alone, L-tryptophane and L-tryptophane with tranylcypromine
did not induce a psychotic reaction in any of the patients who mani¬
fested only behavioural changes vide supra. It was concluded that
a combination of L-methionine + MAO-inhibitors was necessary to produce
a psychotic reaction in schizophrenics which was only suggestive of a
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relapse of their illness. Furthermore, Berlet et al (1965) gave a
mixture of L-tryptophane and L-methionine to eight schizophrenic
patients for a period of thirty days; there was no worsening of
their psychotic symptoms. This procedure, however, increased the
urinary excretion of tryptamine, 5-HIAA and L-methylnicotinamide.
Seven patients who tolerated 30-40 g/day of L-methionine under an
MAO-inhibitor (tranylcypromine) cover had moderate to severe worsen¬
ing of their schizophrenic symptoms.
Brune and Himwich (1963) substituted betaine (another methyl
donor) for L-methionine; they reported exacerbations of schizophrenic
symptoms.
All these workers referred to above conducted their experiments
on the assumption that the reaction produced by giving L-methionine
or betaine to schizophrenic patients was due to the methyl donating
properties of these compounds. On the other hand, Haydu et al (1965]
who reported the ability of L-methionine to exacerbate schizophrenic
symptomatology, found an ameliorating effect from hydroxychloroquine.
They argued that L-methionine, as a precursor of thiol groups, might
be inducing this effect by its action on these groups, and that
hydroxychloroquine produced its amelioration by having an opposite
effect to L-methionine on thiol groups.
Another interesting finding which might support Haydu's hypo¬
thesis was reported by G-reiner and Nicholson (1965). They put for¬
ward the melatonin theory of schizophrenia and suggested that
inhibiting the copper-dependent enzyme tyrosinase by means of a low
copper diet and penicillamine (a copper chelating agent) should
alleviate schizophrenic symptoms. A clinical test of this hypothesis
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led to the report that (i) schizophrenics improved clinically,
(ii) there was a fall in the number of pigmented cells in the epi¬
dermis, and (iii) copper excretion increased. However, these
findings were at variance with those of Hollister et al (1966) and
Walshe (1967). Whether or not penicillamine has a beneficial effect
on schizophrenic symptoms, it is interesting to note that its chemical
structure is similar to that of L-methionine, and moreover it carries
an active thiol group. Thus, its copper-chelating properties might
have nothing to do with any possible clinical effects which may
alternatively be connected with the complex of the thiol groups and
transmethylation.
Other metabolic effects of L-methionine have been studied and
the presently available data may be interpreted as follows:
(i) Giving excess L-methionine might have resulted in a disturbance
of cell membrane transport and cell uptake of other amino acids
(Kakimoto et al, 1967), dopa (Shah et al, 1968). Sprince (1967)
suggested that, in vivo excess L-methionine might favour the chan¬
neling of tryptophane metabolism into indoleaoetic acid production
by inhibiting the nicotinic acid pathway, or stimulating those path¬
ways leading to the formation of indoleacetic acid. It was further
speculated that excess L-methionine and/or its metabolites might
disturb tryptophane metabolism by (i) liberating free tryptophane
from the bound state,and/or (ii) inhibiting oxidation reactions,
and/or (iii) forming N-methylated metabolites, and/or (iv) forming
O-methylated metabolites, and/or (v) forming alpha-methylated meta¬
bolites, and/or (vi) stimulating (and/or depleting) pyridoxal phosphate
activity. The last possibility was later confirmed by Sprince et al
(1969).
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(ii) Methionine is the source of methyl groups for the methylation
of DM bases. Griffith and Mahler (1969) advanced a theory of
memory based on Sussman and Sussman's theory of DM "ticketing".
According to the theory DM bases were altered by methylation, and
it was suggested that methionine deficiency might underlie memory
disorders. Equally, excess methionine could have exerted its
enhancing psychotic effects through a similar mechanism.
The methionine loading experiments referred to above were not
without criticism since (i) procedures were not standardized; for
instance, some used large doses of L-methionine (more than 20 g/day),
whilst others gave it for only two to three days (Kakimoto et al,
1967). (ii) In all the experiments MAO-inhibitors were used which
might have themselves induced a psychotic reaction in the schizo¬
phrenics, or indeed, in predisposed persons. Thus, Birkmayer (1966)
reported that eight out of two hundred Parkinsonian patients given
isocarboxazid (marplan) 30 mgm/day over a long period of time,
experienced psychotic episodes. The phenomenology was similar in
all eight subjects; they became anxious and suspicious, and had
auditory hallucinations and ideas of reference. These symptoms
subsided on stopping the MAO-inhibitor, and reappeared when treat¬
ment was resumed.
Attempts to Decrease Methylation: Because L-methionine and other
methyl donors proved to have a deleterious effect on schizophrenic
symptomatology, Berlet et al (1966) placed nine schizophrenic patienti
on a controlled diet with constant amounts of protein, and reduced
amounts of both tryptophane and L-methionine; their intention was
to improve their clinical state. Tranquillizers were stopped two
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to four months prior to the investigation. After a first period of
six weeks, the content of L-methionine and tryptophane in the food
was reduced for twelve weeks and followed by a second control period
of eight weeks. There was no improvement in the patients' clinical
state during the twenty-eight weeks of the experiment. On the con¬
trary, psychotic episodes preceded by loss of appetite and weight
were observed in two of the patients during both the control periods,
and especially during the experimental phase, when dietary L-
methionine and tryptophane were restricted. In these two patients,
creatinine and indoles, especially tryptamine excretion in the urine
were paradoxically increased during the psychotic episode. Since
there was a correlation between creatinine and tryptamine excretion
irrespective of tryptophane and protein intake, the authors hypo¬
thesized that the deficient amino acid intake might have resulted
in an increase of tissue protein breakdown, leading to increased
creatinine, tryptamine and presumably other psychotomimetic indole
derivatives; the latter produced the worsening in the clinical state.
An observation made by Bogoch (1957) is relevant to these find¬
ings. He assumed that schizophrenia was associated with abnormal¬
ities in the metabolism of aromatic compounds. On this assumption,
he gave twenty-two schizophrenics a synthetic diet, essentially free
of aromatic amino acids (similar to that used for phenylketonuria),
for three weeks. Contrary to his expectation, none improved, and
thirteen patients became clinically worse. When phenylalanine and
tryptophane were added to the diet, these patients improved. He
concluded that both phenylalanine and tryptamine metabolism were
involved in the pathogenesis of schizophrenia.
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In an attempt to deplete the train of amines (serotonin, dopa¬
mine and noradrenaline) Brune and Himwieh (I960) gave nine schizo¬
phrenic, four "oligophrenic" and two phenylketonuria patients
reserpine (4 mgm/day) with a diet which was constant in protein
content. After a first placebo period of twenty days, all patients
received the reserpine for twenty days followed by a second placebo
period of twenty days. Throughout the experiment, urinary tryp-
tamine and 3-IAA (3-indole acetic acid) were determined. In those
patients who had an uneventful clinical course, urinary tryptamine
remained within the normal range. On the other hand, those patients
(five schizophrenic and one "oligophrenic") who experienced exacer¬
bations of their symptomatology during both placebo and reserpine
periods showed an increase of two to three-fold in urinary tryptamine
there was a lesser but still significant increase in urinary 3-IAA.
In these cases the increase preceded the mental disturbance, and
lasted until it abated.
In order to investigate whether there was a correlation between
the excretion of tryptamine and the severity of schizophrenic symp¬
toms, Brune and Himwich (1962b) studied twenty patients who were
placed on a constant protein diet (100 g protein/day) and given
reserpine and placebo alternatively. It appeared that a strong
positive correlation existed between the severity of schizophrenic
symptoms (as rated by the authors) and the levels of urinary trypta¬
mine. This correlation was not influenced by reserpine admini¬
stration. They concluded that dietary indoles were not an important
factor in causing these fluctuations in urinary tiyptamine; however,
they were undecided whether this correlation applied only to schizo¬
phrenic psychoses or to psychoses in general.
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There was a similarity between the mental disturbances observed
in the reserpine experiments and those witnessed during the experi¬
ments using an amino acid deficient diet. Although such distur¬
bances occurred during the placebo or normal diet periods, they were
more frequent during reserpine administration, or a deficient diet.
Since some of the symptoms were not specific to schizophrenia, it
seems unlikely that this was a true exacerbation of the schizophrenic
process in all affected patients. Moreover, it is quite possible
that schizophrenic exacerbations could have occurred as part of the
natural history of the illness and not due to the reserpine or
deficient diet. Although little is known about the effects of a
deficient diet on the metabolism of brain amines, it is interesting
to note that psychotic episodes were not witnessed in the Minnesota
experiment (Keyes et al, 1950) * and German concentration camps
(Helweg-Larsen et al, 1952), both of which shared the common variable
of deficient dietary amino acids. As for tryptamine excretion:
(i) no account was taken, by the authors, of the effect of urinary
faetors such as pH, on the excretion of tryptamine, and (ii) to my
knowledge no study was done to see whether a correlation existed
between creatinine and tryptamine excretion in normals.
In spite of these methodological criticisms, the correlation
between increased levels of urinary tryptamine and manifest psychoses
has previously been reported by Berlet et al (196k) and needs further
* This experiment investigated the effects of semi-starvation on
forty-three volunteers. The dietary content of ami no acids and
vitamins was reduced; during this period metabolic (e.g. hormonal,
biochemical) and psychological changes were assessed in each patient




Krakoff (1961) reported that methionine sulphoximine (MSO), a
methionine antimetabolite, -when given to normal people at a dose of
over 200 mg/day, produced a "toxic" psychosis characterized by
hallucinations, agitation and disorientation. The EEG- changes
were suggestive of an organic disturbance. These effects reverted
to normal by giving methionine, or were prevented by giving L-
methionine together with the MSO in a ratio of nineteen parts to
one respectively. This isolated but interesting finding led Heath
et al (1966) to investigate the effect of MSO on schizophrenic
patients. He gave MSO to ten schizophrenics and eight controls.
Ill the controls, except the ninth, who was given placebo, exper¬
ienced various combinations of psychotic symptoms, including autism,
thought block, disturbances of affect and some catatonic behaviour,
paranoid symptoms, auditory hallucinations and association defects.
The ten schizophrenic patients showed no worsening of their symptoms,
and in fact some were apparently improved. The EE& was abnormal in
the controls but normal in the schizophrenic patients. The authors
concluded that, when methylation was reduced in normals, a psychotic
state developed, while any reduction of methylation which might have
occurred in the schizophrenics would have neutralised the presumed
"overactive" methylating pool.
Abnormal Methionine Metabolism: It is well known that temporal lobe
epileptics are especially prone to a schizophrenia-like psychosis
(Slater et al, 1963). Reynolds et al (1966a, 1967) had suggested
that in many such patients the psychotic illness might be precipitated
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by anticonvulsant drugs partly mediated, through disturbances in
folic acid and vitamin B12 metabolism (Reynolds et al, 1966b).
Folic acid acts as an acceptor and donor of single carbon units
and is required for the synthesis of methyl groups and ultimately
methionine. Vitamin B12 acts as a co-enzyme in the transfer of
the methyl group from 5-methyl tetrahydrofolate to homocysteine
with the eventual formation of methionine (Woods et al, 1965;
Amstein, 1965). These findings are linked with the general
concept of "aberrant methylation" underlying schizophrenia although
they are only suggestive, since folic acid and vitamin B12 deficien¬
cies have not been seen to produce a schizophrenia-like psychosis
generally. However, in a "predisposed individual" with a temporal
lobe lesion, a psychosis may be induced which can, but not invariably
takes a schizophrenic-like form. These observations do not support
the findings in the MSO feeding experiments, where reduced methy¬
lation was associated with an amelioration of the schizophrenic
process. They do, however, imply that abnormal methionine meta¬
bolism might be associated with schizophrenia. Further evidence
in support of this premise came from:-
(i) The discovery in Belfast (Carson et al, 1963) of homocystenuria,
an inborn error of methionine catabolism, in which the normal route
(via cystathionine) is blocked by absence of the enzyme cystathionine
synthetase. Methionine metabolism is diverted and homosyctine is
formed, and excreted in the urine. Affected individuals, when fed
methionine, showed an increase in plasma and urinary levels of
methionine. This rise in urinary levels was five to eight times
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higher than in normal controls. The disease is associated with
mental subnormality but, more interestingly, in the original family
studied the mother and several of her close relations apparently
suffered from schizophrenia. Other reports came from Perry et al
(1967), who found psychotic illnesses in two out of three homocysten-
uric families, and Spiro et al (1965), who reported that a chronic
schizophrenic was later discovered to have homocystenuria. Welch
et al (1969), working with the same patient, failed to detect DMPEA
or 4MPE (4-methoxyphenylethylamine) in her urine or in that of her
mother, who also suffered from schizophrenia. There has as yet been
no systematic survey of the prevalence of psychiatric symptomatology
in these families. These findings perhaps suggest that an intensive
biochemical study of these patients, to determine whether or not they
might show other disorders of transmethylation, is relevant. To
date, to the best of my knowledge, no such study has been completed,
(ii) Israelstam et al (1970) demonstrated that schizophrenics, when
given small doses of radioactive L-methionine (C14-methyl group),
showed a slower clearing rate of the radioactivity, measured as
expired C"^02 over a period of two hours. Normal subjects, as well
as remitted schizophrenics, had a faster clearance rate. Although
the methods used failed to pinpoint the precise "methylation defect",
Israelstam et al tentatively inferred from their data that in some
way schizophrenics might either (i) have a larger methylating pool,
or (ii) a decreased turnover of this pool. This work has yet to be
confirmed by others.
Prom all these studies it appeared that a psychosis of some kind
might result from either (i) "excess" methylation (L-methionine), or
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(ii) "insufficient" (MSO). Detailed examination of the literature
revealed that those authors who reported a psychotic reaction with
methionine and MAO-inhibitors in schizophrenic patients were (i)
unable to describe the reaction in definitive terms, and/or (ii)
to assess whether or not it represented an exacerbation of the
schizophrenic process, or was merely a non-specific toxic psychosis.
Moreover, no verified reports were available on the effects of
similar doses of L-methionine in normal people. However, L-
methionine in lower dosages 10 g/day) did not produce a psychotic
reaction in normal volunteers (Harper et al, 1970). In addition to
the difficulties and discrepancies, so far research workers have been
unable to demonstrate increased methylated metabolites, "normal or
abnormal", in schizophrenics receiving L-methionine. In fact, the
only evidence presently available which suggests that L-methionine
is the major methyl donor in the body has been extrapolated from in
vitro animal experiments. Similarly the experiments done in an
attempt to reduce methylation by either decreasing L-methionine
intake or blocking its action by MSO may be criticized; thus
Berlet et al (1966) did not use normal controls and failed to test
whether or not there was any evidence for decreased methylated meta¬
bolites in their patients. This latter point is especially important
since the study was done on the stated assumption that decreased
methylation might alleviate schizophrenic symptoms. Although MSO
is an antimetabolite of L-methionine, its effects are not confined
to blocking methyl transfer from L-methionine. Since L-methionine
has other functions in the body, it cannot be assumed that MSO
produces its effects by blocking methylation. Furthermore, the
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Heath et al (1966) study did. not mention anything about the state of
consciousness and orientation of their subjects on MSO; however,
they did state that memory was impaired and that the severity of the
reaction was dose dependent. Like Berlet et al, they did not
examine whether MSO administration resulted in a decrease in methy¬
lated metabolites. In the light of the procedural deficiencies
discussed above, many more methodologically adequate experiments
are necessary to supplement these early studies. For instance:
(i) a closer examination needs to be made of the effects of L-
methionine on the excretion of methylated derivatives, (ii) the
alleged effects of betaine and MSO on schizophrenic patients need
confirmation, (iii) the ameliorating effects of penicillamine,
hydroxychloroquine and nicotinamide together with an examination
of their alleged mode of action needs investigation, and (iv)
intensive biochemical investigations are necessary on patients
suffering from homocystinuria, with or without schizophrenia.
Defective Demethylation - a possible defect in schizophrenia:
Many years ago Slotta and Muller (1936) reported that the 2.3.4
analogue of mescaline, inactive in normal people, was more active
than mescaline in schizophrenics. This work, which has not to date
been repeated, is interesting because, if schizophrenia is geneti¬
cally determined, it is more probable that an inborn error of
metabolism is associated with the complete or partial lack of an
enzyme than the presence of an abnormal (metbylating) enzyme. In
the case of schizophrenia the absence of a demethylating enzyme is
a possibility consistent with the transmethylation theory. As
mentioned earlier, Axelrod (1961, 1962b) and later Morgan and
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Mandell (1969) reported the presence of a non-specific N-methylating
enzyme in liver (Axelrod) and brain (Morgan and Mandell). If these
or similar enzymes are found in humans, then it could be postulated
that schizophrenics are unable to demethylate the resultant 0 and
N methylated metabolites, some of which might be hallucinogenic.
Demethylation is an important metabolic reaction in the body and
there is evidence that humans can demethylate mescaline (Harley-
Mason et al, 1958); the Slotta and Mllller (1936) experiment suggests
it would be informative to investigate the demethylating enzyme
system in normals and schizophrenics. Direct confirmation of their
experiment leads, however, to ethical difficulties since it is no
longer regarded as justifiable to feed potentially hallucinogenic
compounds to schizophrenic patients.
Smythies et al (1967a) studied the role of methoxy groups on
the benzene ring and found that, with the exception of the 3,4,5;
2,3,4,5 and 2,3,4,5,6, all the possible methoxylated derivatives
of phenylethylamine were non-hallucinogenic, probably because they
are rapidly catabolized by amine oxidase. They showed that at least
three methoxy groups with a 3,4,5 configuration were necessaxy for
the hallucinogenic properties. The addition of extra methoxy
groups on the 2 and/or 6 positions was seen to enhance these proper¬
ties; this probably being due to the resistance of these molecules
to attack by diamine oxidase, since it is known that any compound
substituted in the 2 and 6 positions is not catabolized by diamine
oxidase.
Similar work on methoxylated amphetamines was done in rats by
Snythies et al (1967b). Shulgin et al (1969) also tested the
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hallucinogenic properties and potency of some of these compounds in
humans. In general it was found that certain configurations of
methoxy groups rendered the molecule hallucinogenic. Shulgin found
that 4-methoxy amphetamine and the 2,5; 2,4; 2,4,5; and 2,4,6
derivatives were significantly more hallucinogenic than mescaline.
These findings suggested that more than one configuration might
render the molecule hallucinogenic. The fact that the amphetamine
molecule was more potent in this respect than the phenylethylamine
analogue was due to the presence of an o^-methoxy group on the former,
which makes it resistant to amine oxidase.
In the light of these latter findings, Slotta and Mflller's (1936)
observations that the 2,3,4-methoxyphenylethylamine was active in
schizophrenics but not in normals might be explained on the basis
of a demethylating defect in the former group. It is feasible
that normals could demethylate the 4 position rendering the molecule
inaotive (since the 2,3 compound is inactive, while the 3,4 is very
weakly active and the 2,4 is very active), whilst schizophrenic
patients could not. Both methylation and demethylation are normal
biochemical processes in the body; disturbance(s) of either could
conceivably be involved in the casual mechanism(s) of schizophrenia.
This hypothesis can be tested by feeding small amounts of the
2,3,4 compounds C"^ labelled on the various methyl groups and




For a long time "biological methylation" was thought to be a
widespread biochemical process in the body with an important role
in the matabolism of various compounds. Since 1950 important
developments have taken place:
(i) The discovery and isolation of S-adenosylmethionine
as a prime methyl donor in transmethylation (Cantoni,
1951a, 1951b, 1952, 1953).
(ii) Assessment of de novo methyl group formation from
"active" formaldehyde in the biosynthesis of the
methyl groups of thymine and methionine (Greenberg,
1963).
(iii) The discovery that folic acid and Vitamin B12 were
important in methyl group transfer (Guest et al,
1962a; Foster et al, 1964).
De Novo Methyl Group Synthesis: Thymine and methionine methyl
groups are the only two groups which are definitely known to be
derived by de novo synthesis from "active" formaldehyde (methylene-
tetrahydrofolic acid). The mechanism in the two reaction sequences
are distinctly different (Greenberg, 1963). The first in vitro
experiment on methionine synthesis was by Berg (1951, 1953) wbo
showed that methionine could be formed from homocysteine and formate.
Later, Nakao and Greenberg (1955, 1958) identified most of the
components and cofactors required for its synthesis. They found
that using a liver enzyme preparation with homocysteine as a methyl
acceptor, formaldehyde or the B-carbon of serine was converted to
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the methionine-methyl group. The reaction required folate - H^*,
ATP**, Mg++ and NAD*** or NADF****. This finding was confirmed
by Doctor et al (1957) who also observed that the reaction rate was
reduced when folic acid was omitted or aminopterin (a folic acid
antimetabolite) was added to the preparation. Adenosyl homocys¬
teine was the only substitute for homocysteine in stimulating the
reaction (Stevens and Sakami, 1959; Wilmanns et al, I960); it was
formed from homocysteine and adenosine through methionine synthesis
(de la Haba and Cantoni, 1959)• However, more recent work suggested
that under certain conditions Vitamin B12 was required for the syn¬
thesis (Foster et al, 1961; Kisluik and Wood, I960; Guest et al,
1962b) and methyl-folate-H^ was the actual methyl donor (Hatch
et al, 1961; Larabee et al, 1961). It therefore appeared that
there were two pathways for methionine synthesis, one of which was
Vitamin B12 dependent. The present state of knowledge about
methionine-methyl biosynthesis is that: homocysteine is the methyl
5
acceptor and N methyl-folate-H^ serves as the methyl donor in an
enzymatic reaction which is mediated through a methyl transferase;
the reaction requires Vitamin B12, NADHX, FAT*1, ATP and Mg++ as
additional cofactors (Diagram l). Other methyl transferases can
convert homocysteine to methionine with dimethyl thetin, methyl
methionine, or betaine as methyl donors (Klee et al, 1961; Ericson,
I960; Durell et al, 1962).
* Folate - H^-5,6,7,8 - tetra hydropteroyl glutamic acid.
** ATP - Adenosine triphosphate.
*** NAD - Niacinadenine dinucleotide.
**** NADP - Niacinadenine dinucleotide phosphate.
x NADH - Niacinadenine dinucleotide (reduced form).
** FAD - Flavin adenine dinueleotide.
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Transmethylation; Transmethylation in the body is a widespread
biochemical process -which is involved in the metabolism and/or
catabolism of many compounds. It takes the form of (i) N-
transmethylation, (ii) O-transmethylation, (iii) S-transmethylation,
and (iv) C-transmethylation. There is evidence for all forms of
transmethylations with perhaps some doubt concerning the identity
of some of the methylated products. It was found by Cantoni
(1951a»"b» 1952j 1953) that S-adenosylmethionine was the co-enzyme
for most methyl transferase reactions. He established that ATP
and Mg++ were essential for all transmethylating reactions involving
methionine (Cantoni, 1951a,b) and were related to the formation of
"active" methionine, subsequently identified as S-adenosylmethionine.
The transmethylating activity of the latter resulted from an energy
rich bond between the methyl group and sulfonium of the compound
leading to labilization of the methyl group.
Of the many transmethylating reactions involving S-adenosyl¬
methionine are the N- and O-methylation of catechol and indole amine
derivatives. The former type of methylation was proved by Keller
et al (1950) who, by feeding C^-labelled-methyl group-methionine,
demonstrated that norepinephrine was converted to epinephrine with
the incorporation of the methyl group from methionine. The enzymic
aspects of the reaction have been studied by Kirshner and Goodall
(1957) who found that S-adenosylmethionine was the essential methyl
donor in the reaction. Since then a number of N-methyl transferases
have been discovered which include the indole - N-methyl transferases,
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Indole and Catechol O-Methyl Transferase Enzymes: The only indole
0-methyl transferase so far identified is acetylserotonine O-methyl
transferase which is found in the pineal gland and converts acetyl-
serotonine to the hormone melatonin in the presence of S-adenosyl-
methionine (Lerner et al, I960; Axelrod and Weissbach, I960).
The most exhaustive work done on catechol O-methyl transferase
(COMT) was by Axelrod and Tomchick (1958) and Pellerin and D'lorio
(1958). The enzyme was found to methylate the 3-hydroxy position
of catechol derivatives and, when further tested, could methylate
all 3,4 dihydroxyphenyl derivatives including 3,4 dihydroxybenzoic
acid and catechol itself, but not monohydroxy phenols. It was
found in liver, brain and, to a lesser extent, in kidney of most
mammals and was specific for S-adenosylmethionine with metal ion
requirement for mg++. Axelrod (1957) and Axelrod et al (1958)
established that O-methylation of catechol amines occurs either
prior to or after oxidative deamination and is the principal route
for their catabolism. In later experiments Kopin et al (1961),
using dual labelled isotopes (C^-MA, H^-NM), showed that NA and KM
were further catabolized in the body by deamination and O-methylation
(Diagram II). The former route was blocked by MAOI and the latter
by pyrogallol (a COMT inhibitor). Such evidence was obtained from
the difference in the levels of O-methylated metabolites found in
the three groups of rats (first group pretreated with MAOI, second
group pretreated with pyrogallol, and third group served as a

















METABOLIC PATHWAYS OF DOPAMINE AND NORADRENALINE
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The role of COMT in the catabolism of catecholamines was also
studied by the use of blocking agents such as pyrogallol and tropo-
lones. Both act as competitive substrates for COMT (Archer et al,
I960) and the latter also specifically inhibits COMT, probably by
complex formation with COMT active sites (Belleau and Burba, 1961).
It was found that COMT inhibitors decreased the levels of 0-
methylated catechol metabolites in vivo (Carlsson and Waldeck, 1963
Carlsson, 1964; Kopin et al, 1961) and potentiated the effects of
ML on adrenergic receptors (Bell, 1967; Belleau and Burba, 1963).
More recent work (R. Sugden - personal communication, 1970) showed
that when rats were injected intraventricularly with pyrogallol
and C^-NA, the ratio, in brain, of 3,4-dihydroxyphenylglycol
(DHPG) to 4-hydroxy, 3-methoxy phenylglycol (HMP&) increased as
compared with the control group of rats where no pyrogallol was
used. Furthermore, the increase in ratio was due to a significant
decrease in HMPG accompanied by only a slight increase in DHPG.
Although all these findings established that catechol amines
were partly catabolized by 0-methylation and that S-adenosyl-
methionine was the co-enzyme for COMT, which was the specific
enzyme for the reaction, no in vivo experiment was done to demon¬
strate the transfer of the methyl group from S-adenosylmethionine
to the 0-methylated catechol catabolites in brain. In all the
experiments on 0-methylation, the enzyme preparation was made from
liver tissue and 0-methylation was demonstrated, in vitro, by
incubating the enzyme preparation with the appropriate substrates.
The resultant labelled 0-methylated metabolite (i.e. NM) was then
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injected into the animal and its O-methylated catabolites were
isolated (i.e. VMA, HMP&). Up to date, there is, therefore, no
direct proof that, in brain, there is a transfer of methyl groups
from S-adenosylmethionine to catechol-O-methylated catabolites.
VMA and HMPG - Two Major Catabolites of NA: Armstrong et al (1957)
showed that 3-Eetho:xy-4-hydroxy mandelic acid (VMA) was the main
O-methylated catabolite of noradrenaline (NA) in the body. How¬
ever, it was later discovered that the major O-methylated catabolite
in rat (Schanberg et al, 1968, 1968a) and cat (Mannarino et al,
1963) brains was 4-bydroxy-3-methoxy phenyl glycol (HMP&). More¬
over, Schariberg et al (1968) reported that in rat brain the majority
of HMP& formed from exogenous labelled KM was identified as HMP&
sulphate conjugate. However, this is not true for all species:
whereas Schanberg et al (1968a) found that in rat brain and human
CSF the majority of endogenous HMP6- is conjugated, in the cat HMP&
is mostly free and in the Rhesus monkey all HMPG is free. The
detection of endogenous free and conjugated HMPG- in brain was also
confirmed by Sharman (1969). Mass and Landis (1966 and 1968),
using double isotope technique in the dog, found that the major
catabolite of brain MA excreted in urine was HMP&. It was con¬
cluded that in the dog 50-60 per cent of the endogenous MA
catabolized in the brain was excreted in urine as HMPG.
It would appear from these findings that, in mammalian species,
HMPG was the major MA catabolite in brain. As a consequence of
this, depending on the size of the brain pool of MA and the amount
of HMPG produced by peripheral stores (La Brosse et al, 1961;
/
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Axelrod et al, 1959b), the catabolism of MA by the brain might
account for a significant amount of the HMP& in the urine. Approx¬
imately 25 per cent of HMPG excreted in urine came from train pools
of NA (Mass and Landis, 1966).
In contrast to this, most of the normetanephrine (KM) and VMA
excreted in the urine comes from peripheral KA stores rather than
brain KA stores for the following reasons:- In different species
there is a barrier to the movement of KM out of the brain (Mass and
Landis, 1966; Schaneberg, 1967; G-lowinski et al, 1965). Although
this barrier may be complete or partial, it is assumed that little
of the KM formed in brain enters the body pool and that the KM found
in urine reflects the metabolism of KA by tissues other than brain.
VMA, on the other hand, can be formed in brain with no existing
barrier to its movement from it (Mannarino, 1963; Mass and Landis,
1966, 1968; Glowinski and Iversen, 1966). However, being the
major KA catabolite in the body of most species, the brain's con¬
tribution to the amounts excreted in urine will be very small. It
was found in the dog that less than 1 per cent of urinary VMA had
its origin in brain (Mass and Landis, 1968).
Although accurate estimates of the different catabolites of KA
in brain are not available, if man is similar to other species, it
is probable that a significant amount of the HMP& excreted in urine
comes from brain, whereas urinary VMA, metanephrine and possibly KM
come from peripheral KA stores.
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Factors Affecting S-Adenosylmethionine Levels in the Body;
Baldessarini (1967) has shown that a number of compounds affected
tissue levels, including brain, of S-adenosylmethionine. In
general, it was found that compounds which enhance methylation,
i.e. MOI and methyl acceptors, lowered the tissue levels of S-
adenosylmethioninej on the other hand, methionine increased its
/
levels considerably and this effect was reduced when MOI were
used together with the methionine. The distribution of S-adenosyl¬
methionine in brain was found to be fairly uniform. Mackenzie et al
(1950) studied the rate of oxidation of the methyl group of dietary
methionine but were uncertain whether oxidation of the methyl group
was associated with the activation of methionine to S-adenosyl¬
methionine or its transfer to methyl acceptors. By giving C^"
methyl-methionine to rats, they found that the oxidation of the
methyl group (as measured by the activity, in the expired
breath, urine and faeces) took place in phases: the first phase,
"assimilation phase", where there was a rapid decrease in radio¬
activity in expired breath about two hours after oral administration
of methionine and one hour after its intraperitonial injection.
There was first a mobilization of already existing S-adenosyl¬
methionine in tissue prior to the incorporation of the administered
methionine. The second phase, "equilibrium phase", consisted of a
steady and gradual fall in radioactivity, mainly in urine and faeces,
which represented a steady incorporation and/or utilization of the
methyl group from tissue methionine and/or S-adenosylmethionine.
Moreover, Baldessarini (1967) showed that, with intravenous injection
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of C^-methyl methionine, there was a rapid formation of S-adenosyl-
methionine from methionine in brain and liver; this was accompanied
by a rapid turnover of S-adenosylmethionine in liver.
In the light of these findings, it seems possible to study, in
animals, the effect of L-methionine loading on the rate of methy-
lation of brain catechol amines. This would provide a direct
evidence whether L-methionine, when given in excess, causes an





During the past decade the transmethylation theory has aroused
general interest and some concomitant research has been carried out.
Workers have taken various methodological approaches with the common
aim of investigating transmethylation processes in schizophrenia.
Although findings have varied and have been generally inconsistent,
one definite and replicated observation has been the occurrence in
schizophrenia of a psychotic reaction with L-methionine. Claims
have also been made that this reaction may be followed in some by
an improvement in their mental state.
The dearth of studies in the literature suggested the relevance
of a systematic investigation into (i) the effects of excess L-
methionine on schizophrenics and their methylation reaction, and
(ii) the role of L-methionine, as a methyl donor, in the metabolism
of catecholamines in vivo.
AIMS
There were four main objectives in the study:
(a) A critical clinical evaluation of the effects of L-methionine
(without MAO-inhibitors) on schizophrenics. (This evaluation was
designed to observe closely the clinical symptomatology during L-
methionine feeding and thereby attempting to differentiate a "toxic
psychosis" from a schizophreniform psychosis.)
- 39 -
(b) To investigate the claims made by previous workers that
schizophrenics who manifested an L-methionine reaction showed
long term improvement of their symptoms.
(c) To conduct a longitudinal biochemical investigation into the
effect of L-methionine on the body methylating pool in schizo¬
phrenics. This was done by measuring urinary levels of the two
major O-methylated catabolites of noradrenaline, HMP& and VMA.
(d) To demonstrate, using in vivo animal experiments:
(i) that L-methionine donates methyl groups to the
O-methylated catabolites of dopamine and noradrenaline,
(ii) whether L-methionine loading increases the brain








(i) SELECTION OF PATIENTS
(i) PILOT STUDY: Five schizophrenic female patients were selected
from the hospital wards. They were all under the age of 65 years
and were not suffering from any other physical illness or psychiatric
illness. The diagnosis of schizophrenia was confirmed by two psy¬
chiatrists.
(ii) MAIN EXPERIMENT: Eleven chronic schizophrenic patients from
the hospital wards, without physical illness or other psychiatric
disorder, were included. Their ages ranged from 46-60 years. Five
of them were females with ages 46-60 years and six were males (ages
49-58 years). Leucotomized patients were excluded. For the pur¬
pose of (future) comparison their hospital course up to the time of
the study was carefully charted for specific phenomena, relapses,
remissions and any possible precipitating causes. Emphasis was
placed on the degree of fluctuation in their mental states during
the year before selection. Response to psychotropic drugs was taken
into account and the patients taking minimal dosages of phenothiazines
or butyrephenones were selected; seven patients were not receiving
any drugs at the time of study. Patients who were not mentally
deteriorated and exhibited subacute symptoms were preferred. The
diagnosis of schizophrenia was confirmed by two psychiatrists. After
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their selection and prior to the experiment, full explanations were
offered to patients and relatives; subjects were only included if
informed consent was obtained.
(2) DESIGN OF THE EXPERIMENT
The patients in the pilot experiment were studied in their
ward, while those in the main experiment were transferred in two
groups (5,6- the first group were females and the second males)
to a special six bedded research ward. Two qualified nursing
staff were with them at all times to ensure close supervision and
assessment of ward behaviour. The patients were encouraged to
participate in occupational therapy, some of which was carried out
in the ward. Entertainment was organized so that the patients
would not feel bored and isolated. They were allowed visitors
within the time limits allocated by the hospital authorities.
An environment resembling that of their own wards was sought in
order to minimize social and environmental factors that might modify
or alter their behaviour.
The patients (except the second group of six patients) received
a normal diet which was standardized, and were allowed fluids ad lib.
The second group received a special diet (vide infra).
The patients in the main experiment were transferred to the
research ward for a period of twelve weeks. The design of the
experiment, for both pilot and main experiment groups, was a double
blind cross over of L-methionine (without MAOl) against glycine as
follows:-
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1. 4 weeks' observation, of which the first 2 weeks
were used for acclimatization to the "new" ward
and the second 2 weeks for rating.
2. 2 weeks of amino acid A.
3. 2 weeks of observation.
4. 2 weeks of amino acid B.
5. 2 weeks of observation.
The rating psychiatrists were not aware of the sequence in
which the amino acids were given and, to protect against chance
identification, were not allowed to handle them or witness their
administration. Another psychiatrist, not involved with the
experiment in any capacity, held the key to the experiment. The
nursing staff, also blind, were only advised that a "reaction"
might follow the amino acid administration. All medications
were stopped six weeks prior to the administration of amino acid
"A". This drug free period provided the base line for clinical
and biochemical evaluation.
(3) ADMINISTRATION OF THE AMINO ACIDS
Both amino acids were given in the crystalline form dissolved
with milk and Ribena (a blackcurrant cordial). The milk minimized
any possible gastric irritation that might be caused by L-methionine
(Reading, W., unpublished observation) and the Ribena masked the odor
and taste of the amino acids. The L-isomers of both amino acids
were given and the crystalline form was preferred to the tablets or
capsules because of better absorption of the former. Both amino
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acids were administered at a daily dose of 20 gms. for the first
week and a daily dose of 10 gms. the second week. Each daily dose
was given in three divided portions.
(4) PSYCHIATRIC ASSESSMENT
(i) Physician's Rating: The patients were rated every other day by
two psychiatrists independently, using the "Lorr" rating scale (Lorr
et al, 1962), a standard validated instrument for assessing schizo¬
phrenia. However, additional information relating to toxic effects
not adequately covered on the scale were sought by an appropriate
daily clinical interview. During these interviews, special
attention was given to thought content, affect, orientation and
state of consciousness; physical signs like vestibular and cere¬
bellar functions were also assessed. The interviews and ratings
were carried out twice a week for one year follow-up period to assess
the patients' long term mental state.
(i*) Nurses' Rating: The patients were rated daily by the nursing
staff, using the Henry Phipps ward behaviour rating scale. In
addition, a detailed description of the patients' activities and
behaviour was charted daily. This included the patients' interests
and participation in the various ward activities, and was amplified
by reports about their progress in occupational therapy. Daily
meetings among the relevant clinical personnel ensured maximum useful
data about each patient.
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(B) BIOCHEMICAL
(l) HMPG (A-hydroxy, 3-methoxy phenyl glycol)
Since the discovery of HMP& as a major O-methylated metabolite
of NA in brain, several investigators attempted to measure it in
brain or urine. Because most of the HMP& found in human cerebro¬
spinal fluid (CSP) is conjugated in the sulphate form (Schanberg
et al, 1968a), hydrolysis of the conjugate is essential prior to
its determination. Two of the methods developed for its estimation
(Ruthven and Sandler, 1965; Nicholas et al, 1969) used column
chromatography (a cation exchange resin) to separate the HMPG- con¬
jugate, which was then hydrolysed, converted to vanillin and deter¬
mined by spectrophotometry. Recoveries were low and the sensitivity ■
of the method was limited by the interference of p-hydroxy phenolic
acids. Another method used column chromatography (an anion exchange
resin) to separate the hydrolysed HMPG-, which was estimated by gas
liquid chromatography (Wilk et al, 1967)• G-as chromatography was
also used by Sharman (1969) to identify hydrolysed HMPG, which was
separated by paper chromatography. Although the Wilk et al method
had reasonable recoveries (5O-6O per cent), and sensitivity and
specificity were good, it was time consuming, especially if the
method had to be used routinely.
It seemed mandatory to develop a relatively simple and short,
yet sensitive and specific, method for measuring HMP& in urine.
This was of interest since it had to be used for a longitudinal
study of the excretion of HMP& in the urine of patients; thus
performed every other day. Sensitivity and specificity were
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important because absolute levels of HMPG, as well as changes in
them, had to be assessed. The present method was developed to
measure urinary conjugated HMPG and it involved enzyme hydrolysis
of the HMPG- conjugate followed by separation of the hydrolysed HMPG
by column chromatography (an anion exchange resin) (Wilk et al,
1967). The isolated HMPG was then measured by spectrophoto fluoro-
metry using the ferric chloride oxidation reaction developed by
Sharman (1963) for the estimation of homovanillic acid (HVA).
(i) MATERIALS
HMPG was obtained from the Sigma London Chemical Company.
All chemicals were "Analar" BDH grade, or purer. The resin was
Bio-Rad AG1~X4» 200-400 mesh in the chloride form (Calbiochem).
"Helicase" enzyme (Industrie Biologique Francaise) which contained
1,000,000 units (Fishman) of B-glucuronidase and 15,000,000 units
(Roy) of sulphatase per gm. Glass distilled water was used through¬
out.
(ii) LABORATORY PROCEDURE
(a) ISOLATION OF HMPG
A 5 ml. aliquote of 24 hour urine was adjusted to pH 1 with
conc. HC1 and the organic acids present were extracted by shaking
the sample with 10 ml. of ethyl acetate for five minutes. After
centrifugation at 2,000 £ for five minutes, the organic phase was
removed and the extraction repeated twice with two further 10 ml.
quantities of ethyl acetate. The pooled ethyl acetate was saved
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for the determination of VMA. To 3 ml. of the aqueous phase, 0.3 ml.
of 1M sodium acetate "buffer pH5> was added, and the pH adjusted to
5 with IN NaOH (glass electrode). The sample was then incubated
in a water bath at 37°C for 24 hours with 27 mg. "Helicase" enzyme
(9 mg/ml. urine). In order to prevent any bacterial decomposition
occurring during hydrolysis, 2 drops of chloroform were added to
each tube prior to incubation.
The hydrolysed sample was centrifUged for five minutes at
3,500 £ and the supernatant removed. The residue was washed with
0.5 ml. distilled water and centrifuged. The combined supernatants
were adjusted to pH6 with IN NaOH and passed over a column (11 x
0.7 cm.) of Bio-Rad A&1-X4 resin. The resin was washed with 6 ml.
water and the HMP& eluted with 12 ml. water. The eluate was
saturated with sodium chloride and extracted twice with 12 ml.,
and a third time with 6 ml. of ethyl acetate. The combined ethyl
acetate extracts were blown down to damp dryness with nitrogen at
room temperature. The sides of the tube were washed with 3 ml.
water, 2 ml. of which were taken for the determination of HMPG- by
fluorometiy.
(b) FLU0R0METRIC METHOD
The reaction to produce the fluorophor from HMP& was carried
out in 15 ml. glass stoppered centrifuge tubes. Because of light
sensitivity (i) the reaction was carried out in a dim3y lit room,
and (ii) the test tubes were placed in racks covered with black
paper. The FeCl^ reagent was freshly prepared, prior to each batch
of estimations, by adding 0.1 ml. 2N NaOH to 5 ml. 1fo FeCl^ solution
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freshly diluted from 60f0 solution. The mixture was shaken thor¬
oughly. The precipitate of ferric hydroxide formed a dark brown
colloidal solution. To the 2 ml. sample containing HMPG was added
0.2 ml. of the ferric chloride reagent. The mixture was shaken
thoroughly and the reaction allowed to proceed for exactly two j
minutes. At the end of that period, the reaction was stopped
by the addition of 0.2 ml. 5N NaOH and the precipitate of ferric
hydroxide removed by centrifugation at 5»000 £ for one minute.
The supernatant was transferred to a 3 ml* cuvette and the fluore¬
scence estimated by activation scans on a Ferrand spectrophoto-
fluorometer. Fluorescence maxima occurred at 325 activation
and 430 nyu emission (uncorrected values) (Figure l).
A blank was prepared by taking 3 nil. distilled water through
the extraction and fluorometric procedures. Recoveries were
assessed by processing duplicate samples of urine, to one of which
was added 5 Aig HMP& after the first ethyl acetate extraction, but
prior to the treatment of the sample with "Helicase". Another
blank of 2 ml. water was used for the external standard (5 jug HMPG-
in 2 ml. water).
(iii) RESULTS
(a) THE SPECIFICITY OF ISOLATION PROCEDURE
The substances found in urine giving a positive reaction with
i : •)the ferric chloride oxidation include the 0-methylated catechols. '
! n N
Of these, 90 - (4) (mean - SD (no. of observations)) of the
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FIGURE 1
FLUORESCENCE MAXIMA - ASSESSED BY
ACTIVATION AND FLUORESCENCE SCANS
Figure shows that presumed HlvIPG
in sample and authentic HMPG- show
maximum fluorescence at identical
activation and fluorescence wave¬
lengths .
FIGURE 2
EFFECT OF REACTION TIME
ON FLUORESCENCE INTENSITY
Figure shows that maximum fluo¬
rescence is at 60 seconds. The
graph is flatter at >60 <140
seconds and indicates that within
this segment fluorescence inten¬











LINEARITY OF HMPG FLUORESCENCE
Figure shows that fluorescence
intensity of HMPG is linear
with concentrations of 50 ng -
10 yug.
HMPG in 2 ml H,0
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phenylacetic (HVA) are removed at pHl in the initial ethyl acetate
extraction. The remainder adsorbs onto the resin and is not eluted
in the fraction containing HMPG. Of the basic compounds, metane-
phrine (m) , normetanephrine (nm) and 3-methoxytyramine (MTYR),
95 - 4$ (6) (mean £ SD (no. of observations)) pass through the
column in the effluent and first wash. The remainder stays in
the aqueous phase of the second ethyl acetate extraction (pH5-6)
to remove HMPG.
The alcohol metabolite of dopamine 4-hydroxy-3-methoxy
phenylethanol (HMPT) could still be a contaminant; however,
chromatography, vide infra, failed to show the presence of this
compound.
The method is essentially a determination of the conjugated
HMPG in urine. The "free" HMPG was found to be 63-5% removed
by the ethyl acetate extraction at pHl (for the removal of acids).
(b) FLTJOROMETRIC METHOD
The time needed for the ferric chloride reaction to give
maximum fluorescence with HMPG was found to be 60 seconds (Figure 2).
However, a very minor variation in time produced a sharp change in
fluorescence intensity, which could have affected reproducibility.
For this reason, 120 seconds was found to be a convenient and optimal
time for giving reproducible results; HMPG fluorescence showed a
linear curve with concentrations of 100 njug - 10 /ig in 2 ml. of
distilled water (Figure 3)•
Exposure to light caused a deterioration in fluorescence
intensity which reverted upon restoring the sample in the dark
for one minute.
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The reaction was inhibited by ascorbic acid, acetate and
phosphate ions; salt quenched the fluorescence.
The limit of sensitivity in the fluorometric procedure, taken
as being amount of HMPG giving a fluorescence intensity of twice
the blank, was of the order of 50 nyig. However, using urine samples
the limit of detection was found to be 100 mpg/ml.
(c) CHROMATOGRAPHY OF PRESUMED HMPG-
In order to validate the identity of the compound in the final
extract as HMPG, qualitative thin layer chromatography was performed.
The final ethyl acetate extract of the column eluate was blown down
to dryness in a stream of nitrogen. The residue was dissolved in
0.2 ml. methanol and applied under a stream of nitrogen to a thin
layer plate of cellulose.* Authentic HMPG carrier was added to a
urine sample which was processed through the method. The ethyl
acetate residue was dissolved in 0.2 ml. methanol which was applied
together with authentic HMPG, VMA, MM and M, HVA and HMPT markers
to each plate alongside the sample. The plates were developed in
one of the following solvent systems:
1. Isobutyl methyl ketone; 4?o formic acid (10:1 v/v) -
2 phase (Figure 4).
2. Butanol:ethanol:water (4:1:1 v/v) - single phase
(Figure 4a).
3. Butanol:acetic acid:water (4:1:1 v/v) - single phase
(Figure 4b).
* TL cellulose precoated plate 20 x 10 cm., 0.1 mm. layer thickness
(without fluorescence indicator), E. Merck, A.G. Darmstadt.
FIGURE4FIGUREaFIGURE4b ASCENDINGTHILAYERCHROMATOGRAPHYF PRESUMEDHMPGISOLATEDTHROUGHHETHOD Cellulosethinlayerplates. Spotsvisualizedbysprayingwithdiazotisedparanitroaniline,thenetha olicINNaOH. SpotsinFigures4andbrerespottedwi hchinai kriortophotographyduetfadingft color. MOPEG=HMP
- 52 -
Two phase solvent system: The mixture was shaken and allowed to
settle; since the solvents are immiscible in each other, two phases
were formed. Most of the organic phase was poured into the chroma¬
tography tank and the remainder was used to develop the plate. The
aqueous phase was poured into a beaker placed at the bottom of the
tank and allowed to flow up a strip of chromatography paper suspended
in the tank and its lower edge dipped in the beaker; thus the two
phases were kept separate from each other in the tank.
Chromatography technique: The plate was placed in a sealed chromato¬
graphy tank containing the solvent system and allowed to equilibrate
with the solvent's vapours for three hours. It was then developed
with an ascending flow until the solvent front reached its upper edge.
The plate was removed from the tank, left to dry and sprayed with
paranitroaniline (saturated solution in 0.5N HCl) : 10% sodium nitrite
in a ratio of 10:1. After drying it was resprayed with IN NaOH in
50% ethanol. The Rf values of the visualised spots were measured
(Table l).
TABLE 1
THIN LAYER CHROMATOGRAPHY OF PRESUMED HMPG IN SAMPLE
_ n , _ . HMPG- VM HVA HMPT M NMSolvent System s* [Mkr.** S|Mkr. s|Mkr. SjlkrT S|Mkr. S[Mkr.
aC±d 0.29+ 0.29 - 0.48 - 0.84 - 0.81 - 0.00 - 0.00
Butanol:ethanol: 0>6l _ Q ^ _____ 0.32 - 0.29
water 14:1:1;
Butanol:acetic
acid:water O.58 O.59 - 0.66 ----- 0.50 - 0.43
(4:1:1)
(+Rf values: as identified by colour spraying;
S* - sample; Mkr.** - authentic marker)
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Comment; In the three solvent systems only one spot with Rf values
similar to authentic HMPG was detected.
(d) RECOVERIES THROUGH THE METHOD
Recoveries of 5 MS HMPG were assessed at the two separative
stages of the procedure: (l) column chromatography, (2) solvent
extraction.
d.l. COLUMN RECOVERIES: The resin only adsorbs the HMPG- loosely
(Wilk et al, 1967), retarding its flow through the column. It was
found that the volume of the sample:wash:eluate had to be maintained
at a constant ratio of 1:2:4, The size of column in relationship
to these washes reduced the interference of urinary pigment (which
is adsorbed to the column) to a minimum. Thus the optimal column
height and diameter for 1:2:3 or 4:5 ml, sample volume were 4 x 0.7:
5 x 0.7: 11 x 0.7 and 7 x 1.2 cm. respectively. In this method
quenching from this source amounts to an 8 - 2$ (4) (mean - SD (no.
of observations)) decrease in fluorescence intensity. The assess¬
ment was done by processing a urine sample through the method and
dividing the residue wash (from the eluate ethyl acetate extract)
into two equal parts. After adding to one of them 5 Mg of authentic
HMPG, their fluorescence intensity was measured. The difference
between the two fluorescence intensities was compared with the
fluorescences of 5 Mg authentic HMPG in distilled water. The
mean column recovery was 84 - (9) (mean * SD (no. of observations)'
d.2. ETHYL ACETATE EXTRACTION OF COLUMN ELUATE
Effect of salt saturation: Pour samples (in duplicate) of 5 Mg HMPG
in 12 ml. water were taken; two of them were salt saturated. They
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were extracted three times with ethyl acetate (12, 12, 6 ml.).
Each pooled ethyl acetate extract was blown down to damp dryness
with nitrogen. Each residue was dissolved in 3 ml. water, 2 ml.
of which was taken for the fluorometric procedure. Fluorescence
intensity of HMPG- in the four samples were then compared with each
other.
Effect of pH: The following samples (in duplicate) of 5 6 HMPG-









They were then extracted three times with ethyl acetate (3, 3,
1.5 ml.). Two ml. of each aqueous phase was taken for assessing
the fluorescence intensity of HMPG.
Extraction recovery; Three samples (in duplicate) of 5 Aig HMPG in
12 ml. water (pH6-7) were salt saturated and extracted three times
with ethyl acetate (12, 12, 6). Each combined ethyl acetate extract
was blown down to damp dryness with nitrogen. Each residue was
dissolved in 3 ml. water, 2 ml. of which was taken for the fluo¬
rescence procedure. The intensity of HMPG fluorescence in each
sample (corrected to 3 ml.) was then compared with fluorescence
intensity of 5 HMPG in 2 ml. water.
Salt saturation improved the extraction of HMPG into the organic
phase by 12 £ kf° (4) (mean £ SD (no. of observations)). The HMPG










into the organic phase decreased by 10 - 3$ (0 (mean - SD (no. of
observations)). Under the conditions of the method, the recovery
of this step was found to be 80 - 7$ (6) (mean ^ SD (no. of obser¬
vations) ).
d.3. HYDROLYSIS; The efficiency of the enzyme hydrolysis, under
the same condition used in the procedure, was assessed by the use
of Radio Isotopes.
d.3.(i) Materials and Methods
Four male Wistar albino rats weighing 150 gm. each were
anaesthetized with ether and each injected intraventricularly
(according to the method of Noble et al, 1967) (Appendix II) with
10 juCi of DL Normetanephrine* 7-H"^ (3.5Ci/mMol.) in 20/al of Merles
solution^. The rats were killed after one hour by cervical
fracture, then decapitated. The brains were removed and homo¬
genized, in all glass homogenizers, with chilled 0.4N PCA^ (O.O^S
ascorbic acid and 0.1$ EDTA^b using 4 ml/gm. brain.
The homogenates were spun in a refrigerated centrifuge (4°C)
for fifteen minutes at 20,000 £. At this stage 0.2 ml. aliquotes
of the supernatants were dissolved in 4 ml. ethanol:methanol (3:1)
and 10 ml. of Toluene (0.426$ PPO^, 0.011$ POPOP^) scintillator
and counted by liquid scintillation, using a Packard (Tri-Carb-Model
3003) liquid scintillation spectrometer to assess the success of the
intraventricular injections. Supernatants with ) 15,000 DPM^Vml.
were pooled and the mixture, which had a pH of 1, was extracted with
double volume of ethyl acetate** by shaking for five minutes and
* DL-Normetanephrine 7-H^ (lmCi in 0.078 mg.), New England Nuclear.
** All reagents used were 'Analar grade* BDH.
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centrifuging at 3,000 £ for five minutes. After removing the ethyl
acetate, the extraction was repeated twice with two further double
volumes of ethyl acetate.
90 - 5$> of the phenolic acids (VMA and HVA) and 65 - 5$ of the
free HMP& were extracted into the organic phase.
The aqueous phase was then adjusted to pH4 (glass electrode)
with 5N and IN KOH and cooled at 4°C for ten minutes to precipitate
the potassium perchlorate. The sample was centrifuged for three
minutes at 4,000 £ and the supernatant was decanted and adjusted to
pH 7.5 (glass electrode) with IN and 0,1N KOH. Ten ml. of the
solution were passed over a 10 x 0.7 cm. O.D. column of amberlite
C&50 resin, 100-200 mesh (NH+^ form pH 7.5)•
The H^-Normetanephrine together with the other 0-methylated
amines and 25 - 4$ (4) (mean - SD (no. of observations)) of the free
alcohols were adsorbed on to the column. The effluent containing
3
the H -HMP& sulphate conjugate was collected and concentrated by
slow evaporation at 37°C under vacuum.
Abbreviations used:
(l) Merles Solution
NaCl - 8.98 gm.
KC1 - 0.25 gm.
CaCl? - 0.14 gm.
MgClp - 0.11 gm.
NaH2P0, - 0.07 8
Urea -0.13 gm.









Ethylene Diamine Tetra acetic acid
2,5-Diphenyloxazol
1,4-D1 (2-(5-phenyloxazolyl)) - benzene
Disintegrations per minute
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Preparation of the resin: The resin used was prepared by washing
three times with IK HC1, stirring for half an hour each time. Then
it was washed with distilled water until it was free of chloride
ions, as tested by the addition Of AgN03. After that it was
washed twice with 3K NH^OH by stirring for half an hour each time.
The NH^OH was removed by washing with distilled water until the pH
fell below 9. The water was decanted and the resin was washed
with 0.2M ammonium acetate pH 7.5 until the pH was 7.5-8. The pH
was finally adjusted to 7.5 (glass electrode) with glacial acetic
acid. At this stage the resin was left overnight and its pH was
rechecked and readjusted to 7.5 if needed. Lastly, the ammonium
acetate was decanted and the resin was stored in 0.2M ammonium
acetate (pH 7.5) ready for use.
d.3.(ii) Purity of presumed H^-HMPG- Sulphate Conjugate
Aliquotes of the concentrate were tested for purity of the
conjugate by (i) high voltage electrophoresis, and (ii) thin layer
chromatography.
3
In order to test whether H -Normetanephrine was metabolized to
7. Tl
H -HMPG after its injection, C -Noradrenaline was injected into
another couple of rats and the C^-HMPG- conjugate was separated.
The two labelled conjugates were compared for authenticity and
purity.
Preparation of the C^-HMPC Sulphate Conjugate: Two male Wistar
albino rats weighing 150 gm. each were anaesthetized with ether and
injected intraventricularly with DL-Noradrenaline* (Carbinol C )
* DL-Noradrenaline (Carbinol C1^) DL-bitartrate - The Radiochemical
Centre, Amersham.
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(25 mCi/mMol.) using 0.5 /iCi in 20 pi of Merles solution per rat.
The rats were killed after one hour by cervical fracture, decapitated
and their brains removed. The procedure of separating the C^-HMPG
3
conjugate was the same as that used in the separation of the H -HMFG
conjugate. Since Noradrenaline was used, the effluent from the
C&50 column contained a mixture of C^-HMPG- and DEPO** sulphate
conjugates. The effluent from the column was also concentrated
under vacuum at 37°C.
High Voltage Electrophoresis: Two aliquotes, 0.2 ml. each, were
taken. One consisted of 0.2 ml. of the concentrate containing
3
H -HMP& conjugate and the other a mixture of 0.1 ml. of the concen-
3
trate containing H -HMP& conjugate and 0.1 ml. of the concentrated
solution containing the C^-HMPG- and EHPG conjugates. Each aliquote
was applied under a stream of nitrogen onto a strip of 3 mm. Whatman
chromatography paper, 47 cm, long and 4 cm. wide. The origins were
7 cm, from the end of the strips on the cathode (negative) side, and
the application of each aliquote was confined to an area of 1 x 4 cm.
The strips were electrophoresed at 5»000 volts for 60 minutes
in a 6.2M sodium borate buffer (pH 10). They were then dried with
nitrogen, cut into 1x4 cm. strips and counted by liquid scintil¬
lation using 4 ml. of Toluene (PP0, P0P0P) scintillator per strip.
Blanks were prepared by cutting 1x4 cm. strips from a 47 x 4 cm.
strip of 3 mm. Whatman chromatography paper which was electrophoresed
** DHP& 3,4-dihydroxyphenylglycol.
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in the same buffer system. Each blank strip was immersed in 4 ml.
of the same scintillator used for the sample strips. Markers of
authentic Wl, HMPG, DM, M and NA* were applied on a separate strip
and electrophoresed together with the sample strips. After drying
the marker strip was sprayed with a mixture of paranitroaniline and
sodium nitrite 10%, allowed to dry and resprayed with ethanolic
IN Na OH. The marker spots were visualized and their distances
from the origin were measured.
Results: All samples were kept in the dark for sufficient time to
reduce chemiluminescence and temperature adapted before counting,
and read against counts obtained from the blank samples. Cal¬
culations were done after correction for quenching by the channel —
ratio method. This method was also used for dual counting (C^
and H5).
At pH 10, HMFG and EHPG conjugates are dissociated since both
are acidic by virtue of the strong anionic sulphate (304"") group on
the phenolic ring. The sulphate group substitutes one of the
phenolic hydroxyl (OH) groups of DHPG and the only hydroxyl group
of HMPG (since the second one is already 0-methylated). By this
DHPG possesses two anionic groups, the sulphate and the hydroxyl,
while HMPG has only one, the sulphate group. For this reason,
the DHPG conjugate is a stronger acid and thus travelled further
than the HMPG conjugate from the origin towards the anode (positive).




The basic compounds (the O-methylated amines) are not disso¬
ciated at that pH and, therefore, remained at the origin. At that
pH the phenolic acids (HVA and VMA), being stronger acids, travelled
further than both conjugates towards the anode. The free alcohols
(HMPG and HMPT*) are only weakly acidic by virtue of their phenolic
hydroxyl (0H)~ group on the 4 position; they travelled only a short
distance from the origin towards the anode.
The sequence in which these metabolites travelled from the
origin to the anode was: basic compounds (at the origin); free
alcohols; HMPG and DHPG conjugates (partially separated) and
phenolic acids (nearest the end of the strip on the anode side).
3
The strips with the H -HMPG- conjugate showed one distinctive
peak 16 cm. from the origin (Figure 5) which was assumed to be that
of the HMPG conjugate. On the other hand, the strip with mixed
3 14 14
H and C -HMPG conjugates showed two overlapping peaks of C and
3 14
H radioactivity 17 cm. from the origin and another peak of C
activity 21 cm. from the origin and only partially separated from
the combined peak. This second peak was assumed to be due to the
DHPG conjugate (Figure 5a). There were no other peaks of radio¬
activity along the strips, especially at distances corresponding to
NM, HA, HMPG and VMA.
Thin Layer Chromatography: Two aliquotes, 0.2 ml. each, from the
concentrate of H^-HMPG conjugate and one 0.2 ml. aliquote from the
concentrate containing C^-HMPG, DHPG conjugates were taken. Each
aliquote was made up to 1 ml, with distilled water and adjusted to

























PURITY OF PRESUMED HMPG CONJUGATE
(High voltage electrophoresis)
Figure shows that there is one peak of H -
radioactivity 16-17 from the origin, presumed




























PURITY OF PRESUMED HMPG CONJUGATE
(High voltage electrophoresis)
3 1L.
Figure shows two overlapping peaks of H anfl C - - radio¬
activity 17 cm. from the origin, partially separated
from another peak of activity. The former peak
is presumed to he HMPG conjugate and the latter DHPG
conjugate.
M 63 **
pH 5 (glass electrode) with 0.1 ml. IM sodium acetate buffer (pH 5)
and 0.5N HC1. To one of the samples containing the H^-HMPG conju¬
gate and the sample containing the C^-HMPG, DHP& conjugates,
Helicase enzyme (powder form) was added using 9 mgm. of enzyme
powder per sample. The three samples were then incubated in a
water bath at 37°C for 24 hours. At the end of that period the
samples were centrifuged for 5 minutes at 3»500 £ and the super-
natants decanted. The supernatant from each sample was reduced
to - 0.4 ml. at 37°C, under vacuum.
From each reduced sample 0.1 ml. was applied, under a stream
of nitrogen, onto a cellulose thin layer plate (20 x 10 cm.). The
three samples were applied onto three different 2 cm. strips, each
of which was delineated on a separate cellulose plate (Appendix
Ilia). The strips were delineated all along the length of the
plates. On each plate, alongside the strip, markers of authentic
HMPG and VMA were applied and onto the plate where the C^-HMPG,
DHPG sample was applied, authentic DHP& marker was also used.
The plates were developed in Isobutyl methyl ketone: 4$ formic
acid (10:1V/vj 2 phase) using the ascending chromatography
technique. They were then removed from the tank and dried with
nitrogenj the sample strip from each plate was delineated into
1x2 cm. portions from the origin to the solvent front. The
portions were scraped off the glass plate and suspended into
separate scintillation vials containing a mixture of Thixotropic
gel* and 10 ml. of Toluene Triton X scintillator (0.4$ FP0, 0.01$
* Thixotropic gel Cab-o-cil (finely divided silica)
Reg. Trade Mark of T.M. Godfrey L. Cabot Inc.
— 6l+ -
POPOP, 50?o Triton X 100*). The vials were then counted by liquid
scintillation. To visualize the marker spots, the unscraped part
of each plate was sprayed with a mixture of paranitroaniline and
lOfo sodium nitrite, allowed to dry and resprayed with ethanolic IN
NaOH. The Rf values of both HMPG and DHPG markers were calculated.
Results
H^-HMPG Conjugate: The hydrolysed sample showed a major peak of
radioactivity at an Rf value identical to that of authentic HMPG.
A minor peak at the origin represented unhydrolysed (conjugated)
HMPG which, in the solvent system used, does not move from the origin
(Figure 6). The unhydrolysed sample showed a single peak of radio¬
activity at the origin. No other peaks of radioactivity could be
detected (Figure 6).
C^-HMFG, DHPG- Conjugates: There were two major peaks of radio¬
activity corresponding to Rf values of authentic HMPG and DHPG. A
minor peak was detected at the origin which probably represented
unhydrolysed (conjugates) HMPG and DHPG (Figure 6a).
d.3»(iii) Assessment of Percentage Enzyme Hydrolysis in Urine
3
Hydrolysis Procedure: The remaining concentrated solution of H -HMPG
conjugate was further reduced in volume to # 0.6 ml. by slow evapor¬
ation at 37°C under vacuum. It was then divided into three equal
samples, 0.2 ml. each. To each of the samples 0.8 ml. of unhydro¬
lysed urine and 0.1 ml. of IM sodium acetate buffer (pH 5) were added.
* Triton X 100 an alkyl phenoxy polyethoxyethanol.
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PURITY OF PRESUMED CONJUGATE
(Thin layer chromatography)
Figure 6 shows that after enzyme hydrolysis the major
peak of radioactivity has an Rf value identical
to that of authentic HMPG. The unhydrolysed
sample shows one peak at the origin assumed to
he HMPG conjugate.
Figure 6a shows that after enzyme hydrolysis there are
two peaks of radioactivity at Rf values iden¬
tical to authentic HMPG and DHPG. A minor
peak at the origin probably represents combined
HMPG and DHP& conjugates.
Marker spots were visualized by spraying with diazotised
paranitroaniline, then ethanolic IN NaOH.
- 66 -
Nine mgm. of Helicase enzyme (in the powder form) were added to two
of the three samples. At that stage 10 jag of authentic HMPG were
added to each sample to protect against degradation of the free HMPG.
All samples were adjusted to pH 5 (glass electrode) with IN and 0.1 N
HC1, two drops of chloroform added to each, and were incubated in a
water bath at 37°C for 24 hours.
At the end of that period, the samples were centrifuged for
3 minutes at 4,000 £ and the supernatants decanted. Each precipi¬
tate was then washed with 0.2 ml. of distilled water, centrifuged
and the washing added to the respective supernatant. The combined
supernatants from each sample were reduced in volume to & 0.7 - 0,8
ml. by slow evaporation under vacuum at 37°C.
Separative Procedures
High Voltage Electrophoresis: An 0.2 ml. aliquote (^ 25,000 DPM)
from each concentrated supernatant was applied under a stream of
nitrogen onto a 47 x 4 cm. strip of 3 mm. Whatman chromatography
paper; the origin was 7 cm. from the end of the strip on the cathode
side. The strips were electrophoresed at 5,000 volts for 90 minutes
in a buffer system (pH 5.3) of pyridine 25 ml. and acetic acid
(glacial) 10 ml. made up to 2.5 It. with distilled water. Markers
of authentic HMPG and VMA were applied on a separate strip which was
electrophoresed with the sample strips.
Each sample strip was then dried with nitrogen and cut into
1x4 cm. strips, each of which was immersed in 4 ml. of Toluene
(PP0, P0P0P) scintillator. They were counted by liquid scintil¬
lation against 1x4 cm. blank strips cut from a strip which was
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electrophoresed in the same buffer. The marker strip was sprayed
with a mixture of paranitroaniline and IQffo sodium nitrite, and the
spots visualized by respraying with ethanolic IN EaOH.
Results: Direct counting of Tritium radioactivity on paper showed
that, owing to self-adsorption of the low energy Beta particles and
the opacity to light, the efficiency of counting by this method was
only 20 per cent.
At an acidic pH of 5.3» basic compounds, like the 0-methylated
amines are dissociated and travel towards the cathode (negative)
side. On the other hand, acidic compounds like the phenolic acids,
free and conjugated alcohols are not readily dissociated and, there¬
fore, travel a shorter distance towards the anode (positive) than in
an alkaline pH. Depending on their acidic strengths they vary in
the degree of dissociation. For that reason the free alcohol (HMPG-)
with the weakest acidic properties is not dissociated and so remained
at the origin. Both the conjugated alcohol (HMP&. S04) and the
phenolic acid (VM) travelled towards the anode but, since VM is
the stronger acid, it travelled further towards the anode than HMP&.
S04 did; thus a separation of 9-10 cm. was obtained (Figure 7).
The duplicate strips on which the hydrolysed aliquotes were
applied showed major peaks of radioactivity at the origin and other
minor peaks 16-17 cm. from the origin (Figure 7)• On the other hand,
the strip on which the control (unhydrolysed) aliquote was applied
showed one peak of radioactivity 17 cm. from the origin (Figure 7)•
Thin Layer Chromatography: Single strips, 2 cm. wide, were delineated


































ASSESSMENT OF PERCENTAGE HYDROLYSIS IN
URINE BY HIGH VOLTAGE ELECTROPHORESIS
Figure shows that in the duplicate hydrolysed samples
the major radioactive peak representing HMPG is at the
origin and another minor peak 17 cm. from the origin.
In the unhydrolysed there is one peak 17 cm. from the
origin, probably representing HMPG conjugate.
Marker spots were visualized by spraying with diazotised
paranitroaniline, then ethanolic IN NaOH.
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An 0.1 ml. aliquote (- 12,000 DPl) from each concentrated supernatant
was applied separately onto each strip. Authentic markers of HMPG
were applied onto the plates alongside the strips. The plates were
chromatogramed in Isohutyl methyl ketone:^ formic acid (10:1 V/v)>
using the ascending technique. They were then removed from the
tank and dried with nitrogen. The sample strip from each plate was
delineated, from origin to solvent front, into 1x2 cm. portions.
Each portion was separately scraped off the glass plate, suspended
in Thixotropic gel and 10 ml. of Toluene Triton X (PP0, P0P0P)
scintillator and counted by liquid scintillation against blanks
obtained from scrapings off a plate developed in the same solvent
system. The unscraped part of each plate was sprayed with a mixture
of paranitroaniline and sodium nitrite, left to dry and resprayed
with ethanolic IN NaOH. The Rf values of the visualized HMPG marker
spots were calculated.
Results: The duplicate hydrolysed samples showed major peaks of
radioactivity at Rf values identical to those of authentic HMPG-
(Figure 8). Minor peaks at the origin were due to the unhydrolysed
(conjugated) HMP& which, in the solvent system used, remains at the
origin. The control, unhydrolysed sample showed one peak of radio¬
activity at the origin (Figure 8a).
Column Chromatography; Two 0.2 ml. aliquotes (^ 25,000 DPM) were
taken from each of the three concentrated supernatants. One of
the two aliquotes from each supernatant was dissolved in 10 ml. of
Toluene Triton X (PP0, P0P0P) scintillator and counted by liquid
scintillation, thus giving the total radioactivity of both free and
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ASSESSMENT OF PERCENTAGE HYDROLYSIS
IN URINE BY THIN LAYER CHROMATOGRAPHY
Figure 8 shows that the duplicate hydrolysed samples
have a major peak of radioactivity at an Rf
value identical to authentic HMPG.
Figure 8a shows that the unhydrolysed sample has only
one peak at the origin, presumed to he HMPG
conjugate, which does not travel in the solvent
system used.
Marker spots were visualized hy spraying with diazotised
paranitroaniline, then ethanolic IN NaOH.
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conjugated HMPG- in the aliquote of each concentrated supernatant.
Each of the other 0.2 ml. aliquotes was made up to 1 ml. with
distilled water and passed over a column (1+ x 0.7 cm. 0D) of
untreated Bio-Rad AGI-X4 resin. Each column was then washed
with 2 ml. of distilled water and the HMPG was eluted off the
column with 6 ml. of distilled water. A 1 ml. aliquote from
each eluate was dissolved in 10 ml. of Toluene Triton X (PPO,
P0P0P) scintillator and counted by liquid scintillation.
Results; The HMPG conjugate adsorbs onto the column and partially
elutes off with a strong acid (i.e. 6n acetic acid) and not water
which elutes off 80 per cent of the free HMPG.
The 1 ml. aliquote from the eluates of the duplicate hydrolysed
samples showed high levels of radioactivity while that from the
eluate of the control (unhydrolysed) sample had a blank (background)
level of radioactivity.
Results of Percentage Hydrolysis
All counts of radioactivity were corrected for quenching by the
channel ratio method, thus values were expressed as DPM. Assessment
of percentage hydrolysis, using high voltage electrophoresis and thin
layer chromatography, was obtained by adding the total radioactivity
representing both free and conjugated HMP& and calculating the per¬
centage of each from values obtained from the individual peaks
separately (hydrolysed HMP& and conjugated HMP&). Percentage hydro¬
lysis, using column chromatography, was calculated from the ratio of;
Radioactivity (DPM) in the eluate from hydrolysed sample
Total radioactivity (DPM) in 0.2 ml. aliquote of supernatant.
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TABLE 2
RESULTS OF PERCEHTA&E HYDROLYSIS
EXP HVE TLC c.c.
Si* S2** SI S2 SI S2
1 78 80 75 76 80 82
2 82 81 80 77 & CO0
HVE - High voltage electrophoresis
TLC - Thin layer chromatography
C.C.- Column chromatography
Comment: Prom the above figures the efficiency of enzymatic
hydrolysis appeared to be fairly uniform with a mean of:
79.58 £ 2»(Sfo (12) (mean £ SD (no. of observations)).
(e) TOTAL RECOVERY
This was assessed by processing, in triplicate, eight different
samples of urine, to each of which had been added 5/ig HMP& prior to
the enzyme hydrolysis step. The recoveries from each sample are
given in Table 5»
♦ SI - Sample 1
** S2 - Sample 2
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TABLE 3
TOTAL RECOVERY OF HMPG THROUGH THE METHOD
Urine Sample No. % Recovery of HMPG
1 55 £ 2 (3)*
2 57-3 (3)
3 59 £ 3 (3)
4 61 £ 3 (3)
5 60 £ 3 (3)
6 56 £ 4 (3)
7 63 £ 2 (3)
8 £ 1+ ro V>l
* Mean value £ SD (no. of estimates)
Total recovery = 59 - 4$ (24) (mean £ SD (no. of observations))
(f) LEVELS OF HMPG IN URINE OF NORMALS
Urine was collected over a 24 hour period from five male and
seven female subjects (age range 25-50 years) who were on a diet
which reduced the intake of sympathomimetic compounds, amines and
their precursors. The urine was preserved with 10 ml. 6n hc1 at
4°C until assay, which was carried out within 24 hours after the
collection. The results for the concentration of hmp& in these
samples are shown in Table 4.
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TABLE 4
HMPG- EXCRETION IN NORMALS









Mean £male and female) 756,29 - 459.46 (12)
Mean - SD (no. of observations)
The t-te3t for uncorrelated means (G-uilford, 1956) showed that
t (d.f. 10) = 1.078 (t > 2.228, significant at 0.05 level).
The HMPG- values (756.29 £ 459.46 jug/24 hours) found in normals
using this method fall within the range published by Wilk et al
(1967) (0.25 - 1.49 ;ug/mgm. creatinine - mean 0.86 t 0.5 SD) and
Maas et al (1968) (1660 - 892>ug/24 hours). No statistically sig¬
nificant sex difference was found (M - 923.86 £ 318.96 SD; P -
636.61 £ 528.3 SD) although (i) the number of subjects was small,
and (ii) the values fall over a wide range. This is important
because Maas et al (1968) have reported such a difference when HMPG-
values were expressed as ;ug/24 hours.
(2) VMA (3-wethoay, 4*-hydroxy mandelic acid)
The 24 hour urinary VMA levels were determined using the
method of Pisano et al (1962). The pooled ethyl acetate con¬
taining VMA (extracted from 5 urine aLiquote, vide supra -
HMPG- method) was extracted with KgCO, buffer; VIA in the buffer
layer was then converted to vanillin. The latter was extracted
into Toluene and back extracted into YL^CQy its concentrations
were measured by spectrophotometry. The sensitivity of the
method was adequate for assessing any change in urinary levels
of VMA. Levels of VMA in the aliquotes* extracts were within
the sensitivity range of the method. Recoveries of VMA by the
method were uniform with a mean value of 84 - 8fo (36) (mean i SD
(no. of observations)).
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APPLICATION 0 F B I 0 C H EMICAL MET HODS
(A) CHRONIC SCHIZOPHRENIC PATIENTS (RECEIVING L-METHIONINE)
(1) SELECTION OF PATIENTS; Six male patients, comprising the third
group transferred to the metabolic ward, were studied.
(2) URINE COLLECTION: Urine was collected from each patient for
24 hours, every other day throughout the twelve week period. The
urine was put in bottles containing 10 ml. (6n) HC1 and stored at
4°C. The collection was tinder close surveillance by the nursing
staff and during the 24 hours of collection the patients were con¬
fined to the ward. The door of the metabolic toilet was provided
with a warning bell so as to ensure complete collection.
(3) DIET: Throughout the twelve week period the six patients
received a standardized diet which was reduced in items containing
"sympathomimetic compounds" (i.e. Tyramine) and amines or their
precursors. Items excluded were: yoghurt, fava beans, cheese,
wine, citrus fruits and juices, cola beverages, bananas, chocolate
and cocoa, coffee, tea and vanilla. Fluid intake was not restricted
but a fluid balance sheet (intake - output) was charted for each
patient throughout the twelve week interval.
(4) ESTIMATION OF VMA AND HMP&: All urine samples were analysed
fresh after collection. The volume of each sample was measured
and an aliquote of 5 ml* was taken. The 24 hour urinary levels
were calculated from the values of each in the aliquote and the
24 hour urine volume. The values were expressed as/ig/24 hours.
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(E) ACUTE SCHIZOPHRENIC PATIENTS
(1) SELECTION OF PATIENTS: The criteria for selection were age,
sex and treatment. Five acute male admissions, ages ranging
between 25-60 years, were included. None had received any drugs
(phenothiazines, butyrephenones or barbiturates) for at least six
weeks prior to admission. As each patient was admitted he was
transferred to the metabolic ward for a "drug free" period of
three days. The diagnosis of acute or subacute schizophrenia
was made by the admitting psychiatrist and confirmed by the inves¬
tigator (F.A.). All the patients were free from physioal or other
psychiatric illnesses.
(2) urine collection: During the period of stay in the metabolic
unit, three 24 hour urine collections were taken under the same
close surveillance obtaining for the schizophrenic patients. The
urine was collected in plastic bottles containing 10 ml. (6n) hc1
and stored at -20°c until the last sample was collected three days
later. All three samples were assayed at the same time.
(3) DIET: An identical diet as was used for the chronic schizo¬
phrenics was given to the patients during urine collection and for
one day prior.
(4) ESTIMATION OF HMPG: The three urine samples were defrosted
and their volumes measured. A 5 ml. aliquote was taken from each




(1) SELECTION OF SUBJECTS (7 females and 5 males): Twelve normal
volunteers, free from mental and/or physioal ailments, ages ranging
between 25-50 years, were selected.
(2) urine collection: Three 24 hour samples of urine were collec¬
ted from each subject on alternate days and stored in plastic
bottles with 10 ml. (6n) hc1 at 4°c until assay. The volunteers
were informed about the importance of complete collection.
(3) DIET: The same diet used for the schizophrenic population was
given to the controls for a period of eight days, including a 24
hour interval prior to urine collection,
(4) ESTIMATION OF HMP&: The 24 hour urine samples were measured
and assayed for HMPG in one batch within 24 hours of collection.
An aliquote of 5 ml« was taken from each sample for the determin¬
ation of HMPG; the values were expressed as /ig/24 hours. The
HMP& results from both groups were used to assess the reliability
of the HMPG method, vide supra, and the HMPG levels from the male
group were used for comparison with the HMPG levels from the chronic




Before the start of the experiment, two out of the five
patients in the pilot study and seven out of the eleven patients
in the main experiment were receiving psychotropic drugs (i.e.
phenothiazines and butyrephenones). None of these nine patients
showed any worsening of their schizophrenic symptoms when these
were stopped. On the contrary, one patient (Appendix I (b) l)
showed a minor improvement in her mental state.
(l) PILOT STUDY; Of the five patients, two showed a reaction to
L-methionine, becoming deluded and exhibiting thought content and
form disorders (Appendix I (a) 1,2). The other three did not
show any changes in their clinical states on either L-methionine
or glycine (Appendix I (a) 3,4,5). In neither group was there any
clouding of consciousness or signs of vestibular and/or cerebellar
dysfunction. The "methionine reaction" became less acute after
two days and persisted until the amino acid was withdrawn. In
both affected patients a remission to the pretreatment mental state
followed the discontinuation of L-methionine. None of the five
patients showed any clinical improvement after L-methionine.
Glycine proved inert.
On the Lorr rating scale (two independent raters) similar
patterns of symptom fluctuations were apparent (Figure 9 - 1,2).
The symptom ratings on the scale were generally in agreement with
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The Henry Phipps nurses' rating scale and observations from
the patients' ward behaviour showed clinical changes in the two
patients which were in broad agreement with the changes observed
by the rating physicians (Figure 9 - 1>2).
Both the medical and nursing staffs were in accord that the
L-methionine reaction was schizophreniform in nature. Neither
group could detect any signs or symptoms indicating a "toxic"
delirium.
(2) MAIN EXPERIMENT: Of the eleven patients (five female and six
male), seven showed a clearcut reaction to L-methionine, and four
were not affected. None of the patients reacted to glycine. All
the eleven patients tolerated both amino acids well physically and
none showed gastrointestinal disturbance.
In two of the seven L-methionine reactors (one female and the
other male), the amino acid "B" (found later to be L-methionine)
had to be withdrawn owing to the marked psychiatric symptoms. In
the case of the female patient (Appendix I (b) l) L-methionine was
discontinued after seven days. After an interval of ten days
(day seventeen), phenothiazines were started, to which she responded
favourably. In the male patient (Appendix I (b) 7) L-methionine
was stopped after eight days; he also was given phenothiazines on
the fourteenth day and responded well to them. In both patients
there was an initial reaction to L-methionine, apparent after the
first day, which lasted for 24-48 hours. This was toxic in nature
with vestibular signs and ataxia, coupled with disordered sensorium
and orientation. After the reaction subsided, a twelve hour period
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of remission followed "before another reaction of a different
nature appeared. This latter, which developed in all seven
patients about three to four days after the start of L-methionine,
was characterized by the absence of any such disturbances in the
levels of consciousness, or other toxic signs, and was schizo¬
phreniform in nature (Appendix I (b) 1,2,5,6,7,10,11). In five
reactors (Appendix I (b) 1,2,7,10,11) there was a worsening of the
existing symptoms, some of which became more frequent and florid.
In three reactors, quiescent schizophrenic symptomatology (which
the patients showed during the earlier stages of their schizo¬
phrenia) returned and became clinically obvious. Three of the
patients who reacted to L-methionine had a recurrence of specific
elements of thought content disorder that they had shown years
before (Appendix I (b) 1,2,11).
In all seven patients the schizophreniform psychoses subsided
on withdrawing L-methionine. five of these patients were started
on phenothiazines (Appendix I (b) 1,2,6,7,10) and two were not
(Appendix I (b) 5,H)» Only three of the seven reactors (Appendix
I (b) 1,2,6) showed minor improvement that was characterized by
"greater spontaneity" and more social interaction. In one the
improvement was short-lived, whilst in the other two patients (2,6)
it was sustained. None of the group who reacted to L-methionine
became worse after its withdrawal, and they all reverted to their
pre-methionine mental states. None of the reactors not requiring
drugs before the experiment needed them at the end. In the
remaining four patients, no significant clinical changes were
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noticed during the entire experiment (Appendix I (b) 3,4,8,9),
although one of these did become slightly better (Appendix I
(b) 3). At follow-up, one year later, all except one patient
(Appendix I (b) 8), who died from an unrelated physical disease,
were essentially the same mentally as at the pre-experimental
assessment.
The two rating psychiatrists were in agreement about the
development and nature of the symptoms. Their conclusions,
based on the Lorr scale scores and psychiatric interviews, were
similar to, and complemented, the findings obtained from the
Henry Phipps' scores and ward behaviour observations (Figure
10, l-ll). The latter helped the psychiatrists to probe for
symptoms and signs which otherwise might have been overlooked.
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(i) vma Excretion; The 24 hour urinary vma levels in each of the
six male patients showed wide fluctuations over the twelve week
period (Appendix iv ). The Kruskal Wallis one-way analysis of
variance (Siegel, 1956) showed that vma mean values increased after
the Nil 1 condition (the four week observation before amino acid a)
(Tables 6 and 6a). There was no sharp increase in the vma 24 hour
urinary levels during L-methionine feeding.
table 6
vma excretion












1+ 1777.3 2788.1 2427.4 2895.1 2242.0
2+ 2236.5 2885.3 3346.8 2805.0 3401.1
3 988,2 3185.9 1798.7 2613.5 1865.8
4 2025.0 2191.6 3940.6 3193.3 3091.4
5+ 1289.4 2947.7 4927.7 2539.2 3885.9
6+ 1803.7 3451.6 2440.5 3199.5 2626.1
No. 1-6 = 6-11 in Table 5 and Appendix I (b)
+
The patient reacted to L-methionine clinically.
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TABLE 6a
KRUSKAL WILLIS (ONE-WAY ANALYSIS OF VARIANCE)






- 1 5 84 **
- 1 5 84 **
_ - 4 83 **
79 *
* p<0.06 ** p<0.05
The tables show that VMA excretion increased after the Nil 1
condition hut showed no significant increase on L-methionine
loading.
(ii) HMPG Excretion: The 24 hour urinary HMPG- levels varied less
over the twelve week period, within each patient, than those of VMA
(Appendix IV). In one reactor (Appendix I (b) 10) the mean values
of 24 hour urinary HMPG from each two week period showed a tendency
to increase after the Nil 1 interval (four weeks prior to amino acid
A)j this increase was about threefold during L-methionine feeding
(Table 7, no. 5). However, as a group there was no statistically
significant increase in the 24 hour urinary excretion of HMP& on L-










*Nil 2 Glycine Methionine yrR***
1+ 1665 1319 1007 1959 5950
2+ 1516 1917 1718 1372 6523
3 1381 1478 1232 1878 5969
4 1694 1017 1557 700 4968
5+ 1784 2825 2245 658I 13435
6+ 1327 1591 1048 1514 5480
9367 10147 8807 14004 /}■
No. 1-6 = 6-11 in Table 5 and Appendix I (b).
+
The patient reacted to L-methionine clinically.
* Nil 2 - After L-methionine and glycine, values of both
periods were combined and the mean value calculated.
♦* tc - Total columns
*** TR - Total rows
Two-way analysis of variance gave an F-value of 1.03 (E >3.29,
significant at 5%); thus there was no increase of HMPG urinary
levels on L-methionine loading.
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(2) ACUTE SCHIZOPHRENICS - Normal Controls
HMPG Excretion: A one-way analysis of variance (Bliss, 1967) was
done to see if there was a statistically significant difference in
the levels of 24 hour urinary HMPG among the acute schizophrenics,
normal controls and chronic schizophrenics. The F-value was 7.15
(F >6.7; significant at Ifo level) (Table 8).
TABLE 8








1 3358.75* 1977.4** 518.67**
2 1370.00 5820.15 1224.78
3 1492.25 1855.82 938.57
4 1630.75 3485.00 1270.65
5 1242.00 3650.00 696.67
6 1487.5
C 10581.25 16788.37 4649.34 G-32018.96
* Mean value of HMPG (^ig/24 hours) during twelve weeks
** Mean value of HMPG (ng/24 hours)
C - Sum of column; G - Grand total of + C2 +
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To determine the location of the difference, Tukey's test for all
pairwise differences was used. The studentized range (q ), as
tabulated by Pearson and Hartley (1966), and the calculated values
were as follows:-
q^r (chronic-acute) = 3.60 (qyr >3.18 - significant at lO^S)
2
q^ (chronic-normal) =1.88
q^r (acute-normal) = 5.25 (lvr - significant at 1$)
As seen from the results there were significant differences in the
levels of 24 hour urinary HMPG- between (i) the acute and chronic
schizophrenic groups, and (ii) the acute schizophrenic and normal
control groups; the greater difference being between the latter
two groups. No significant difference was found between the




The present findings, in broad agreement with those of previous
workers, have shown that chronic schizophrenic patients tend to fall
into two populations - L-methionine "reactors" and "non-reactors";
there was no obvious clinical difference between these two groups.
That is, it was not possible clinically to predict whether any
particular patient would react or not. It was felt that the
reaction observed was most likely due to L-methionine rather than
a relapse secondary to phenothiazine withdrawal because (i) three
reactors had not received any medication for four to five years
prior to the experiment, and (ii) some of the non-reactors did not
show any relapse on withdrawal of the phenothiazines. It could
be argued that L-methionine produced a non-specific stress reaction
which might have triggered a schizophrenic relapse, especially in
patients unprotected by psychotropic drugs. Such stress phenomena
are known to contribute to schizophrenic relapses but, interestingly
enough, of all the compounds previously administered to schizo¬
phrenics, only L-methionine (Pollin et al, 1961) and betaine (Brune
and Himwich, 1963) were reported to give such a reaction. Although
the reaction to betaine has yet to be confirmed, betaine and L-
methionine have in common methyl donating properties.
In spite of the finding that L-methionine induced an acute
schizophreniform psychosis in a proportion of chronic schizophrenic
patients, and despite the fact that a disturbance in L-methionine
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metabolism has been reported in schizophrenics (israelstam et al,
1970), it cannot be assumed that this resulted from faulty trans¬
methylation, since methionine is concerned in other metabolic
reactions. Irrespective of the mechanism by which L-methionine
produced this reaction, two possibilities about its pathogenesis
exist: (i) that it represents an exacerbation of the schizophrenic
process, i.e. that L-methionine "converts" "chronic symptoms" into
subacute or acute, or (ii) that it is a non-specific psychosis which
is superimposed on the schizophrenic illness. Although such a
psychosis was not witnessed when normals were given L-methionine
(Alexander et al, 1963; Harper et al, 1970), since schizophrenics
may have a disordered metabolism, this could explain the discrepancy.
In the present investigation it was shown that L-methionine
could induce what was considered to be an acute schizophreniform
wo ^
psychosis in some chronic schizophrenic patients. This psychosis y
was clinically distinct from another reaction which preceded it in /• o_a>; L c
some reactors, and was considered to be toxic in nature. However,
this cannot be regarded as conclusive, since judgments made solely
upon phenomenology are obviously subject to the prejudices of the
rating psychiatrists. Although the clinicians in this study were
in agreement, as reported, it is possible that other olinicians
might have come to different conclusions, especially when diagnostic
criteria in schizophrenia differ widely among psychiatrists.
The alleged therapeutic effect of L-methionine in schizophrenia
previously reported was not observed in the present study. The two
reported reactors who were thought to have had a minor long term
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improvement were recommenced on phenothiazines immediately after
the experiment, which could have affected the clinical course of
the illness, and minor fluctuations of this nature are to he
expected during a schizophrenic illness.
(B) BIOCHEMICAL
As mentioned earlier, the HMPG and VMA values were calculated
as Me/2k hours. The precautions enforced during the urine collec¬
tions obviated the need to present the values as jug/mgm. creatinine;
this would have been unreliable due to the effect of L-methionine
on the nitrogen balance in the body (Phear et al, 1956), which in
turn would have affected creatinine clearance. The 24 hour urinary
excretion of HMP6- was not found to be dependent on urine volume;
thus the fluctuations detected most probably gave a rough estimate
(since fluctuations in peripheral NA stores would influence the
levels of total urinary HNP&) of the rate of central NA metabolism.
The same argument holds for YMA 24 hour urinary levels, which served
as a rough index for peripheral NA metabolism.
Schildkraut et al (1964) and Kopin et al (1961) found that
MAO-inhibitors decreased urinary levels of VMA and HMPG respectively.
In addition, the former group found that NM and NA were increased
after the administration of MAO-inhibitors, indicating that the
MAO-inhibitors block deamination (intracellularly), thus preventing
further catabolism of brain amines. Sinoe MAO-inhibitors were not
used in this experiment, theoretically an increase in the 0-
methylation of NA produced by L-methionine loading would have been
parallelled by an increase in the urinary levels of VMA and HMPG.
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The failure to deteot any such changes did not, however, rule
out the possibility that L-methionine might have aggravated the
postulated aberration of transmethylation by increasing the body
methylating pool. This is because (i) both VM and HMPG are 0-
methylated metabolites of noradrenaline; thus the"toxin" might
have been an N-methylated derivative of tryptamine, histamine,
any of the polyamines (little is known about their role in brain
metabolism) or a methylated nucleic acid. Schizophrenics, by
virtue of a possible transmethylation defect, might have failed
to respond (to L-methionine) by an increase of normally occurring
methylated metabolites. This is of special interest since no
comparative study has been done to establish the effect of L-
methionine on VM and HMPG excretions in non-schizophrenics,
(ii) Despite the precautions taken in standardizing the diet
and keeping the environmental factors as constant as possible,
inevitable sooial and psychological stresses could have caused
fluctuations in VM (Weil-Malherbe, 1967) and HMPG excretion;
this could have masked statistically significant changes induced
by L-methionine feeding. This was especially observed in the
case of VM where 24 hour urinary levels fluctuated, showing an
increase after any stress condition (i.e. glycine or methionine).
Again, no study has yet been done to examine the effects of stress
on HMPG excretion in normals. (iii) Although L-methionine had
been 3hown in in vitro experiments to donate methyl groups to a
number of metabolites in the body (including catechol metabolites),
giving it in excess might not increase methylation. This could
have been due to a rate limiting factor in the body which ohecks
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the rate of methylation under a non-physiological condition; rate
limiting factors are known to exist in many metabolic pathways in
the body. However, schizophrenics might have defective demetby-
lation and hence a slower clearance of the body methylating pool.
Since there were no statistically significant changes in VMA
and HMPG excretions, there were no correlations between increased
methylation (as reflected by increases in VM and HMPG- urinary
levels) and the clinical reaction to L-methionine. Even if a
correlation was demonstrated, a cause and effect relationship
could not have been postulated because, as mentioned earlier,
L-methionine has other metabolic effects in the body.
However, the above findings are not contradictory to the
"transmethylation hypothesis". Further study geared to a better
understanding of L-methionine metabolism in normals and schizo¬
phrenics is required. A more exhaustive and direct approach to
the problem of methylation and demethylation reactions should,
therefore, be pursued.
Because MAO-inhibitors were not given during the experiment,
and there was no significant increase in the levels of urinary HMPG
on L-methionine loading, it was possible to oompare the levels of
urinary HMPG- in the chronic schizophrenics with those of the acute
schizophrenics and normals.
The difference in urinary levels of HMPG between acute schizo¬
phrenics and normals could have been due solely to the effects of
stress and physical agitation in the acute population since (i) there
was a difference between the acute and chronic groups of schizo-
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phrenics, and (ii) there was no difference between the chronic
schizophrenics and the controls. However, some of the acute
schizophrenics were not overtly or unduly overactive physically
and stress phenomena could have occurred in all three groups.
Moreover, those chronic schizophrenics who reacted to L-methionine
showed acute symptoms and were physically overactive, yet did not
show any increase in urinaiy HMPG-.
This preliminary finding needs further investigation using
a longitudinal study of the excretion of HMPG in a larger sample








The four main objectives of this study were to (i) demonstrate
the transfer of the methyl group from L-methionine to catechol-O-
methylated catabolites, in brain, (ii) demonstrate such a transfer
in total body, (iii) show that the methods used in the separation
and identification of these O-methylated catabolites are valid, and
(iv) demonstrate the authenticity of the O-methylated catabolites.
EXPERIMENT I
Three groups of male Wistar albino rats, weighing 150 g each,
were taken.
G-roup I (9 rats) - each was injected through the tail vein with
25 /iCi of L-methionine (methyl-C^) (60 mCi/mMol) * in 1 ml. of
physiologic saline. The rats were killed two hours after the
injection by cervical fracture, decapitated, and their brains
removed.
*L-methionine (methyl-C^) - CFA.152, The Radiochemical Centre,
Amersham.
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Group II (2 rats) - each was anaesthetized with ether, then injected
intraventricularly (Noble et al, 1967) with 0.5 ^uCi of DL-
noradrenaline (carbinol C^) (25 mCi/mMol) ** in 20 /il of Merles
solution. The rats were killed one hour after the injection by
cervical fracture, decapitated, and their brains removed.
Group III (3 rats) - each was injected through the tail vein with
25 JuCi of L-methionine (methyl-C^1") (60 mCi/mMol) in 1 ml. of
physiologic saline. The rats were then placed in metabolic cages
and their urine collected for the 24 hour period following the
injection. No plasma expanders were used and the rats were given
water ad lib.
EXPERIMENT II - Consisted of Groups I and III only.
(b) preliminary assays
(l) Brain Assay: Each brain (from Group I and II) was homogenized
in an all-glass homogenizer with chilled 0.4N PCA (0.05$ ascorbic
acid and 0.1$ EDTA) using 4 ml/g brain. The homogenate was spun
in a refrigerated centrifuge (4°C) for 15 minutes at 20,000 £.
At this stage an 0.2 ml. aliquote of the supernatant was dissolved
in 4 ml. ethanol:methanol (3:1) and 10 ml. of Toluene (0.426$ PP0,
0.011$ P0P0P) scintillator and counted by liquid scintillation to
assess the success of the intravenous (Group l) or intraventricular
(Group II) injection. The supernatants from Group I and II were
** DL-noradrenaline (carbinol C"^), DL-bitartrate -
The Radiochemical Centre, Amersham.
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pooled separately; the two mixtures were adjusted to pH4 (glass
electrode) with 5N and 1NK0H and cooled to 4°C for 10 minutes to
precipitate the potassium perchlorate. They were then centrifuged
for 3 minutes at 4,000 g and the supernatants decanted and adjusted
to pHl (glass electrode) with concentrated HC1.
(2) Urine Assay: The 24 hour urines were pooled and adjusted to
pHl (glass electrode) with concentrated HC1.
(C) SEPARATIVE PROCEDURES
(l) Phenolic Acids: Each of the two supernatant mixtures (pHl)
(from G-roups I and II) and the combined urine sample (pHl) (from
Group III) was extracted with double volume of ethyl acetate by
shaking for 5 minutes and centrifuging at 2,000 £ for 5 minutes;
after removing the ethyl acetate the extraction was repeated twice
with two further double volumes of ethyl acetate. The aqueous
phase was saved for the estimation of the alcohols and 0-methylated
amines. The combined organic phase (ethyl acetate) was extracted
once with one-sixth its volume of lMKgCOj buffer (pHlO) by shaking
the mixture for 5 minutes and centrifuging for 5 minutes at 2,000 £.
The buffer layer (containing the acids) was adjusted to pHl (glass
electrode) with concentrated HC1 and extracted with double volume
of ethyl acetate; the extraction was done three times. At that
stage (i) 10 fxg of authentic unlabelled VMA and HVA were added to
the combined ethyl acetate fractions from Groups I and III, and
10 yug of VMA to that from Group II. (ii) The combined ethyl acetate
fraction from Group I was divided into three equal portions.
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Each combined ethyl acetate fraction from Groups II and III
and the three portions from Group I were blown down under a stream
of nitrogen to - 0.2 ml. and stored at -20°C until applied to
chromatography paper.
Recovery from Extraction: Two samples (in duplicate) of 5 ml. water
were taken; to one was added 5 /ig VM. and the other 5 jug of HVA.
The samples were adjusted to pHl with conc. HC1 and extracted in
the same way as in the method (first ethyl acetate - K^CO^ buffer -
second ethyl acetate)* The combined second ethyl acetate fraction
from each sample was blown down to damp dryness with nitrogen. Each
residue was dissolved in 3 ml* distilled water, 2 ml. of which was
taken for the fluorometric determination of HVA or VIA by the FeCl^
oxidation reaction.
The overall recovery of VMA and HVA, under these conditions,
was 80 £ 5$ (4) (mean * SD (no. of observations)).
(2) Alcohols from 0-methylated amines: The aqueous phase of each
sample was adjusted to pH5 (glass electrode) with 5N and 1HK0H, and
reduced to 1 ml. under vacuum at 37°C.
(i) Hydrolysis; To each concentrate were added (i) 9 mg. of
Helicase enzyme (powder form), (ii) 0.1 ml. of IM sodium acetate
buffer (pH5), (iii) 10 /lg of authentio unlabelled HMPG, HMPT, KM,
M and MTYR* for Groups I and III, and HMPG, KM and M for Group II,
and (iv) two drops of chloroform. The mixture was incubated at
37°C for 24 hours then centrifuged for 5 minutes at 3,500 £ and the
supernatant decanted.
* MTYR - 3-methoxy tyramine (3-methoxy dopamine).
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(ii) Column Chromatography
(a) Alcohols; Each supernatant was adjusted to pH7.5 (glass
electrode) with IN and 0.1N KOH and passed over a column (4 x 0.7
cm.) of Bio-Rad AGI - X4 untreated resin (chloride form, 200-400
mesh). The column was washed with 2 ml. of distilled water which,
together with the effluent, was saved for the determination of the
0-methylated amines. The alcohols (only HMPG in Group II) were
eluted off the column with 8 ml. of distilled water; the eluate
from Group I was divided into three equal portions.
Each eluate from Group II and III and the three portions from
Group I were reduced to ^0.2 ml. under vacuum*at 37°C and stored
at -20°C until applied to chromatography paper.
Column Recovery: Two samples (in duplicate) of 5 /*g HMPG in 1 ml.
of distilled water were passed over columns (4 x 0.7 cm.) of AG1-X4
resin. The columns were washed and eluted with 2 and 8 ml. of
distilled water respectively. Each eluate was reduced to damp
dryness under vacuum and the residue dissolved in 3 ml. distilled
water, 2 ml. of which was taken for the fluorometric determination
of HMPG by the PeCl^ oxidation method. The overall recoveiy was
78 i 4$ (4) (mean - SD (no. of observations)).
(b) 0-Methylated Amines: The pH of each mixture (3 ml.) of effluent
and wash from the Bio-Rad resin was checked and readjusted to pH 7.5
(glass electrode) if necessary. It was passed over a column
(10 x 0.7 cm.) of Amberlite CG 50 resin (HH^+ form, pH7.5). The
column was washed with 10 ml. of distilled water and the 0-methylated
amines were eluted off the column with 15 ml. of 3N NH40H.
* Ascorbic acid+ 200/ig) was added to each sample before it was
reduoed in volume.
+
L-Ascorbic acid - Analar Reagent (BBH).
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At this stage the eluate from Group I was divided into three
equal portions, and together with the eluates of Groups II and III,
was reduced to & 0.2 ml. under vacuum♦♦at 37°C; they were stored
at -20°C until chromatography.
CG 50 Column Recovery: The column adsorbs NA, dopamine and the
0-methylated amines. Using labelled NM and fluorometric measure¬
ment of MTYR and M, according to the method of Axelrod et al (1958),
it was found that the column size in relation to the sample, wash
and eluate volumes was important for obtaining maximal recovery.
Eluting the 0-methylated amines with 3N NH^OH gave uniform recoveries
from the column. A sample volume of 1 or 3 ml. required a column
size of A x 0.7 cm. 0D or 10 x 0.7 cm. 0D respectively. Under
these conditions, washing the column with water only eluted a small
proportion of the 0-methylated amines, thus:
The effluent contained $ 5 - 2f° of the 0-methylated amines.
The 10 ml. water wash contained + 9 £ 3$ of the 0-methylated
amines.
The 15 ml. 3N MH,OH eluate contained + 86 £ 5% of the
0-methylated amines.
+
The value represents the mean of:
1 sample (duplicate^ - containing H^NM 20,000 DPM) 1 in 3 ml.
1 sample (duplicate) - containing M (20yug) ) water
1 sample (duplicate) - containing MTYR (20 /ig) ) (pH 7.5)
♦ (mean £ SD (6)).
When the eluate volume was less than 15 ml. there was a decrease
in recovery.
w Ascorbic acid+ (^ 200 ;ug) was added to each sample before it was
reduced in volume.
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Sinoe 90 - 5% of the 0-metbylated amines are recovered in the
effluent 60%) and wash 25%) of the AG-1-X4 column (see HMP&
method - specificity of isolation procedure), the overall recovery
of these amines was 83 - 5%.
L-methionine and S-adenosylmethionine - recoveries through the
separative procedures:
The following samples were tested for recoveries through the
method:-
1. Ethyl acetate extraction: Two samples, one containing labelled
L-methionine (50,000 DPM) and the other labelled S-adenosylmethionine
(50,000 DPM) in 2 ml. of water were adjusted to pHl. They were
extracted three times with double volume ethyl acetate. One ml.
of each aqueous phase and 6 ml. of the organic phase were dissolved
in two separate 10 ml. fractions of Toluene Triton X (PP0, P0P0P)
scintillator and counted by liquid scintillation against appropriate
blanks.
2. Bio-Rad A&1-X4 column: Two samples, one containing labelled
L-methionine (50,000 DPM) and the other labelled S-adenosylmethionine
(50,000 DPM) in 1 ml. of water were adjusted to pH7*5» They were
passed over columns (4 x 0.7 cm. 0D) of A&1-X4 resin. Each column
was washed with 2 ml. of water and eluted with 8 ml. of water.
One ml. of each effluent, wash and eluate was dissolved in a separate
10 ml. fraction of Toluene Triton X (PP0, P0P0P) scintillator and
counted by liquid scintillation against water blanks.
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3. Amberlite CG- 50 column: Two samples, one containing labelled
L-methionine (50,000 DPM) and the other labelled S-adenosylmethionimi
(50,000 DPM) in 3 ml. of water were adjusted to pH7.5» They were
passed over columns (10 x 0.7 cm. 0D) of C& 50 resin. Each column
was washed with 10 ml. of water and eluted with 15 ml. of 3N HH^OH.
One ml. of each effluent, wash and eluate was dissolved in a sepa¬
rate 10 ml. fraction of Toluene Triton X (PP0, P0P0P) scintillator
and counted by liquid scintillation against appropriate blanks.
Results
1. L-methionine organic phase - 1$
and -
S-adenosylmethionine aqueous phase - 99$
2. L-methionine - effluent 39$
wash 6i$
eluate 1$
S-adenosylmethionine - effluent 54/2
wash 32$
eluate 5$
* remainder adsorbs to resin.
S-adenosyl-
Methionine L-methionane
3. L-methionine - effluent 4$
and





(i) Paper chromatography: Each 0.2 ml. ethyl acetate concentrate
(Croups II and III; three portions of Croup i) was applied, under
a stream of nitrogen, to a separate sheet of Whatman No. 1 chroma¬
tography paper (46 x 50 cm.) (Appendix III (h)). Then the sides
of each tube were washed with 0.1 ml. of methanol which was also
applied to the paper on the same spot as the sample. The origin
(point of application) was at one corner of the paper, 10 cm. from
both edges (Appendix III (b)). Markers of authentic VMA and HVA in
Croups I and III, and VMA in Croup II were applied on the same spot
as each sample.
Using the "Two dimensional descending technique": The paper
chromatograms were plaoed in sealed chromatography tanks* containing
the first solvent system and left to equilibrate with the solvents'
vapours for at least six hours. They were then developed, removed
from the tanks and dried with nitrogen for six to eight hours. The
papers were rotated 90°, placed in other sealed tanks containing
the second solvent system, and allowed to equilibrate for six hours
with the solvents' vapours. They were then developed, removed from
the tanks and dried with nitrogen.
To visualise the mixed sample and marker spots the developed
chromatograms were sprayed with paranitroaniline: 10$ sodium nitrite
(10:1) and allowed to dry (Figures ll-a,b,c; 12-iii; 13-iii).
* All the chromatography tanks used were saturated with nitrogen
before sealing.
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1. 1st System - Isobut^l methyl ketone:2$ formic acid
(10:1 /v) - 2 phase (organic phase used)
Developing time: 5 hours.
(Appendix V,l,a)
2nd System - Chloroform:methanol:ammonia (0.88)
(12:7:1 /v) - single phase
Developing time: 5 hours.
2. 1st System - Isopropyl alcohol:ammonia (0.88):
water (20:1:4 /v) - single phase
Developing time: 20 hours.
(Appendix V,l,b)
2nd System - Butanol^ethanol:water
(4:1:1 /v) - single phase
Developing time: 17 hours.
3. 1st System - Butanol:pyridine:water
(14:4:5 /v) - single phase
Developing time: 1hours.
(Appendix V,l,c)
2nd System - Butanol:acetic acid (glacial): water:
dichlorethane (1:1:1:3) /v) - 2 phase
(organic layer used)
Developing time; 5 hours.
Two phase solvent system: The mixture was shaken and left to settle,
forming two layers. Most of the organic layer was poured into the
chromatography tank and the remainder was used to develop the chroma-
togram. The aqueous layer was poured into a trough, placed in the
upper part of the tank and allowed to flow down on a sheet of chroma¬
tography paper, the upper edge of which was dipped in the trough.
The lower edge of the paper hung into another trough placed at the
bottom of the tank to collect the down flowing aqueous phase, thus
preventing it from mixing with the organic phase.
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(ii) Liquid Scintillation Counting: In area measuring 10 cm. in
the direction of the second solvent flow and 5 cm. wide was drawn
over each spot and then cut into ten strips of 1 x 5 cm. Each
strip was immersed in 4 ml. of Toluene (PPO and P0P0P) scintillator
and counted by liquid scintillation against 1x5 cm. blank strips
cut from strips of paper which were developed in the same solvent
systems used for the sample chromatograms, then sprayed with a
mixture of paranitroaniline and sodium nitrite (Figures ll-a,b,c;
12-iiij 13-iii).
(2) Alcohols
(i) Paper Chromatography; Each 0.2 ml. concentrated eluate from
the Bio-Rad resin (Groups II and III; three portions of Group i)
was applied to a separate 46 x 50 cm. sheet of Whatman No. 1 chroma¬
tography paper in the same way as in the case of the acids, except
for the markers, where authentic HMPG and HMPT in Groups I and III
and HMPG in Group II were applied instead.
The same chromatography technique and solvent systems used for
the acids were utilized, i.e. -
Combination (l) for Groups I,II and III (Appendix 7,1,a).
Combinations (2) and (3) for Group I (Appendix V,l,b,c)
The developed chromatograms were sprayed with a mixture of
paranitroaniline and sodium nitrite and allowed to dry (Figures
11 (l)-a,b,c; 12-ii; 13-ii).
(ii) Liquid Scintillation Counting; The method for cutting out the
spots and counting their radioactivity was the same as that used for
the acids (Figures 11 (l)-a,b,c; 12-ii; 13-ii).
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(3) O-Methylated Amines
(i) Thin Layer Chromatography: Three of the 0.2 ml. concentrated
eluates from the Amberlite resin (Groups II and III; one of the
three portions from Group I) were applied under a stream of nitrogen
on three separate silica gel thin layer plates (20 x 20 cm.)*. The
sides of each tube were washed with 0.1 ml. methanol which was
applied on the same spot as the sample itself. The point of appli¬
cation was at the corner of the plate, 3 cm. from each edge
(Appendix V,2,a). Markers of authentic M, MM and MTYR in Groups I
and III, and M and MM in Group II were applied on the same spot as
each sample.
Using the two dimensional ascending technique: the three plates
were placed in a sealed chromatography tank containing the first
solvent system of Isopropyl alcohol:ammonia 5% (4:1 V/v) (single
phase) and allowed to equilibrate with the solvents* vapours for
three hours. They were then developed until the solvent front
reached the upper edge of the plates. The plates were removed from
the tank and dried with nitrogen for six to eight hours. They were
rotated 90° and placed in another sealed tank containing the second
solvent system of Benzene:acetic acid (glacial):water (62.5:36:1.5
V/v) (single phase). After an equilibration period of three hours
with the solvents* vapours, the plates were developed until the
solvent front reached the upper edge of the plates. They were
removed from the tank, dried and redeveloped twice more in the
second solvent system, allowing each time for the solvent front to
reach the upper edge of the plates (Appendix V,2,a).
* TL - Silica gel precoated plates - 20 x 20 cm., 0.25 mm. layer
thickness (without fluorescence indicator) - E. Merck, A.G. Darmstadl;.
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After the third development the plates were dried, the mixed
marker and sample spots were visualised by spraying the plates with
a mixture of paranitroaniline and sodium nitrite (Figures 11 (il)-a;
12-i; 13-i).
(ii) Paper Chromatography: The remaining two concentrated portions
(from the eluate of the Amberlite resin) of Group I were applied,
under a stream of nitrogen, to two separate sheets of Whatman No. 1
chromatography paper (46 x 50 cm.) in the same way as in the case
of the acids and alcohols except for the markers, where NM, M and
MTYR were used instead.
Using the two dimensional descending technique, the following
two combinations of solvent systems were used:-
1. 1st System - Butanol:acetic acid (glacial):water
(4:1:1 /v) - single phase
Developing time: 18 hours.
(Appendix V,2,b)
2nd System <




Developing time; 4 hours.
Butanol:ethanol:ammonia 0.88
(4:1:1 V/v) " single phase
Developing time: 17 hours.
Nitroethane 70%:acetic acid (glacial)
(9:4 /v) - single phase
Developing time: 5 hours.
Group I
The developed chromatograms were sprayed with a mixture of
paranitroaniline and sodium nitrite; the mixed sample and marker
spots were visualised (Figure 11 (ll)-b,c).
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(iii) Liquid Scintillation Counting
Thin Layer Chromatography; An area measuring 7 cm. in the direction
of the second solvent flow and 4 cm. wide was drawn over each spot,
then scraped in seven portions of 1 x 4 cm. Each portion was
suspended in a mixture of Thixotropic gel and 10 ml. Toluene
Triton X (PPO, P0P0P) scintillator and counted by liquid scintil¬
lation against blanks. The blanks were 1x4 cm. scrapings from
a plate developed and sprayed in the same way as the sample plates
were (Figures 11 (il)-a; 12-i; 13-i).
Paper Chromatography; The developed chromatograms were cut and
counted in the same way as in the case of the acids and alcohols
(Figure 11 (ll)-b,c).
RESULTS
1. All values of radioactivity were corrected for quenching by
the channel ratio method, thus expressed as DPM.
2. Using the"internal standard method", it was found that the amber-
yellow colour of the spots, obtained from spraying the developed
chromatogram with paranitroaniline:sodium nitrite, did not cause
any quenching of the "fluor".
3. After correcting for percentage recoveries from the method, the
values were expressed as per cent of the intra-group total radio¬
activity for (i) M. and (ii) Dopamine 0-methylated catabolites,
.
_ VMA activity (DPM) ,nne*g* VMA. + HMPG- + NM + M activity (DPM) A x
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TABLE 9
CATABOLITES 07 KA. AND DOPAMINE
AS PER CENT OF TOTAL O-METHYLATED CATABOLITES
HA Catabolites DopamineCatabolites

























* Group I - values represent mean per cent obtained from the
(i) three chromatography combinations.
(ii) two experiments.
** Group III - values represent mean per cent obtained from the
two experiments.
Group I - Endogenous catechol-0-methylatedL, patabolites in brain
after intravenous injection of C -L-methionine.
Group II - Catabolism of C^-NA in brain after intraventricular
injection.
Group III - Endogenous catechol-O-methylated catabolites in 24 hour
urine after intravenous injection of C -L-methionine.
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FIGURE 11
Croup I C"-METHYL-L-METHIONINE-INTRAVENOUS-BRAIN ASSAY
- ACIDS
1st SYSTEM I 5hrs I 1st SYSTEM ( 20 hrs) 1st SYSTEM | T61/2 hrs)































Figure represents the acid catabolites HVA and VMA
of endogenous dopamine and NA respectively in brain.
It shows that the spots corresponding to HVA in the
three chromatographic solvents (a,b,c) have more
radioactivity than those of VMA which have background
levels of activity.
The spots were visualized by spraying with diazotised
paranitroaniline.
Whatman No. 1 chromatography paper was used.
The results represent an average of two experiments.
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FIGURE 11 (i)
Group I C -METHYL-L-METHIONINE-INTRAVENOUS - BRAIN ASSAY
ALCOHOLS
1st SYSTEM I 5 hrs I 1st SYSTEM (20 hrs) 1st SYSTEM 116 V2 hrs)



































Figure represents alcohol catabolites - HMPT and
HMPG - of endogenous dopamine and NA respectively
in "brain. It shows that the spots corresponding
to HMPG in the three chromatographic solvents
(a,b,c) have appreciable levels of radioactivity
while those of HMPT have background levels of
activity.
The spots were visualized by spraying with diazotised
paranitroaniline.
Whatman Wo. 1 chromatography paper was used.
The results represent an average of two experiments.
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FIG-URE 11 (II)
Group I C'-METHYL-L-METHIONINE-INTRAVENOUS-BRAIN ASSAY
0-METHYLATED AMINES
1st SYSTEM 116 hrs)
BUTANOL: ACETIC ACID : WATER (1:1:1 I
NMN MTVR
MN
ORIGIN SILICA DEL I TEC )
1st SYSTEM 117hrs)
BUTANOL:ETHANOL:NHj135%) U:l:1|
BENZENE:ACETIC ACID: WATER (62-5:36:1-5)

























Figure represents the O-methylated amine catabolites -
NM and Mj MTYR of endogenous NA and dopamine respectively
in brain. It shows that the high levels of radioactivity
in the three chromatographic solvents (a,b,c) correspond
to the NMN spots. The spots corresponding to MN and MTYR
have much lower activity.
The spots were visualized by spraying with diazotised
paranitroaniline.
(a) Thin layer precoated silica gel plates (20 x 20 cm.)
were used.
(b,c) Whatman No. 1 chromatography paper was used.
The results represent an average of two experiments.
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FIGURE 12









•ORIGIN SILICA GEL I TLC1
1st SYSTEM I Shrs)
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Figure represents the O-methylated catabolites of exogenous
M in brain. It shows that the highest radioactivity
corresponds to the HMPG (ii) then NMN (i) spots. The spot
corresponding to VIM. has much lower activity, while that of
MN has the least.
The spots were visualized by spraying with diazotised
paranitroaniline.
(i) Thin layer precoated silica gel plate (20 x 20 cm.)
was used.
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Figure represents the O-methylated cataholites of endo¬
genous M and dopamine in urine. It shows that the
area corresponding to WiA has the highest radioactivity
while HMPT is found in negligible amounts.
The results represent an average of two experiments.
The spots were visualized by spraying with diazotised
paranitroaniline.
(i) Thin layer precoated silica gel plate was used.




The results of this study show that the separative and
identification procedures were adequate for isolation of the
various catechol-O-methylated catabolites. This was clearly
seen in the control group (G-roup II), where C^-NA was injected
intraventricularly. In this group percentages of the different
O-methylated NA catabolites tended to fall within the range
reported by other workers (Diagram III), allowing for the fact
that all the present results express the percentages of the 0-
methylated catabolites only. In other words, the percentages
reported in the experiment were calculated from the sum total
radioactivity of the O-methylated catabolites only; thus they
would be higher than percentages of total catabolites (O-methylated
and dihydroxy).
Rutledge and Jonason (1967) used rabbit brain slices to study
the catabolism of exogenous and endogenous NA. The former was
3
assessed by incubating the brain slices with H -NA and the latter
by incubating with C^-dopamine and isolating the catabolites of
the newly formed C^-NA. They reported that 53 per cent of
exogenous NA total catabolites were HMPG and DHPG, with predominance
of the latter, while NM accounted for 20 per cent and VMA 7 per cent.
On the other hand, the majority of the newly formed C^-NA was
catabolized into HMP& and DHP&, with the latter occurring in
quantities twice that of the former; NM and VMA were found in
negligible amounts. The authors suggested that these obser¬
vations support the view that endogenous NA is initially catabolized
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by intraneuronal MAD, whereas exogenous NA can he catabolized
initially by either MAO or extraneuronal COMT. The high values
of DHPG- obtained were probably due to the fact that (i) Rutledge
and Jonason determined free HMP& and DHP& only. Schanberg et al
(1968) reported that rat brain slices are capable of forming HMP&
conjugate. Thus, if there is no species difference a similar
situation might occur in rabbit brain slices, (ii) Although there
is a high concentration of S-adenosylmethionine (active methyl
groups) in brain, there exists a fast and continuous turnover of
S-adenosylmethionine in the body, with constant replenishment of
tissue stores (Baldessarini, 1967). Therefore, it is quite
possible that in vitro S-adenosylmethionine in brain slices is
not at an optimal concentration for enhancing maximum O-methylation
by COMT. Schanberg et al (1968) also studied the catabolism of
exogenous NA in vivo and reported that in rat brain, 90 minutes
after intracisternal injection of H^-NA, 44 per cent was catabolized
and of this 36 per cent appeared as HMPG- conjugate, while NM
accounted for 4 per cent and VMA and free HMP& 3 per cent. More¬
over, there was a decrease in NM with time after the injection;
hence NM accounted for 7 per cent at 33 minutes.
On the other hand, R. Sugden (1970 - personal communication)
found that 68 per cent of intraventricular C^-NA was catabolized
by brain one hour after injection. He reported that 26 per cent
of the catabolized NA was identified as HMP& conjugate while NM and
VMA accounted for 14 per cent and 4 per cent respectively.
Considering the difference in the time interval of labelled
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NA injection and assay between the Schanberg et al experiment and
the present one, the results of both experiments (Sugden;
Schanberg et al), when expressed as per cent of total catabolites,
are also broadly similar to the present values in Group II,
except for KM (Diagram III). The latter is higher than the
values reported above and by Glowinski et al (1965, 1966) who
also studied, in vivo, the catabolism of exogenous NA in brain.
The percentages of NA and dopamine catabolites in brain and
urine (Groups I and III) after intravenous C^-L-methionine
represent the catabolism of endogenous catechols. To date, there
is no detailed study of in vivo catabolism of endogenous NA in
brain. Schanberg et al (1968a) and Sharman (1969) were able to
detect (in vivo) in rat and mouse brains endogenous HMPG, the
majority of which was in the conjugate form. On the other hand,
endogenous VMA in brain has not been detected in vivo (Anden et al,
1964; Laverty and Sharman, 1965) and only in negligible amounts in
vitro (Rutledge and Jonason, 1967 - vide supra). In urine
endogenous VMA and HMPG have been detected (Pisano et al, 1962;
Wilk et al, 1967). However, VMA was found to be the major
catabolite of exogenous NA and excreted at a more rapid rate than
HMPG (Maas and Landis, 1966, 1968). Provided the catabolism of
endogenous NA in brain and body is similar to that of exogenous
NA, the major catabolites in brain and peripheiy are HMPG and
VMA respectively (Diagram III, Groups I and III).
The high levels of endogenous NM in brain, reported in this
study (Diagram III, Group i), perhaps reflects the effect of time
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between injection and assay which is less important when studying
NA catabolism in vitro. Both in vitro and in vivo NM is further
catabolized to the various deaminated derivatives. However, in
vivo, the percentage of NA catabolites found at any one time is
the result of possibly unequal efflux from brain into the general
circulation (G-lowinski and Baldessarini, 1966; Werdinius, 1967).
KM does not readily cross the blood brain barrier (Maas and Landis,
1966; Schanberg et al, 1967) and it is possible that the deaminated
catabolites are eliminated from brain at a more rapid rate than NM;
thus there may be an initial (i.e. 1-2 hours) accumulation of KM in
brain which is cleared as KM gets further deaminated by MO. This
might also explain why Rutledge and Jonason (1967) could not detect
endogenous NM from newly formed C^-NA. in 'in vitro' brain prep¬
arations while Haggendal (1962) was able to detect it in brain,
in vivo.
The low, but significant, levels of M in brain (Diagram III,
G-roup i) are broadly similar to those reported by Ciaranello et al,
1969). They found that brain tissue can convert NA to adrenaline
which, in turn, is catabolized to M; the latter constitutes 4-17
per cent of the combined NM and M fraction, depending upon the
species (Barchas et al, 1969). The majority of the M and adre¬
naline found in brain comes from central stores, since both do not
readily cross the blood brain barrier (Barchas et al, 1968} Axelrod
et al, 1959c). Probably a greater proportion of endogenous M is
converted to adrenaline than exogenous NA which is rapidly cata¬
bolized in brain after injection (Schanberg et al, 1968). This
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might explain the much lower percentage of M in Group II, where
C"^-NA was injected.
The catabolism of dopamine has been studied extensively in the
past. Anden et al (1963) found that the major catabolite of endo¬
genous dopamine in brain was HVA; this was later confirmed by
Rutledge and Jonason (1967) who found that in rabbit brain slices
HVJL was 81 per cent of the total catabolites of exogenous C^-
dopamine, MTYR accounted for 8 per cent and HMPT was only detected
in negligible amounts (Diagram III). Moreover, the only endogenous
dopamine catabolites (other than HVA) isolated from brain so far
are dihydroxyphenylacetic acid (DOPAC) (.Anden et al, 1963a) and
MTYR (Carlsson and Waldeck, 1964). These results are at variance
with NA where the glycols are the major catabolites. This probably
suggests that either the dopamine alcohols are eliminated from brain
at a higher rate than the acids and MTYR or the NA deaminated
aldehyde is primarily reduced to phenolic glycols while the dopamine
aldehyde is oxidized to the phenolic acids. Although little is
known about the enzyme system(s) responsible for further catabolism
of these aldehydes, Eccleston et al (1966) found that in 'in vitro'
brain preparations, serotonin (5HT) is catabolized to 5-hydroxy-
acetaldehyde which in turn is mostly oxidized to 5-hydroxyindole-
acetic acid (5HIAA) rather than reduced to the alcohol, 5-hydroxy-
tryptophol. However, it was found that the ratio of acid/alcohol
depends on an intricate balance of co-enzymes (reduced nicotinamide
adenine dinucleotide phosphate for reduction and both nicotinamide
adenine dinucleotide and nicotinamide adenine dinucleotide phosphate
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for oxidation) which alters the rate of reduction or oxidation.
Furthermore, in brain,the reduction depends on the ratio of
NADPH2 (reduced):NADP1.
It is interesting to note that, in urine, the per cents of
HVA and MTYR are similar to those in brain. However, comparative
values by other workers were unobtainable.
Indeed, the experiment was not set out to investigate the rate
of catechol amine catabolism, yet the fact that the pattern of
predominance of these "presumed" catabolites (Groups I and III)
compares with that reported by other workers is a suggestive
evidence for their authenticity. This is not to deny that (i) it
is very difficult to make any conclusive interpretations when the
levels of radioactivity are very low and, therefore, the possible
experimental error is high, and (ii) L-methionine donates methyl
groups to a host of metabolites in the body, and the radioactivity
of these catabolites comes from L-methionine C^-methyl groups.
Although using different chromatographic solvents, as adopted in
this study, reduces the chances of contamination from other
methylated metabolites, it is virtually impossible to rule out
all of them. Ideally, a more direct proof would have been to
block O-methylation by inhibiting COMT (e.g. pyrogallol) and deter¬
mining whether the peaks of radioactivity, presumed to be methylated
catechols, disappear. However, this approach would have been
technically very difficult since pyrogallol, as well as the tropo-
lones, blocks COMT by competitive substrate inhibition, thus
competing for the methyl group (Archer et al, 1960; Belleau and
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Burba, 1963). This would have resulted in C1^ labelled methylated
derivatives which had to be identified to make sure they did not
behave like O-methylated catechol metabolites through the separative
procedures, thus acting as contaminants.
The experiment shows that in vivo some of the C^4" radioactivity,
originating from the C^-methyl groups of L-methionine, is isolated
from brain and 24 hour urine, and demonstrated, using chromatographic
procedures, as probably O-methylated catabolites of NA and dopamine.
The percentage of each catabolite falls within the range reported by
other workers, thus suggesting evidence for their authenticity.
DIAGRAMIII



































































EFFECT OF L-METHIONINE LOADING
ON NORADRENALINE CATABOLISM IN BAT BRAIN
MATERIALS AND METHODS
(A) EXPERIMENT'S DESIGN
Two groups of albino Wistar rats, each weighing 120 g were put
in two separate cages and starved for twelve hoursj at the end of
that interval -
Group I - Control (5 Rats); Each rat was fed with about 14 g/day
of diet (Appendix Vl) in pellet form for a period of four days. On
the fifth day they were injected intraperitonially with a suspension
of glycine in saline, using 1.5 g of glycine/Kg body weight in 1 ml.
saline per rat.
Group II - L-methionine (6 Rats): Each rat was fed with about
14 g/day of a diet containing (ffo L-methionine*. The diet was
given for a period of four days and on the fifth day each rat was
injected intraperitonially with 1 ml. suspension of 1.5 g L-
methionine/Kg body weight in saline.
Three hours after the intraperitoneal injection, each rat from
both groups was anaesthetized with ether and injected intraventri-
cularly (Noble et al, 1967) with 0.5/iCi of DL-noradrenaline
(Carbinol-C (25 mCi/mMol)** in 20yul of Merles solution.
* Pellets (identical to those used for Group i) were ground and
L-methionine, in the crystalline form, was added. The mixture
was then hydrated and reconstituted into pellets similar to the




One hour after the intraventricular injection, the rats were killed
by cervical fracture, decapitated and their brains removed.
(B) SEPARATIVE PROCEDURES
Each brain was homogenized, in an all glass homogenizer, with
6 ml. of chilled 0.4N PCA (0.05% ascorbic acid and 0.1% EDTA); the
homogenate was spun in a refrigerated centrifuge (4°C) for fifteen
minutes at 20,000 £. At this stage, an 0.2 ml. aliquote of the
supernatant was dissolved in 4 ml. ethanol:methanol (3:1) and 10 ml.
of Toluene (PP0, P0P0P) scintillator and counted by liquid scintil¬
lation: thus the total radioactivity in the supernatant of each
sample was assessed. The remaining supernatant was adjusted to
pH4 (glass electrode) with 5N and IN K0H and cooled at 4°C for
ten minutes to remove the excess PCA by precipitating it as the
potassium salt. The sample was centrifuged for three minutes at
4,000 £ and the supernatant decanted and adjusted to pHl (glass
electrode) with concentrated HC1.
(l) Phenolic Acids: Each supernatant (pHl) was extracted thrice,
each time with double volume of ethyl acetate. The aqueous phase
was saved for the determination of the glycol conjugates and 0-
methylated amines; the pooled organic phase was extracted once
with one-sixth its volume of 1 M K^CO^ buffer (pHIO) . The buffer
layer (containing the acids) was adjusted to pHl (glass electrode)
with concentrated HC1 and extracted thrice, each time with double
volume of ethyl acetate. To each combined ethyl acetate fraction
10 ^g of unlabelled VMA and DHMA* were added, and the samples were
* DHMA - Dihydroxymandelic acid.
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"blown down to ^ 0.2 ml. under a stream of nitrogen, then stored at
-20°C until chromatography.
(2) 0-methylated Amines from Glycol Conjugates: Each aqueous phase
was adjusted to pH7.5 (glass electrode) with 5N, IN and 0.1N KOH,
and passed over a 10 x 0.7 cm. column of Amberlite C& 50 resin
(NH^+ form, pH7.5). The effluent was saved, the column was washed
with 10 ml. of distilled water and the 0-methylated amines were
eluted off the column with 15 ml. of 3N NH.0H. To each effluent
4
(containing the glycol conjugates) and eluate ™200 jug of ascorbic
acid was added; 10 jug of NM and M were added to the latter. They
were then each reduced in volume to - 0.2 ml. under vacuum at 37°C
and stored at -20°C until chromatography.
/
(C) IDENTIFICATION
The acids, glycol conjugates and 0-methylated amines were
identified using descending paper chromatography. All tanks were
saturated with nitrogen before sealing and the chromatograms were
left to equilibrate with the solvent vapours for eight hours before
developing.
(l) Phenolic Acids: Each 0.2 ml. ethyl acetate concentrate was
applied to a 46 x 4 cm. strip of Whatman No. 1 chromatography paper*;
the sides of the tube were washed with 0.2 ml. of methanol which was
also applied to the strip. Markers of authentic DHMA, VMA, DHP&
and HMP& were applied onto separate strips. The sample and marker
* A sheet of Whatman No. 1 chromatography paper was cut (along its
length) into 4 cm. wide strips separated from each other by 1 cm.
wide gaps. The gaps did not reach the opposite edges of the paper;
thus the strips were connected to each other.
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strips were developed in Isobutyl methyl ketone:/$ formic acid
(10:1 v/v; 2 phase) for six hours; then they were removed from
the tank and dried.
The marker strips were sprayed with a mixture of paranitro-
anilinejlO^ sodium nitrite (10:1), allowed to dry and resprayed
with IN NaOH in 50/« ethanol. The visualized marker spots were
localized and their distances from the origin measured (Figure 14,14a).
The sample strips were cut into 1x4 cm. strips, each of
which was immersed in 4 ml. of Toluene (PPO, POPOP) scintillator
and counted by liquid scintillation against blank strips developed
in the same solvent system (Figure 14,14a).
(2) Glycol Conjugates: Each 0,2 ml. concentrated effluent was
applied to a 46 x 4 cm. strip of Whatman No. 1 chromatography paper;
the sides of the tube were washed with 0.2 ml. of methanol, which
was also applied to the strip. Paranitrophenol was applied onto
separate strips which, together with the sample strips, were
developed in chloroform:methanol:ammonia (0.88) (12:7:1 V/v» single
phase) for thirteen hours, according to the method of R.F. Sugden
(personal communication)*.
* The paranitrophenol gives a yellow colour in a basic medium, thus
is a convenient marker during development of the chromatogram. At
about thirteen hours it reaches the lower edge of the paper and
that is the time to stop the chromatogram, since the HMPG conjugate
runs just behind it. In that solvent system the glycol conjugates
run slowest with the DHPG conjugate moving only a short distance
from the origin; the HMPG conjugate runs further from the origin
and therefore is separated from it. The chromatogram is developed
for thirteen hours because by that time: (i) the free alcohols and
phenolic acids run off the lower edge of the paper, (ii) the HMPG
conjugate is well separated from the DHPG conjugate without the
former running off the paper, and (iii) the DHPG conjugate is well
separated from contaminants which remain at the origin.
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The sample strips were removed from the tank, dried and cut
into 1x4 cm. strips, each of which was immersed in 4 ml. of
Toluene (PPO, P0P0P) scintillator. They were counted by liquid
scintillation against blank strips developed in the same solvent
.system (Figure 15,15a).
(3) O-methylated Amines: Each 0.2 ml. concentrated eluate was
applied to a 46 x 4 cm. strip of Whatman No. 1 chromatography paper;
the sides of the tube were washed with 0.2 ml. of methanol which was
also applied to the strip. Markers of authentic NM, M and NA were
applied onto separate strips which, together with the sample strips,
were developed in butanol:ethanol:ammonia (0.88) (4:1:1 V/v - single
phase) for seventeen hours. At the end of that time they were
removed from the tank and dried -
1. The marker strips were sprayed with a mixture of paranitroaniline:
10% sodium nitrite (10:1), dried and resprayed with ethanolic IN NaOH.
The visualized spots were localized and their distances from the
origin were measured (Figure 16,16a).
2. The sample strips were cut into 1x4 cm. strips, each of which
was immersed in 4 ml. of Toluene (FP0, P0P0P) scintillator and
counted by liquid scintillation against blank strips developed in
the same solvent system (Figure 16,16a).
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RESULTS
1. All values were corrected for (i) quenching by the channel ratio
method; thus expressed as DPM, and (ii) recoveries, except the con¬
jugates.
2. In the case of the glycol conjugates and acids, the ratio of the
O-methylated/dihydroxy catabolite was calculated.
3. In all three (acids, glycol conjugates and O-methylated amines),
the value of each catabolite in any one sample was expressed as -
(i) Per cent of total radioactivity in the supernatant,
(ii) Per cent of total catabolites obtained from adding
the individual peaks of radioactivity from all the
catabolites, e.g. -
/
BHMA (in DPM) y ioo
(DHMA + VMA) + (DHPG + HMPG conjugates) + KM (in DPM)
(l) Phenolic Acids
As seen in Figures 14 and 14a, there was some carry over of
free (unconjugated) HMPG- and a lesser amount of free DHPG. However,
they were well separated from DHMA.
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FICURE 14
+ DHPG IS HMPG ^VMA^WW
CONTROLS
ORIGIN
DESCENDING CHROMATOGRAPHY ISODUTYL METHYL KETONE: 4"A FORMIC ACID 110:11 6 hrs
ACIDS
ACID CATABOEITES OF C12f~NA IN RAT BRAIN
ONE HOUR AFTER ITS INTRAVENTRICULAR INJECTION
(Control (glycine) group)
Whatman No. 1 chromatography paper strips (46 x 4 cm.).
Markers were visualized by spraying with diazotised




ACID CATABOEITES OF C +-NA IN RAT BRAIN
ONE HOUR AFTER ITS INTRAVENTRICULAR INJECTION
(L-Methionine group)
Whatman No. 1 chromatography paper strips (46 x 4 cm.)
Markers were visualized by spraying with diazotised
paranitroaniline, then ethanolic IN NaOH.
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TABLE 10
RATIO OF WiA/DHMA IN BRAIN ONE HOUR AFTER
INTRAVENTRICULAR INJECTION OFClif-NA
CONTROL* L-METHIONINE**
1 1.4132 6 5.3064
2 2.3329 7 5.5447
3 2.3464 8 3.7866
4 1.3101 9 4.2791
5 2.2571 10 4.0280
11 2.6101
* Croup of rats which were injected intraperitonially
with glycine.
** Croup of rats which were fed and injected intra¬
peritonially with L-methionine.
The t-test for uncorrelated means (Cuilford, 1956) showed
that t (d.f. 9) = 3.9739 (t > 3.250 significant at 0.01 level).
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TABUS 10a
DHMA AM) VMA PER CENT OF TOTAL RADIOACTIVITY IN SUPERNATANT
OF BRAIN OKIE HOUR AFTER C^-M INTRAVENTRICULAR INJECTION
CONTROL L-METHIONINE
DHMA VMA DHMA VMA
1 1.17 1.5 6 0.24 1.31
2 0.79 1.86 7 0.38 2.15
3 0.70 1.65 8 0.35 1.34
4 0.89 1.17 9 0.18 0.57
5 O.67 1.53 10 0.48 1.94
11 0.74 1.93
DHMA - The t-test for uncorrelated means showed that
t (d.f. 9) = 3.292? (t > 3.250, significant at 0.01 level).
VMA - The Wilcoxon Rank Sum Test (Wilcoxon and Wilcox, 1964)
showed that T = 28 (for significance T <20 or >40).
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TABLE 10b
DHMA AND VMA. PER CENT OF TOTAL CATABOLITES IN BRAIN
ONE HOUR AFTER C^-NA INTRAVENTRICULAR INJECTION
CONTROL L-METHIONINE
DHMA VM DHMA VMA
1 4.60 5.88 6 1.90 10.11
2 3.33 7.77 7 1.74 9.69
3 2.94 6.91 8 1.45 5.51
4 6.71 8.80 9 0.59 2.85
5 3.74 8.44 10 2.19 8.82
11 3.81 9.96
DHMA. - The t-test for uncorrelated means showed that
t (d.f. 9) = 2.9986 (t >2.262, significant at 0.05 level).
VM - The Wilcoxon Rank Sum Test showed that T = 25
(for significance T <20 or >40).
Comment; The significant difference in VMA/DHM ratios between the
control and L-methionine groups was due to a change in DHMA and not
VIA. The results showed a decrease of DHM in the L-methionine group
(Tables 10a and 10b), hence the increase in VMA/DHMA ratio (Table 10).
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(2) Glycol Conjugates (HMPG S04 and DHFG- S04)
(Figures 15 and 15a).
TABLE 11
RATIO OF HMPG S04/DHP& S04 IN BRAIN
AFTER INTRAVENTRICULAR INJECTION OF Clif-M
(Time interval - 1 hour)
CONTROL L-METHIONINE
1 2.1545 6 2.8555
2 1.5926 7 2.2615
3 1.3707 8 1.4568
4 1.3803 9 1.3111
5 1.8988 10 1.4321
11 1.4884
The Wilcoxon Rank Sum Test showed that T = 29
(for significance T <20 or >40).
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TABLE 11a
DHPG- S04 AMD HMP& S04 PER CENT OF TOTAL RADIOACTIVITY IN SUPER¬
NATANT OF BRAIN QUE HOUR AFTER C^-M. INTRAVENTRICULAR INJECTION
CONTROL L-METHIONINE
EHPG- S04 HMPG- S04 HHP& S04 HMPG- S04
1 6.62 14.27 6 2.52 7.20
2 7.09 11.58 7 5.38 12.16
3 6.99 9.81 8 7.65 11.15
4 3.68 5.08 9 6.09 7.98
5 4.81 9.13 10 6.72 9.62
11 5.31 7.90
DHP& S04 - The Wilcoxon Rank Sum Test showed that T = 31.
HMPG- S04 - The Wilcoxon Rank Sum Test showed that T = 33
(for significance T <20 or >40).
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TABLE lib
EHPG S04 AMD HMPG S04 PER CENT OF TOTAL CAT&BOLITES
IN BRAIN OME HOUR AETER C^-NA INTRAVENTRICULAR INJECTION
CONTROL L-METHIONINE
DHPG S04 HMPG S04 DHPG 304 HMPG S04
1 25.91 55.82 6 19.37 55.33
2 29.57 48.30 7 24.16 34.64
3 29.26 41.02 8 31.27 45.56
4 27.51 37.97 9 30.09 39.45
5 26.50 50.33 10 30.51 43.70
11 27.37 40.74
DHPG S04 - The Wilcoxon Rank Sum Test showed that T = 28.
HMPG S04 - The Wilcoxion Rank Sum Test showed that T = 31
(for significance T <20 or >40).
Comment: There was no change in either ratio (Table 11) or per¬
centage of the glycols (Tables 11a and lib) between the two groups,




DESCENDING CHROMATOGRAPHY CHLOROFORM : METHANOL: AMMONIA 1357.): ( 12:7:1) 13 hrs
ALCOHOLS
CONJUGATED G-LYCOL CATABOLITES OF C1Z|'-M IN RAT BRAIN
ONE HOUR AFTER ITS INTRAVENTRICULAR INJECTION
(Control (glycine) group)





CONJUGATED GLYCOL CATABOLITES OF C12f-NA IN RAT BRAIN
ONE HOUR AFTER ITS INTRAVENTRICULAR INJECTION
(L-Methionine group)
Whatman No. 1 chromatography paper strips (46 x 4 cm.)
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(3) O-methyiated Amines
As seen in Figures 16 and 16a there were no peaks of radio¬
activity corresponding to M, which accounted for an insignificant
percentage of the total catabolites.
TABLE 12
MM PER CENT OF TOTAL RADIOACTIVITY IN SUPERNATANT
OF BRAIN ONE HOUR AFTER INTRAVENTRICULAR INJECTION OF C14-NA
NM NM
CONTROL L-METHIONINE
1 1.98 6 1.72
2 2.64 7 2.17
3 4.74 8 3.96
4 2.54 9 5.46
5 1.99 10 3.25
11 3.51
The Wilcoxon Rank Sum Test showed that T = 26
(for significance T <20 or >40).
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TABLE 12a
KM PER CENT OF TOTAL CATABOLITES IN BRAIN
AFTER C^-KA INTRAVENTRICULAR INJECTION
CONTROL L-METHIONINE
NM NM
1 7.7 6 13.25
2 11.00 7 9.74
3 19.85 8 16.19
4 18.99 9 27.00
5 10.97 10 14.76
11 18.09
The Wilcoxon Rank Sum Test showed that T = 27
(for significance T <20 or >40).






























DESCENDING CHROMATOGRAPHY BUTAN0L: ETHAN0L: NH, 1 357.) 11:1:11 17 hrs
O-METHYLATED AMINES
NORMETANEFHRINE IN BAT BRAIN ONE HOUR AFTER
INTRAVENTRICULAR INJECTION OF C^-NA
(Control (glycine) group)
Whatman No. 1 chromatography paper strips (46 x 4 cm.)
Markers were visualized hy spraying with diazotised





DESCENDING CHROMATOGRAPHY BDTANOL : ETHANOL : NH31357.] [t: 1:1 I 17 hrs
O-METHYLATED AMINES
NORMETINEPHRINE IN HAT BRAIN ONE HOUR AFTER
INTRAVENTRICULAR INJECTION OF Clzf--NA
(L-Methionine group)
Whatman No. 1 chromatography paper strips (46 x 4 cm.)
Markers were visualized hy spraying with diazotised
paranitroaniline, then ethanolic IN NaOH.
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table 13
INTRA GROUP MEAN PER CENT OF TOTAL CATABOLITES
IN BRAIN AFTER C^-KA INTRAVENTRICULAR INJECTION





















13.70 46.69 27.75 hSk
±0.53
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The object of the experiments was to determine whether changes
in O-methylation of NA could be demonstrated in animals given high
doses of methionine over a long period. Mackenzie et al (1950)
showed that there was an increase in turnover of methyl groups in
the body following L-methionine feeding. This was investigated by
14
feeding rats small doses of C -methyl labelled L-methionine with
or without L-methionine loading and measuring the radioactivity excre¬
ted in breath, urine and faeces. Their results showed that in the
L-methionine loaded rats maximum turnover, thus possible utilization, /
of methyl groups occurred three hours after the administration of
j
the labelled L-methionine and was sustained till six hours.
Following that period there was a gradual decrease in turnover,
reaching a plateau by twelve hours.
In this experiment the group of rats fed with L-methionine for
four days were injected with C^-NA three hours following the intra-
peritonial injection of L-methionine. According to the above
findings, this time interval represents maximum availability of
methyl groups for transmethylation. However, the present results
do not show evidence of increased O-methylation of NA catabolites,
which suggests that, although there is an increase in tissue levels
of S-adenosylmethionine (active methyl group) on L-methionine loading
(Baldessarini, 19^7)» either (i) there is no increase in methylation.
This could perhaps be due to a reaction rate limiting factor which
protects the body against non-physiological conditions; such
limiting factors are known to exist in various metabolic reactions
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in the body (e.g. active absorption of iron from the intestinal
mucosa is limited by catalytic conversion of the ferric ion).
Indeed, the limiting factor could be the methyl transferase
(i.e. COMT) itself, which, like other enzyme systems, can be
inhibited in the presence of excess co-enzyme (i.e. methyl donor)
(Meister, 19&5), or (ii) possibly an increase in methylation rate
does occur but in turn leads to excess demethylation; the latter
acts as a protective mechanism.
Regardless of the mechanism in which the body protects itself
against non-physiological transmethylation, it is interesting to
note that at one interval in time homeostasis was maintained where
neither an increase in the O-methylated NA catabolites nor an
increase in the dihydroxy catabolites (suggestive of increased
demethylation) occurred. The decrease in DHMA on L-methionine
loading is probably not indicative of increased methylation for
the following reasons:-
(i) There was no concomitant decrease in DHPG (another dihydroxy
catabolite) or a significant increase in KM to assume that this was
due to a shift in the degradation of NA in favour of O-methylation
and at the expense of deamination.
(ii) There was no accompanying increase in VMA. Although it is
claimed that COMT is probably also found intraneuronally (Weiner,
1970 - personal communication with Iverson and Jarrott), it is
believed that intraneuronal NA is deaminated by MO forming the
dihydroxy catabolites which then are transported from the cell and
are O-methylated by extraneuronal COMT (Carlsson and Hillarp, 1962;
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Kopin and Gordon, 1962). If the decrease in DHMA was due to
increased O-methylation, then it is expected that VMA should also
have increased unless such absolute increase was not shown because
VMA is eliminated from brain and body at a rapid rate (Maas and
Landis, 1968).
The mean values shown in Table 13, except for DHMA in the
control group, are in agreement with those reported by Sugden, R.
(1970 - personal communication). He studied the catabolism of
C^-NA in brain ab various time intervals after its intraventricular
injection. He showed that after one hour the values of the various
catabolites, expressed as per cent of total catabolites, were as
follows: 20$ NM, 38$ HMPG conjugate, 22$ DHPG conjugate, 6$ VMA
and 1.5$ DHMA. The higher percentage of DHMA in the control group
probably represents wide variations in the formation and/or isolation
of this catabolite (C. Yates - unpublished observations). However,
there is the remote possibility that this could be a glycine effect.
It is very difficult to interpret this variation in DHMA since the
Sugden experiment represents control conditions, yet the DHMA value
is similar to that in the L-methionine group and lower than that in
the control group. Although this might suggest that there was no
decrease in DHMA on L-methionine loading but only an experimental
variation, it is interesting to note that the individual DHMA values
within each group show that the control values are invariably higher
(Tables 10a and 10b).
There was no statistically significant increase in the 0-
methylated catabolites of NA on L-methionine loading. This possibly
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suggests, provided O-methylation is representative of other types
of methylation (i.e. N-methylation, etc.), that in the body there




The present study has shown that L-methionine (without MAOl)
can produce an acute psychosis in a proportion of chronic schizo¬
phrenics; these "reactors" cannot he differentiated from "non-
reactors" on clinical grounds. The "methionine reaction" is
schizophreniform in nature and is sometimes preceded hy a toxic
reaction. Although it takes the form of a schizophrenic psychosis
and sometimes even exacerbates specific and latent symptoms, it
cannot be considered for certain to be a specific exacerbation of
the schizophrenic illness; it could very well be a non-specific
superimposed psychosis produced by L-methionine, which may take
this form in schizophrenics. However, comparable (Alexander et al,
1963) or lower (Harper et al, 1970) dosages of L-methionine do not
produce a similar reaction in non-schizophrenic patients or normals
respectively.
Following the immediate reaction to L-methionine there was no
significant improvement in the mental state of any of the patients;
however, none became worse. It may be concluded, therefore, that
L-methionine is without therapeutic effect.
The mechanism by which L-methionine produces this reaction is
quite unknown. The following points are, however, relevant,
(l) L-methionine has been shown to be the prime methyl donor in
the body (Cantoni, 1951L) and to donate methyl groups to brain
monoamines in vitro (Axelrod et al, 1958) and most probably in vivo
(the present study - Section IV). (2) There was no increase in
0-methylation of catechol amines on L-methionine loading, as
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reflected by the absence of an increase in (a) HMPG and VMA in the
urine of schizophrenics, and (b) the O-methylated noradrenaline
eatabolites in rat brain. However, the possibility that, in
schizophrenia, there is a "transmethylation defect" and that L-
methionine (being a methyl donor) produces its effects through this
mechanism cannot be completely ruled out. This is because,
firstly, only the O-methylation of catechol amines was studied,
thus L-methionine, being a methyl donor for other compounds in the
body (i.e. N and O-methylation of indole amines), could have exerted
t
its effect through these compounds. As mentioned in the literature
review, little is known about these methylating enzymes and many
0 and N-methylated derivatives of indole amines are psychotomimetic.
Secondly, the defect in schizophrenia could very well be that of
demethylation. Such a defect would result in an increased body
methylation pool, on L-methionine loading, without an absolute
increase in the rate of methylation.
Moreover, L-methionine has functions in the body other than
that of methyl donation. Such functions include thiol group
activity, interaction with tryptophane metabolism, cell membrane
transport, etc. (See literature review). It is quite possible,
therefore, that its effects could have been mediated through any
of these functions which could be unrelated to the pathogenesis of
schizophrenia. On the other hand, abnormal methionine metabolism
(which includes the above functions) might be involved in schizo¬
phrenia (israelstam et al, 1970; Spiro et al, 1965).
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This study has suggested further investigations into biological
transmethylation and its enzyme systems in animals as well as humans,
both schizophrenics and normals. Specifically, (i) the confir¬
mation of relevant previous work and the study of specificity and
nature of methylating and demethylating enzymes; (ii) investigation
of indole amines and their catabolites in normals and schizophrenics;
(iii) a study of methionine metabolism in schizophrenics; and
(iv) a further longitudinal study of HMP& urinary levels in a
larger group of schizophrenics and normals, and the effect of
L-methionine loading on these levels in the latter group.
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1. Age: 52 years
Hospital Diagnosis: Schizophrenia
Duration of Hospitalization: 30 years
The patient was apathetic and withdrawn. At times she showed
manneristic behaviour and auditory hallucinations. In the ward she
was tidy and aware of her environment. She was on Largactil, 50 mgm
at bedtime. When the medication was stopped she did not show any
change in her mental state.
On the second day of drug A (found later to be L-methionine) she
became more withdrawn and disinterested in her surroundings. At
times she became restless and showed severe thought blocking. The
auditory hallucinations became more frequent and were suspected to
influence her behaviour in the ward. The manneristic movements
became more pronounced. There were no signs or symptoms of clouding
of consciousness or disorientation. This condition remained until
L-methionine was withdrawn when her mental state reverted to that of
the pre-L-methionine period. She became more sociable and respon¬
sive. The hallucinations became less frequent and, in the ward, she
showed more interest in other patients and the nursing staff. Pheno-
thiazines were not restarted and the long term follow-up for one year
did not show any significant changes in her mental state.
2. Age: 58 years
Hospital Diagnosis: Schizophrenia
Duration of Hospitalization: 24 years
Before the beginning of the trial, this patient was sociable and
active in the ward. She showed thought dissociation and bizarre
ii
thought content. At times she manifested with outbursts of impul¬
sive behaviour and paranoid feelings against the nursing staff.
She admitted hearing voices that instructed her to do certain things,
which she did not divulge. Her affect was incongruous. She was
not receiving any medication.
On the third day of drug B (later found to be L-methionine) she
became very deluded, showing continuous signs of persecutory thoughts.
She became antagonistic to everybody and, at times, showed aggressive
behaviour. The auditory hallucinations became more marked and
frequent and the patient could be observed talking to herself. The
patient's affect was blunt. She did not seem to be disorientated
and did not show signs of clouding of consciousness. When L-
methionine was stopped she gradually improved by becoming friendlier,
sociable and communicative. The auditory hallucinations became less
frequent and the patient had partial insight into the episode. The
long tern follow-up did not show a significant change in her mental
state.
3. Age: 61 years
Hospital Diagnosis: Chronic schizophrenia
Duration of Hospitalization: 35 years
This patient was withdrawn unless approached. She responded to
her environment but showed no stamina or interest to communicate with
others. She was negativistic but,when talked to, betrayed thought
form and content disorder. She denied being hallucinated and did
not show outward delusions; her affect was flat. She was on no
medications.
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There was no observable change in her behaviour throughout the
experiment and she did not show signs of a toxic delirium.
Long term follow-up was uneventful,
4. Age: 54 years
Hospital Diagnosis: Paranoid schizophrenia
Duration of Hospitalization: 16 years
This patient was sociable and communicative. She admitted
having auditory hallucinations (mainly persecutory) at night. She
got along with everybody and did not show signs of antagonism or
hatred to anybody. She was keen on participating in social events
and was reported to be helpful in the ward. Her affect was rather
flat. No reaction to L-methionine was observed, and the patient's
long term follow-up was uneventful. She was not receiving drugs
before or after the experiment.
5. Age: 46 years
Hospital Diagnosis: Heberphrenic schizophrenia
Duration of Hospitalization: 15 years
This patient showed frequent manneristic behaviour and incon¬
gruity of affect. She admitted experiencing auditory hallucinations
but it was very difficult to assess her thought content and form
because of her short attentive span. In the ward she was active
but not very helpful. L-methionine did not produce any worsening
of her symptoms.
She was on Fentazin 4 mgm b.i.d. and her mental state did not
deteriorate after stopping it. After the experiment, only a night
sedative was given and the long term follow-up showed little change
in her mental state.
iv
(B) MAIN EXPERIMENT
(1-5 female; 6-11 male)
1. Age: 60 years
Hospital Diagnosis: Heberphrenic schizophrenia
Duration of Hospitalization: 25 years
At the start of the experiment she was sociable, orientated and
showed minimal schizophrenic symptoms. These symptoms comprised of
thought form disorder as well as those of thought content. The
latter were in the way of persecutory delusions and auditory hallu¬
cinations, which were intermittent. At times she showed withdrawal
and negativism along with suspiciousness. These symptom fluctua¬
tions were never severe and subsided within a day or two; on few
occasions they were triggered by environmental factors. She was
on Stelazine 5 mgm b.i.d. and the clinical picture before the start
of the experiment showed more sociability and less apathy and with¬
drawal following discontinuation of the phenothiazines.
She reacted to L-methionine (amino acid B) firstly by a toxic
psychosis, which was characterized by disorientation and altered
sensorium, accompanied by neurological signs of vestibular dys¬
function (ataxia, Romberg sign). This reaction subsided after
24-48 hours and was followed by a symptom free period lasting
12-14 hours. The second reaction was schizophreniform in nature
and was free of any toxic signs or symptoms. The patient became
impulsive and very suspicious. Her ward behaviour indicated that
she felt persecuted by the staff and other patients. She was
i
agitated and restless with continuous auditory hallucinations which
in content were similar to those experienced by the patient some
years ago. Her affect became blunt and she became negativistic.
V
Her mental state was considered acute and it was felt that the amino
acid (later found to be L-methionine) should be withdrawn. On the
eighth day of the L-methionine period, one day after L-methionine
was stopped, the acute symptoms started becoming less severe and
on the fourteenth day she settled down. She was reported by the
nursing staff to be more sociable and less suspicious than before
the experiment started; the delusions and hallucinations were less
apparent clinically. However, this improvement did not last and
the patient showed a minor relapse. Stelazine (5 mgm t.i.d.) was
started on the seventeenth day and the patient responded well to it.
The long term follow-up proved uneventful and the patient maintained
a mental state similar to that before the experiment.
2. Age: 46 years
Hospital Diagnosis: Heberphrenic schizophrenia
Duration of Hospitalization: 10 years
Before the experiment the patient showed incongruous affect,
thought blocking and moderate thought form disorder. She was
manageable but unsociable and at times experienced auditory hallu¬
cinations. She was on Melleril (50 mgm hi.d.) and showed no relapse
after its discontinuation. She reacted to L-methionine by worsening
of the above symptoms, which subsided on its withdrawal two weeks
later. Specific hallucinations and delusions pertaining to the
same situations and persons which she had some years ago were
experienced by the patient. At the end of the experiment she was
restored on phenothiazines (Melleril 50 mgm b.i.d.), to which she
responded. Her affect became less incongruous and the hallucin¬
ations were less frequent. In the ward she was reported to be more
vi
sociable and communicative than she had been before the experiment
started. The long term follow-up showed that these changes persisted.
3. Age: 59 years
Hospital Diagnosis: Schizophrenia
Duration of Hospitalization: 29 years
This patient was withdrawn and asociable before the experiment.
At times she was hallucinated, showed thought blocking, and her
affect was flat. She was not receiving any medications. She did
not react to L-methionine and at the end of her stay in the metabolic
ward she was reported by the nursing staff to be more manageable,
sociable and attentive than she had been before. She was not put
on any drugs and kept well after transfer to her ward.
4. Age: 55 years
Hospital Diagnosis: Sohizophrenia
Duration of Hospitalization: 37 years
Before the experiment she was apathetic, withdrawn, but at times
showed impulsive behaviour. She was suspected to be hallucinated
but the patient was negativistic. Her affect was flat and she did
not show any fluctuations of her symptoms. She was not receiving
medications.
She did not react to L-methionine and there was no change in her
behaviour or clinical state throughout the experiment. She was not
put on drugs at the end of the experiment, and the long term follow-
up was uneventful.
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5. Age: 57 years
Hospital Diagnosis: Schizophrenia
Duration of Hospitalization: 25 years
This patient was sociable in the ward, helpful and interested
in her environment. At times she showed paranoid behaviour and
became withdrawn. Auditory hallucinations were not noticed at any
time and the patient denied experiencing them. She was not on any
drugs before the experiment. The natural history of her illness
was stable, without fluctuations for the past four to five years.
She reacted to L-raethionine in that she became negativistic,
withdrawn, suspicious and developed persecutory delusions. She
was overtly hallucinated and her behaviour was suspected to be
influenced by the auditory hallucinations. There were no signs
or symptoms of a toxic state.
All the symptoms subsided three days after L-methionine was
discontinued. She was not put on medications and, at the end of
the experiment, she showed no significant changes in behaviour as
compared to previous ratings. Long term follow-up was uneventful.
6. Age: 51 years
Hospital Diagnosis: Heberphrenic schizophrenia
Duration of Hospitalization: 20 years
This patient reacted to L-methionine with acute schizophreni¬
form symptoms and, prior to the experiment, discontinuation of the
medication (Haloperidal 5 mgm b.i.d.) did not result in a relapse.
At the start of the experiment he was communicative, interested in
his environment, but some times showed paranoid behaviour. No
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auditory hallucinations were reported and his affect was rather
blunt. Before the start of Haloperidal (which he received for
two years) he was more withdrawn and some times acted upon his
paranoid feelings. He was not hallucinated. The reaction to
L-methionine (amino acid A) took the form of auditory hallucinations
(mainly with persecutory overtones), paranoid delusions, withdrawal,
thought block and lack of concentration. There was no clinical
evidence to suggest a toxic psychosis. Ward behaviour and the
nurses' rating confirmed the above findings. These symptoms sub¬
sided gradually on stopping L-methionine. Haloperidal (5 mgm b.i.d.)
was restarted at the end of the experiment and he was reported to be
sociable, free of apparent symptoms and more communicative than he
was before the experiment. Long term follow-up showed that he
maintained an improved mental state.
7. Age: 53 years
Hospital Diagnosis: Catatonic schizophrenia
Duration of Hospitalization: 16 years
Prior to the experiment he showed lack of concentration,
manneristic behaviour and thought form disorder. Phenothiazines
(Largactil 50 mgm b.i.d.) were stopped, giving no worsening of his
mental condition. He reacted to L-methionine (amino acid B),
firstly by a toxic psychosis where he became disorientated, wandering
about aimlessly; his sensorium was dulled and he showed at times
ataxic gait. This reaction lasted for a period of about 36 hours
and was followed by a symptom free interval of 24 hours. The
second reaction was schizophreniform in nature, without any toxic
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symptoms or signs, and took the form of a worsening in his pre-
methionine mental state. Due to the marked exacerbation of his
symptoms, L-methionine was withdrawn after eight days. The patient
became better, but Melleril 50 mgm t.i.d. was restarted on the four¬
teenth day (six days after stopping L-methionine) and he showed a
good response to it. At the end of the experiment he was observed
to be sociable in the ward, doing things for himself, and his
behaviour was manageable. Long term follow-up showed that he was
no better or worse at the end of the experiment than he was at the
beginning.
8. Age: 55 years
Hospital Diagnosis: Paranoid schizophrenia
Duration of Hospitalization: 27 years
This patient showed minimal clinical symptoms other than inter¬
mittent overtalkativeness and suspiciousness. All through he
admitted having auditory hallucinations which did not influence
his behaviour in any way. He did not relapse on stopping the
phenothiazines. He did not react to L-methionine and towards the
last six weeks of the experiment he was slightly more suspicious,
admitting at times persecutory delusions; his overtalkativeness
was slightly more marked. He was restarted on phenothiazines
(Pentazine 8 mgm t.i.d.) at the end of the experiment and the above
symptoms subsided, except for the auditory hallucinations, which
became less frequent. The patient died three months after the
end of the experiment, due to intussusception and intestinal
gangrene.
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9. Age: 58 years
Hospital Diagnosis: Schizophrenia
Duration of Hospitalization: 36 years
The patient showed manneristic behaviour, apathy and flatness
of affect. He was withdrawn but manageable in the ward, and only
occasionally was suspected to experience auditory hallucinations.
He was on Largactil 25 mgm t.i.d. and after stopping the drug he
did not show a relapse.
He did not react to L-methionine and his clinical mental state
was unchangeable except for minor changes in ward behaviour from day
to day. He was not restarted on phenothiazines and his long term
follow-up was uneventful.
10. Age: 51 years
Hospital Diagnosis: Paranoid schizophrenia
Duration of Hospitalization: 14 years
At the beginning of the experiment he showed manneristic
behaviour, withdrawal and incongruity of affect. He was at times
hallucinated and manifested thought block, lack of concentration
and thought dissociation. These symptoms did not increase in
severity after discontinuation of the phenothiazines (Melleril
50 mgm b.i.d.) but did so on L-methionine. After the withdrawal
of L-methionine he gradually became better and at the end of the
experiment was restarted on Melleril 50 mgm b.i.d., on which further
improvement occurred. Long term follow-up showed that the patient's
mental state was similar to that before the experiment.
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11. Age: 49 years
Hospital Diagnosis: Catatonic schizophrenia
Duration of Hospitalization: 12 years
This patient showed catatonic behaviour, negativism, withdrawal
and thought blocking. He manifested thought form disorder but
denied experiencing auditory hallucinations, and was communicative.
The above symptoms were present at the beginning of the experiment
and became exaggerated on L-methionine. Auditory hallucinations
became continuous and their content was the same as those experienced
years ago by the patient. In fact, the same voices were heard
giving the same commands and slogans to the patient.
After stopping L-methionine he became gradually better and
reverted to his pre-methionine mental state. He was not receiving
any drugs prior to the start of the experiment and was not given any
after it. The long term follow-up was uneventful.
APPENDIX II
DIAGRAM FOR INTRAVENTRICULAR INJECTION
APPENDIX II
DORSAL VIEW OR RAT SKULL






... ^DIAGRAM for INTRAVENTRICULAR INJECTION, . . .
Procedure
1. A 2-3 cm. midline incision is made on dorsum of skull.
2. A. burr hole is made 1 mm. from the central and transverse sutures.
3. The injecting lance is inserted into the burr hole and the
solution is injected.
4. The injecting lance is left in place for 15-20 seconds to
avoid back flow of the solution.
5. The lance is removed and the incision edges are approximated
with a Michael clip.
APPENDIX III
THIN LAYER CELLULOSE PLATE
WHATMAN NO. 1 CHROMATOGRAPHY PAPER
APPENDIX III
(a) Thin layer precoated cellulose plate (20 x 10
2 - Dimensional Decending Chromatography
(h) Whatman No. 1 chromatography paper.
APPENDIX IV
HMPG- AND VMA EXCRETION
(Main experiment - males)
 
APPENDIX V
TWO DIMENSIONAL CHROMATOGRAPHY SYSTEM
1. Acids and Alcohols
2. O-Methylated Amines
ACIDS AND ALCOHOLS
Two Dimensional Descending Chromatography
1.
(a)
1st System - Isobut^l methyl ketone:2$ formic acid(10:1 /v) ~ 2 phase (organic phase used)
Developing time: 5 hours.
2nd System - Chloroform:methanol:ammonia (0.88)
(12:7:1 /v) - single phase
Developing time: 5 hours.
a,b,c;
Whatman No. 1 chromatography paper.
L-methionine and S-adenosylmethionine shown,
adrenaline and noradrenaline (not shown in
Figures) are separated from the catabolites.
Spots were visualized by spraying with diazotised
paranitroaniline, then ethanolic IN NaOH.
1stSystem-Butanol^pyridin :water (14:4:5/v)-singlephas Developingtime:17hours. 2ndSystem-Butanol:aceticci(glacial):w t r: dichlorethane(1:1:1:3)/v)-2phase (organiclayerused) Developingtime:5hours.
(*)
I30PB0PYLAle.i2 APK0NIA(0.£6)I1 WAT23.bI 1stSy tem«-Isopropylalcohol:ammonia(0.88): water(20:1:4/v)-singleph s Developingtime:20hours. 2ndSystem-Butanol^ethanol:water (4:1:1/v)-singlephas Developingtime:17hours.
2.
O-METHYIATED MIMES
Two Dimensional Ascending Chromatography
(a)
1st System - Isopropyl alcohol:ammonia 5^
(4:1 /v) - single phase
Developing time: 9 hours.
2nd System - Benzene:acetic acid (glacial):water
(62.5:36:1.5 /v) - single phas e . 3 nuns.
Thin layer precoated silica gel plate (20 x 20 cm.)
L-methionine and S-adenosylmethionine (not shown
in (a) but shown in (b) and (c)) plus noradrenaline
and adrenaline (not shown in Figures) are separated
from the catabolites.
Spots were visualized by spraying with diazotised
paranitroaniline, then ethanolic IN NaOH.
(c)
WhatmanNo.1chro atographypape .




CALCULATED ANALYSIS OE RAT DIET
APPENDIX VI
CALCULATED ANALYSIS ispl
, * n • r
Crude Oil • > 3.80% ; • , Lysine 1-10%
Crude Protein 20.14% ,1;. Methionine 0.39%
Crude Fibre 2.54% Cystine 0.36%
Digestible Oil ( .2.74% ; : Tryptophane 1 0.23%
Digestible Crude Protein 17.31% V Valine 0.96%
Digestible Fibre 1.16% ; ; Leucine 1.30%
Digestible Carbohydrate . 46.71% : Isoleuclne I 0.87%,
Linoleic Add i-os% ; Threonine 0.64%:
v;; Phenylalanine 0.87% j
ti":■ "t Tyrosine 0-61% I
Metabolizable Energy Histidine 0.49% '





Vitamin B, ' 5.7 mg/kg.
Vitamin Bt : • 8.0 mg/kg.
Vitamin B1t j, - 33.6 mcg/kg.
Pantothenic Add 18.1 mg/kg.
Biotin ' V/.!' ' 0.15 mg/kg.
Pyridoxlne q/( ; > 8.5 mg/kg.
Inositol; I / . 0.22 gm/kg.
















































Diet (in pellets) containing 0.39%
methionine fed to the control group
of rats.
The experimental group were fed the
same diet with added L-methionine
as to constitute Qfo.
PHYSICIANS AM) NORSES' RATING SCALES
LORR SCALE; Was adapted from the "In-patient Multidimensional Psychiatric
Scale" (Lorr et al, 1962). The scale consists of 18 items each item com¬
prising 4 sub-items rated from 0-3 except for one item which is rated from
0-2. Thus the total maximal rating on the scale is 53•
The items cover affect, thought process, content and form, psychomotor
behaviour, attention span, orientation and insight.
HENRY PHIPPS SCALE: (The Johns Hopkins Hospital - Psychiatric Clinic) -
The purpose of the scale is to obtain a graphic picture of patient's
day to day behaviour during the trial. Recording is carried out daily
by a nurse. Each 'day' consists of a 24 hours period beginning and
ending at 7 a.m.
All items describe undesirable behavioural features. Each is
scored 0-3 according the the nursed global judgement of its severity/
persistence during the 24 hours period.
The total maximum daily score is 108, however the maximal daily
score recorded during the trial was 65.
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PHYSICIAN'S RATING SCALE FOR CHRONIC SCHIZOPHRENIA
Adapted from the M.S.R.P.P, (Lorr Scale)
P,l, How direct and relevant are his responses to questions or to the topic
discussed?
0 Direct and relevant
1 Somewhat rambling and tangential
2 For the most part irrelevant
3 Wholly irrelevant
P.2 Does he assume or maintain peculiar, unnatural or bizarre postures?
0 None
1 For short periods
2 Throughout most of the interview
3 Throughout the entire interview
P.3 Are his thoughts consistent with his mood, or is there a discernible
lack of harmony between them?
0 Consistent
1 A little disharmonious
2 Distinctly disharmonious
3 Appear totally unrelated,





3 Throughout the interview
N.5 Does he tend to suspect or to believe on slight evidence or without
good reason that people and external forces are trying to or now do
influence his behaviour and control his thinking?
0 No unjustified suspicion
1 Inclined to suspect
2 Believes others are trying to control him
3 Believes ha is influenced or controlled
P.6 Are the elements of his speech logically consistent and connected by
some idea of relationship, or do they tend to be inconsistent and
disconnected? (Rate what is more representative during the interview,)
0 Coherent and consistent,
1 Slightly incoherent and inconsistent
2 Distinctly incoherent and inconsistent
3 Conspicuously scattered,, disconnected or incoherent,






P,8 Does he have any insight into his hallucinations? (Score 0 for no
evidence of hallucinations)
0' Full insight
1 Possibly full insight
2 Some insight
3 No insight
P.9 How frequently does he speak, mutter or mumble to himself, seemingly
to carry on conversations with hallucinatory voices?
0 Not at all
1 Occasionally
2 Fairly frequently
3 Throughout the interview
- 2 - ,
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P, 11 Does the patient ever glance up as if listening to auditory hallucinations?
0 Not at all
1 Doubtfully or occasionally
2 Fairly frequently
3 Throughout the interview,,






P.13 Is his speech irregularly interrupted, halted or blocked for varying
periods of time because of difficulty in finding words for his thoughts?
0 No speech blocks
1 A few interrupt ions
2 Many interruptions and conversations very difficult.
N.14 Does he have an exaggeratedly high opinion of himself, or an unjustified
belief or conviction of having unusual ability, knowledge, power, wealth or
status? ....
_
0 No exaggerated high opinion of himself,
1 An exaggeratedly high opinion
2 Conviction of unusual 'power, wealth etc,
3 Conviction of grandiose or fantastic power, wealth etc.
N.15 Does he tend to suspect or to believe on slight evidence or wirhout
good reason that some people are against him (persecuting, conspiring,
cheating, depriving, punishing) in various■ ways?
0 No unjustified suspicions
1 Inclined to suspect,
2 Inclined to believe
3 Has firm conviction.
N.16 Dees he tend to suspect or to believe•on slight evidence or without
good reason, that oorce people talk about, refer to, or watch him?
0 No unjusti f.'i e:l suspicions
1 In kilned to-suspect
2 Inclined' to believe
3 Has firm conviction.
N.17 ' Is there evidence of false ideas or beliefs? If present,, are these
ideas or beliefs (a) sufficiently plausible as to be accepted by a
normal person unirfirmed as to the facts, (b) implausible but not
impossible, (c.i impossible or bizarre (e.g.) mind controlled by
radio waves, he-art removed or dead)?
0 No evidence ; f false beliefs
1 Plausible- t- bhe uninformed
2 Irulwj.ctbbe
3 possible or bizarre
P.18 Does the patient - nn.u. and emotional response show blunting?
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INTRODUCTION: Some Principles of Rating Scale
Design and Use
The use of ratings of some sort to record or to
classify judgments or observations is ancient. There
are many hundreds of words in our language that
are evaluative terms, and many of them have quan¬
titative implications with respect to their referents
(e.g., "good-better-best"). A rating scale consists
of a defined continuum or dimension (hot-cold,
active-inactive) along which judgments are placed.
The scale may be a set of ordered categories with
numbers attached; it may be a series of adjectives,
phrases, or statements arranged in a sequence cor¬
responding to an increasing or decreasing amount,
severity, or other quantitative characteristic of the
phenomenon being observed; or it may be a line on
a page with its end-points labeled with two num¬
bers (e.g., 0-100 or 0-10) upon which the rater
makes his estimate of the degree or amount of the
observed phenomenon with respect to some stand¬
ard. The "standard" in psychiatric and psychologi¬
cal research is usually a class of persons, such as
chronic schizophrenics, normal adolescents, or some
other reference group, and the task of the rater is
to locate graphically or numerically the individual
under consideration with respect to the appropriate
reference group. For example, if a psychiatric
patient is judged to be about average in his refer¬
ence group in a certain trait (say, "overt hostility")
and is to be rated on a scale having numerical
indices ranging from 0 to 10, then a rating of 5
would be appropriate.
There are other instruments, perhaps improperly
called scales, requiring that the judge make dis¬
crete responses to a number of items. A list of
adjectives that the rater checks "yes" or "no," de¬
pending upon whether the item is or is not descrip¬
tive of the subject or patient, is an example of this
kind of device. For many of these, "scores" are
computed by counting the number of responses in
one or several categories, perhaps attaching differ¬
ent weights to certain items, depending upon their
differential significance for the purpose at hand. If
these scores are conceived as defining a quantitative
dimension corresponding to a trait or characteristic
under study, then we may consider such a score to
represent a point on a scale, provided certain other
basic requirements are met.
For many assessment instruments numerical
indices from several closely related scales or scales
believed to form a useful or meaningful constel¬
lation or syndrome may be added into a single
score. A descriptive name may be given to such a
score, which may be called a "scale." Sometimes
an entire instrument comprising a number of such
composite scales may be called "a scale." This can
lead to some confusion, particularly when investi¬
gators use rating devices constructed by themselves
and do not give adequate descriptions of their in¬
struments in published reports.
In the scale reports in this Handbook we have
usually followed the author's own terminology but
have attempted in the scale descriptions to clarify
the usage of words such as "item," "scale," "score,"
"cluster," etc., where necessary. In this introduc¬
tory discussion an individual statement, question,
or adjective to which a rater is required to make a
response will be called an item. A numerical index
derived from responses to a set or group of items
will be called a score or scale score.
In recent years much attention has been given to
the "theory" of scales from the mathematical point
of view. Principles and methods have been devel¬
oped in attempts to make ratings and other psy¬
chological measures comparable in some of their
characteristics to physical measurements (e.g., that
a difference of 5 points represents the "same" differ¬
ence in magnitude anywhere within the scale's
range in the same way that differences in pounds or
inches are equivalent). There are both philosophi¬
cal and technical issues here. Elaborate procedures
have been devised for the construction and scoring
of scales to achieve or approximate some of these
aims, but they have had little influence upon makers
or users of psychiatric rating scales, and there is
little or no evidence that the usefulness of these
scales would be significantly increased by such
refinements.
A Historical Note
Sir Francis Galton was one of the first investi¬
gators to apply systematic rating methods in be¬
havioral science. Late in the 19th century he
devised an eight-category scale and asked his sub¬
jects to evaluate the "vividness" of their visual
images.
Soon scales of various types were being used in
psychological laboratories to quantify judgments
of sensory and perceptual responses. The applica¬
tion of ratings in the educational and personnel
(industrial and military) areas thrived during and
after World War I, and many of the principles of
scale construction and the analysis and use of rat¬
ings were developed in these situations and during
this period. By and large, these principles apply
to psychiatric rating scales today.
The use of rating scales and similar devices for
psychiatric purposes developed more slowly,
although a pioneer example was the Phipps Psy¬
chiatric Clinic Behavior Chart, constructed and
used at Johns Hopkins about half a century ago.
At least several such instruments were devised
during the 1920's and 1930's but their use appears
to have been primarily local, i.e., for a specific re¬
search purpose or within a single hospital.
During and following World War II the rapidly
growing concern over the problems of mental health
and illness, the stimulation of research by the mili¬
tary services, the Veterans Administration, the
National Institute of Mental Health, state govern¬
ments and private foundations, and the increasing
research spphistication of professional persons in
the mental health field, have led to the development
of a number of assessment devices that can yield
information suitable for research as well as other
purposes. The recent introduction of tranquilizers
and other psychologically active drugs and the
encouragement of controlled drug tests by the Psy-
chopharmacology Service Center of NIMH have
further stimulated scale use and scale development.
Advantages of Quantitative Rating Scales
Interview Guide.—Many clinicians have re¬
ported that a schedule of items covering a variety
j. of observable symptoms and relevant questions
concerning patients' attitudes and feelings helps to
assure a more thorough and complete psychiatric
interview. There is less likelihood that possibly
significant phenomena may be omitted or over¬
looked. This is valuable, whether or not the infor¬
mation so derived is later reduced to numerical
form for other purposes.
Communication.—In contrast to narrative de¬
scriptions, numerical or graphic ratings are more
likely to be interpreted within the same semantic
frame of reference. Clinicians with different back¬
grounds and holding different theoretical views find
it valuable to have on record information gathered
in a systematic and common format. This can be
of considerable importance when patients are re¬
assigned to other wards within a hospital or to
other physicians.
Record of treatment progress.—A scale or set
of scales appropriate to the disorder under treat¬
ment ("valid" in one of the meanings described
in another section of this survey) can be an ex¬
tremely useful device for recording behavioral or
other trends indicative of changes during the course
of treatment. Numerical or graphic ratings of
presence-absence or severity of symptoms can serve
a purpose similar to a "fever-chart" in recording
treatment results.
Research.—Efficient and productive research re¬
quires objective data, data that can be manipulated
statistically, data that have sufficient dependabil¬
ity ("reliability"), and data obtained in such a way
that other researchers can repeat the study in an
attempt to confirm (or challenge) the original find¬
ings. The most sensitive of modern research designs
demands information in numerical form, derived
from the same instrument or instruments, and
gathered in a uniform or reproducible manner.
Well-constructed rating scales, as other psycho¬
metric devices, when properly used, meet most of
the requirements of the most elaborate and sophisti¬
cated of today's experimental and statistical proce¬
dures.
Format.—The major varieties of scale format
are illustrated by the descriptions and sample items
given in this Handbook. Usually the rater's task
is to check one of several words, phrases, or state¬
ments making up a given item. In some scales the
rater is free to make a mark at any point along a
line indicating the degree or magnitude of the
characteristic being reported, and the position of
the mark may then be translated into a number for
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scoring purposes. Generally the typography and
the physical arrangement of items on the page
reflect attempts to facilitate the rater's job and the
subsequent handling and scoring. In some scales
the item format is deliberately varied to minimize
the likelihood that a rater will fall into a response
pattern, such as making most of his ratings in the
same direction or in a limited part of the scale. ■
Another format that has seen increasing use in
recent years is the card-sort scale. Statements or
adjectives are printed on individual cards and the
rater's task is to sort them into several piles or
stacks (4, 5, or 7 are frequently used) ranging from
"most descriptive" to "least descriptive." Essen¬
tially, this does hot differ from the usual numerical
or graphic format (in fact, some scales have been
produced and used in both forms). It may have
several advantages in certain rating situations:
(1) The "novelty" may appeal to some raters. (2)
The rater is not likely to skip items inadvertently.
(3) A judgment is less likely to be influenced by
the immediately preceding ratings. (4) If the items
are printed on pre-punched I.B.M. cards, the piles
may be stacked in order and taken directly to
machines for scoring or other statistical treatment.
On the other hand, in some projects problems of
handling, storage, and manual scoring may make
this method less efficient. Difficulties will also arise
if the results, including the individual rater re¬
sponses, are wanted as a document of record.
Psychometric Principles and
Characteristics
This is an introduction to some key concepts of
reliability and validity. The discussion is neces¬
sarily simplified, and many readers familiar with
basic psychometric theory may want to omit it.
The Correlation Coefficient
A tool frequently used in evaluating reliability
and validity of ratings is the correlation coefficient.
This is a numerical index expressing the extent of
agreement between two sets of data (e.g., ratings
on scale A and scale B for a group of patients, or
ratings on the same scale by Judge 1 and Judge 2).
There are several ways of deriving and computing
such a coefficient, depending upon the character¬
istics of the data and the purpose of the investi¬
gator. All have in common the fact that the range
of values is from —1.0 through zero to a maximum
of +1.0, with —1.0 reflecting perfect or complete
disagreement; zero, chance agreement or no relation¬
ship; and +1.0, perfect agreement. With a corre¬
lation of +1.0 between scales A and B, knowing
the value of one scale for an individual permits
perfect prediction of the other. (This would imply,
of course, that the two scales supply the same infor¬
mation and that one—either one—is unnecessary.)
A graphic presentation of a perfect correlation (on
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In this diagram the numbers in the lower-left to
upper-right cells represent numbers of individuals
in the rated samples. Note that a subject's position
on one of the six-category scales corresponds pre¬
cisely to his position on the other. A perfectly
negative correlation would yield a configuration
with a reversed appearance—the frequencies would
be distributed from upper left to lower right.
(Actually, however, this could have precisely the
same interpretation as the positive case and can
be transformed into it by merely reversing the
direction of scoring, e.g., by assigning high numbers
to that end of the scale previously identified by low
numbers.) A correlation of zero means that the two
variables have merely a chance relationship with
each other, and that knowledge of one for an indi¬
vidual is of no value at all in predicting the other.
Such a case might look like this:
HIGH 5
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Note that here, within each row or column, the fre¬
quencies distribute themselves about the central
tendency or the mean of the entire group.
Actually, perfectly zero correlations (and per¬
fectly positive ones) are almost never found in re¬
search. But the statisticians have devised methods
for assessing the "significance" of correlation co¬
efficients to determine the degree of confidence with
which we may conclude that a relationship exists
or that a given coefficient is "significantly different
from zero."
These methods, with the results usually expressed
in percentages (most commonly .05 and .01), are
interpreted to mean that if the "true" correlation
were in fact zero, chance fluctuations in the sample
of data at hand would give rise to a coefficient as
large as that found in no more than 1 in 20 (or 1
in 100) repetitions of the study using similar sam¬
ples.
Factor Analysis
In the discussions of some of the rating scales in
this report there are references to "factor analysis,"
"factors," or "factor loadings." Factor analysis is
a fairly complex set of arithmetical operations that
begins with a table displaying the correlations of
each variable under consideration (scale or item)
with every other one. Then further computations
are performed leading essentially to a reduction in
the number of variables or dimensions that "account
for" or "explain" the observed relationships among
the original set of data. Thus, for example, after a
factor analysis of 100 rating scale items, it may be
concluded that six factors are present, which would
indicate that the 100 items are yielding information
about six different aspects or modes of behavior. A
"factor loading" is a numerical index (with a maxi¬
mum value of 1.00) reflecting the degree of asso¬
ciation that»a particular item has with the factor
concerned.
For rating scales, factor analysis has been used
for two major purposes: (1) to identify clusters or
families of items that "hang together" and can be
scored as a scale or sub-scale, thereby reducing the
amount of information an interpreter or user must
consider, and (2) to organize a mass of data in such
a way that an investigator can more easily under¬
stand it or formulate or test hypotheses concerning
the meaning or significance of the behavioral dimen¬
sions that his scales are measuring.
The reader should be warned that differences in
purpose, differences in theoretical points of view,
ll
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and differences in mathematical techniques are
such that detailed results of one factor analysis may
not necessarily be comparable to those of another,
even though the same variables are involved.
Reliability
The term "reliability" refers to several different
but related concepts in psychometric theory. Basic
to all of them is the notion of "measurement error,"
which recognizes the fact that test scores, ratings,
and other, quantitative observations are subject to
fluctuations from a hypothetical "true" value that
itself cannot be determined with assurance of per¬
fect accuracy but is "estimated" by the observed
score or rating. The smaller this error, the more
"reliable" are the data. Independent observations
that do not agree with each other are presumed to
contain some "error," although it may not be pos¬
sible to discover whether the error is in one set of
data or both, or which set is the more dependable.
On the other hand, observations that agree highly
or even perfectly may contain error factors if they
have been subject to similar distortions; as, for
example, when ratings are obtained by the use of a
poorly-constructed instrument or are made by
different observers sharing the same systematic
biases.
Indices of Reliability
One obvious index of reliability is agreement
among two or more raters. There are two standard
methods of assessing such agreement: (1) by deter¬
mining the proportion of judgments assigned to the
same categories by both members of a pair of
raters or (2) by computing the correlation between
their numerical ratings. These two indices of agree¬
ment have different properties and do not convey
the same information. Consider these extreme
examples of what might happen with 50 patients














Here the percentage of agreement is substantial
—80% (since 40 of the 50 patients were rated "2"
by both judges), but the correlation coefficient is
—1.00.
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Judge A
In this case the percentage of agreement is ex¬
actly zero, since no patient was assigned to the same
category by both judges. The correlation coefficient
however, is 1.00!
In the first example the two raters were obviously
in complete disagreement concerning the trait or
symptom they were observing. As "measuring
instruments" they were performing in precisely
opposite directions, and their 80% agreement con¬
sisted merely in recognizing the neutral or mid¬
point of the scale they were using.
In the second case, the two judges appear to be
in complete agreement on the meaning of the scale
and their observations seem to be equally sensitive
(within the limitations of the scale's format), but
they obviously have different frames of reference
or different "zero-points," since one judge's ratings
are consistently one point higher than the other's.
Both kinds of information are valuable. A high
inter-rater agreement would ideally mean that one
rater could be chosen at random and his ratings
could be used interchangeably with those of another.
For this to be the case, we would want both a high
correlation and a high degree of agreement on cate¬
gory placement.
If the ratings of two judges indicate significant
disagreement in either of these two senses, one may
conclude that (1) the trait or characteristic is
elusive, ill-defined, or not ratable, (2) the wording
of the item or the response alternatives is unclear or
misleading, or (3) the raters (or at least one of
them) are not sufficiently perceptive or not prop¬
erly trained for the task. It should be noted, how¬
ever, that two raters may be in perfect agreement
as a result of sharing the same biases or the same
distorted understanding of their task or of the
phenomena they are observing.
There are other methods of estimating reliability
widely used in psychometric work. One is the test-
retest (or rate-rerate) coefficient, the correlation
between sets of ratings made at different times (say,
with the lapse of a day or a month). It is thus a
measure of the stability of the trait or character¬
istic over a period of time. This index has certain
advantages when used with tests of cognitive abil¬
ities or of certain "basic" personality variables that
would not be expected to change significantly with
the passage of time. But with mental patients,
especially with an active treatment program, one
expects changes in behavior, and the longer the
time interval, the greater the likelihood of sig¬
nificant change. For this reason, the rate-rerate
correlation is likely to be a distorted index of re¬
liability. If the time interval is shortened in an
effort to overcome this difficulty, another problem
arises in that raters in a conscious or unconscious
effort to be "consistent" may be influenced on the
second occasion by memory of their first ratings.
Reliability may also be estimated by so-called
"internal consistency" indices. These are estimates
of how well items in a test or a scale "hang to¬
gether" with respect to the characteristic or trait
they presume to measure. Consistency, homogene¬
ity, equivalence, and "purity" are terms that have
been used to describe it. A "split-half" coefficient
may be computed by dividing the items within a
scale into two sets (randomly or by taking odd-
versus even--numbered items) to form the two halves
and adjusting the correlation obtained so that it is
appropriate to the entire set rather than to half.
This method, used with some rating scales, is not
suitable for many, because a given scale frequently
includes only a small number of items.
Other consistency measures are variations of the
"Kuder-Richardson" coefficient, often abbreviated
as K-R. These coefficients, like the standard or
"product-moment" coefficients, can range in value
up to +1.00, but are not exactly comparable
numerically. The most widely used of this class
were originally developed for ability tests scored
1-0; right-wrong, or yes-no. More recently, they
have been generalized for test items and scale items
having a numerical range extending beyond a
dichotomous or two-category scoring system. High
K-R coefficients result when items which are re¬





rater receive positive responses from most other
subjects or raters; and similarly for negative re¬
sponses.
Another reliability index sometimes used is the
intraclass coefficient. This measure is valuable in
situations where, for example, one may have two
or more ratings, for each patient but they are not
made by the same set of raters. The first patient
may have been rated by rater A and rater B, the
second by raters A and C; the third by raters D
and E, etc. It is clearly impossible to compute for
the entire sample of subjects a standard correlation
coefficient expressing agreement between any pair
of raters. The intraclass coefficient is a statistic
that in effect ignores rater identity and considers
all raters interchangeable. Since differences in rater
standards and rater skills are not taken account of,
the intraclass coefficient can be expected to be
numerically smaller than an ordinary correlation
computed from ratings made by the same team of
raters for all patients. Values as high as .80 have
been reported for some scales, indicating agreement
quite satisfactory for most research purposes.
One problem of evaluating reliability indices for
check lists and ratings is the fact that in many col¬
lections of items a considerable amount of agree¬
ment is "built into" such instruments as a conse¬
quence of the semantic structure of our language.
One can go to a thesaurus or a dictionary of syno¬
nyms and assemble lists of adjectives and be con¬
fident that judges would respond to the lists simi¬
larly. For example, a widely used scale includes in
one score the terms "tired" and "fatigued." A study
of depression used a symptom inventory containing
the items "decreased appetite" and "diminished
appetite." To the extent that such pairs (or larger
groups) of items evoke similar responses from
raters, consistency coefficients are thereby larger,
but with qp corresponding increase in the amount
of information contained in the scale scores.
The question of how large the reliability coeffi¬
cient for a given population should be to justify
the use of scale results has no precise answer, since
it depends upon how the ratings will be used, the
kind of coefficient, the number of cases, etc. For
clinical use, i.e., in making decisions concerning
diagnosis or treatment of individuals, many clini¬
cians would want reliabilities as high as .80 or .90.
For research purposes, to test hypotheses concerning
group differences, treatment comparisons, etc.,
lower reliabilities may be acceptable, particularly
where reasonably large numbers of cases are in¬
volved. If treatment differences are sufficiently
great, scales with reliabilities as low as .50 or even
.40 may differentiate the groups and enable the
investigator to reach a conclusion. On the other
hand, if the discrimination is not statistically sig¬
nificant, one is left uncertain as to whether more
reliable measures would have led to more confident
conclusions.
In addition to the standard techniques there may
be indirect evidence that may assure an investigator
that the instrument he is using may be sufficiently
reliable for his purpose without, however, providing
a numerical index. If it is found that a scale sig¬
nificantly differentiates two or more treatment
groups or predicts an outcome criterion (is "valid"
in one of the senses discussed below) then one may
assume that it is reliable. The reasoning here is that
if the ratings were reflecting merely "chance" or
"error," they could not possibly make such dis¬
criminations or predictions; and this is the basis for
one of the elementary principles of psychometric
theory: that a score cannot be valid for any pur¬
pose unless it has reliability.
Validity
Validity in psychometric theory has to do with
whether and to what degree a test or rating device
accomplishes the purpose its user intends. Depend¬
ing upon the purpose, several kinds of validity may
be distinguished:
Predictive validity.—This concept of validity is
of most concern to the typical user of rating scales
or to one who wishes to choose among the large
number available a scale suitable for his particular
study or experiment. Predictive validity is oriented
toward a criterion or outcome in which an investi¬
gator is interested. The purpose in one type of
study may be to compare the effectiveness of two
or more methods of treatment, and the question is
whether a scale can detect significant differences
among the treatments, hence among the groups of
patients, thereby leading the investigator to a deci¬
sion or recommendation.* Another form of predic¬
tive validity is concerned with the use of a score
(or some combination of scores) to "predict" a later
outcome variable for an individual. A familiar ex¬
ample is the use of intelligence test scores as an aid
in the selection of college students, or performance
* This has been called "discriminative validity" by some
writers.
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tests in the selection of industrial workers. In the
psychiatric setting such validity information would
be useful in deciding which patients should be ad¬
mitted to which type of treatment. Other things
being equal, a patient could be assigned to that
treatment for which his predicted outcome is most
favorable. The usual index of this second form of
predictive validity is the correlation coefficient as
described above.
Three additional kinds of validity are distin¬
guished, but they are ordinarily of less concern to
the user of psychometric instruments than is pre¬
dictive validity. They are, however, of considerable
importance in the construction, development, and
evaluation of certain types of scales, since they
deal largely with properties of the scales themselves.
Following are brief definitions of these:
Concurrent Validity.—This concept deals with
the comparability of two sets of measures (e.g.,
score and criterion) determined at essentially the
same time. (There is nothing to be predicted, since
the criterion data are already known.) The extent
to which scale scores can differentiate currently
diagnosed groups of psychiatric patients is an ex¬
ample of this type of validity.
Content Validity.—This refers to a test or scale
made up of items randomly drawn from a popu¬
lation or pool of items assembled because they rep¬
resent some area of interest to the investigator. The
term "content" derives from the fact that the con¬
tent of the random sample is an acceptable reflec¬
tion of the content of the parent pool and is hence
"by definition" valid.
Construct Validity.—If a score is intended to be
a measure of some hypothetical characteristic which
itself cannot be directly observed or measured, the
attempt to verify, at least provisionally, that the
test or scale yields results not inconsistent with the
investigator's hypothesis, involves the concept of
construct validity. "If my hypothesis concerning
the dynamics underlying such-and-such personality
dimension is tenable, then my rating scale should
have such-and-such characteristics (form of score
distribution, correlation with other measures, differ¬
ences in scores between Groups A and B, etc.)."
"If I am correct in my interpretation of a certain
Rorschach score, then this score from my rating
scales should correlate highly with it." These are
examples of construct validity.
Concluding Remarks on Reliability and
Validity
It is important to keep in mind that there is no
such thing as the reliability or the validity of a rat¬
ing scale. A reliability coefficient is not an intrinsic
property of the scale for which it may have been
reported. Factors affecting reliability and validity
include the skill and motivation of the rater, the
rater-scale combination or "team" (including the
rater's attitude toward or "rapport with" the scale
used), the range or variation in the trait or symp¬
tom under observation, and the conditions under
which the ratings were obtained—to name several
of the more important ones. In the scale summaries
that follow, the reader should not assume that he
will obtain results comparable to those reported
for a given scale even when the experimental or
treatment situation appears to he similar or identi¬
cal.
Norms
Early in the history of intelligence testing and
educational testing the producers of tests were
aware of the need for "yardsticks" for evaluating
an individual's standing with respect to other mem¬
bers of a group, to compare the achievement of a
school class with that of other classes, etc. Large
and well designed samples of the population or
populations with which the test is intended to be
used are needed for dependable "norms" (from the
Latin norma, a rule). Separate norms for such
characteristics as age, sex, school grade, or combi¬
nations of these, have been compiled for many tests.
It should be noted that, although published norms
for standard tests have been extremely useful, few
have escaped criticism on technical grounds, such
as size and appropriateness of samples, etc.
For several of the scales discussed in this report,
norms are reported by the authors. Most of these
are difficult to evaluate because of insufficient in¬
formation concerning the samples used or because
they are largely local, i.e., obtained from one or a
very few hospitals or other sources. With differ¬
ences in admission practices, diagnostic policies,
social and racial composition, etc., from hospital to
hospital, the investigator is advised not to take these
norms too seriously. Perhaps the most dependable
norms are those assembled by the Veterans Admin¬
istration for scales developed in their programs
(especially when used with patients comparable in
age, sex, etc.,;to the VA hospitalized populations).
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Data from the NIMH-PSC collaborative studies
will be valuable as normative information, since
the hospitals participating approach the goal of a
stratified sample of hospitals.
Research involving the use of rating scales can
be carried out successfully with no reference to
norms at all, provided the scales have acceptable
reliability and validity. Many investigators, how¬
ever, will wish to establish their own local norms,
as a matter of interest or as a "quality control"
device to help assure that rating standards are
reasonably stable over time.
The Inpatient Multidimensional Psychiatric
Scale
Lorr, M., McNair, D. M., Klett, C. J. and Lasky,
J. J. Evidence of ten psychotic syndromes.
J. consult. Psychol., 1962, 2, 26, 185-189.
Lorr, M., Klett, C. J., McNair, D. M. and Lasky,
J. J. Inpatient Multidimensional Psychiatric
Scale. Palo Alto: Consulting Psychologists
Press, 1963.
General description.—The Inpatient Multi¬
dimensional Psychiatric Scale consists of 75 brief
questions designed to measure 10 psychotic syn¬
dromes. The clinicians' ratings are based on obser¬
vations of patient behavior and verbal reports of
beliefs, attitudes and feelings as obtained in an
interview of 30 to 45 minutes. Completion of the
form should require 10 to 12 additional minutes.
Type of patient.—Functional psychotics or
severe psychoneurotics who can be interviewed.
Those inaccessible are better described with a ward
rating form.
Type of rater.—Trained interviewers and ob¬
servers experienced in interviewing psychiatric
patients and familiar with psychiatric symptomol-
ogy. It is suggested that the rater explain the pur¬
pose of the interview, be nondirective, and leave
direct questioning or probing to the end. It is
recommended that there be an interviewer and a
silent observer.
Basis for rating.—The focus of the interview
should be on discernible behavior and on patient
self-reports of current feelings, attitudes and be¬
liefs. The emphasis is on current behavior or ex¬
perience. Social history, previous interview notes
and reports of ward observations are to be dis¬
regarded. i .
Source of items.—The scale is a complete revi¬
sion of the MSRPP (Multidimensional Scale for
Rating Psychiatric Patients, Lorr, 1953), a rating
schedule designed to record descriptions of psy¬
chotic behavior and symptoms. Many of the items
were rewritten and certain other changes were
made. The "Unratable" category of the MSRPP
was eliminated,^ bipolar scales were converted to
unipolar form, and two sets of adverbs were used to
characterize the intensity and the frequency of be¬
haviors reported on the five- and nine-point scales.
The first experimental form consisted of 42 nine-
point scales and 48 dichotomous items. Ratings
were collected on four to ten patients in each of 47
hospitals by teams consisting of an interviewer and
a silent observer independently rating each patient.
Patients were selected as being representative of
one of the following patterns by a professional per¬
son other than the interviewer:
"Anxiously depressed, markedly delusional,
hostile-belligerent, well-integrated paranoid,
apathetic and unmotivated, markedly halluci¬
nated, disorganized in thought processes, retarded
and depressed, and manic excited."
The sample consisted of 296 patients. Correla¬
tions among the 77 variables selected for analysis
were computed and 10 syndromes or clusters were
found.
Revision of the experimental form was based on
the initial analysis, a study of inter-rater reliabil¬
ities, and other considerations. The final form was
then employed in obtaining a normative sample of
566 cases on which the score norms (centiles) are
based.
Application of a further analysis based on hy¬
pothesized groupings of variables yielded the same
10 syndromes as the first analysis. "Each syndrome
is regarded as a unitary pattern of response present
to a greater or lesser degree in all patients. Further,
it is assumed that the more severe the syndrome,
the more probable that deviant behaviors will be
manifested." They are each defined by a group of
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items measuring in common a "unitary reaction
tendency." The 10 scores are largely independent.
Intercorrelations range from —.37 to .56, with a
median of .16.
Type of items.—Statements in non-technical
language are arranged without regard for their
relationship to a particular scale. In this report
the syndromes are listed and described, with ex¬
amples of each.
A. EXCITEMENT (EXC). Characterized by
an excess and acceleration of the individual's speech
and motor activities and also by lack of restraint
in the expression of emotions and feelings. Mood
level and self-esteem are usually high.
COMPARED TO THE NORMAL PERSON
TO WHAT DEGREE DOES HE ... .
1. Express or exhibit feelings and emotions
openly, impulsively, or without apparent
restraint or control?
Cues: Shows temper outbursts; weeps or
wrings hands in loud complaint; jokes or
talks boisterously; gestures excitedly.
9. Manifest speech that is hurried, acceler¬
ated or pushed?
Cues: Pressure of speech.
B. HOSTILE BELLIGERENCE (HOS). A
complaining, griping, attitude, manifest hostility;
and an inclination to express resentment towards
and to feel suspicious of others' intentions are evi¬
dent in this syndrome.
5. Verbally express feelings of hostility, ill
will, or dislike of others?
Cues: Makes hostile comments regarding
others such as attendants, other patients,
his family, or persons in authority. Re¬
ports conflict on the ward.
11. Express a feeling or attitude of contempt,
disdain, or scorn towards other people as
Unworthy or beneath him?
Cues: Derogatory or snide comments
about others; sarcasm or ridicule of others;
condescending.
C. PARANOID PROJECTION (PAR). The
syndrome is defined by beliefs that attribute a
hostile and controlling intent to the world around
the patient.
TO WHAT EXTENT DOES HE APPEAR
PREOCCUPIED WITH OR DISTRESSED
BY ... .
44. Delusional beliefs or convictions?
i ' ■
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59. Does he believe that some people talk
about, refer to, or watch him?
D. GRANDIOSE EXPANSIVENESS (GRN).
The syndrome appears to represent a stage beyond
paranoid projections. The individual characterized
by this syndrome has found an explanation for his
persecution. He is really an important personage
with a divine mission and unusual powers.
COMPARED TO THE NORMAL PERSON
TO WHAT DEGREE DOES HE
15. Exhibit in demeanor and/or in verbaliza¬
tions an attitude of self-importance,
superiority, or conceit?
Cues: Speech is pompous or stilted; boasts
of his accomplishments; demands and ex¬
pects special privileges.
HOW OFTEN DID HE
54. Hear voices that praised, extolled, or
spoke to him about divine missions?
E. PERCEPTUAL DISTORTION (PCP). Hal¬
lucinations that threaten, accuse, and demand de¬
fine this syndrome. The underlying mechanism is
one of distortion of sensory and perceptual stimuli.
Voices say "bad" things about the patient.
TO WHAT EXTENT DOES HE APPEAR
PREOCCUPIED WITH OR DISTRESSED
BY ... .
45. Hallucinatory voices?
HOW OFTEN DID HE
53. Hear voices that accuse, blamed, or said
"bad" things about him, e.g., that he is a
spy, homosexual, murderer?
F. ANXIOUS INTROPUNITIVENESS (INP).
Three elements appear to characterize this syn¬
drome: anxiety, turning against the self, and
lowered mood level. The reaction is one in which
the individual experiences guilt and remorse and
holds himself to blame for real or imagined faults.
COMPARED TO THE NORMAL PERSON
TO WHAT DEGREE DOES IIE
14. Tend to blame, criticize, condemn, or
otherwise hold himself responsible for past
or present, real or fancied, thought or
actions?
Cues: Blames self for failure, difficulties,
and frustrations in family relations, work,
or finances.
21. Report or admit being uneasy or anxious
in anticipation of specific future difficulties
or problems?
A •' .
Cues: Worried about his symptoms, his
family, or his finances.
G. RETARDATION AND APATHY (RTD).
The syndrome is defined by a slowing down and re¬
duction of ideation, speech, and motor behavior.
At the extreme there is apathy and disinterest.
COMPARED TO THE NORMAL PERSON
TO WHAT DEGREE DOES HE. , . .
1. Manifest speech that is slowed, deliberate,
or labored?
8. Exhibit indifference or apathy towards
such matters as his treatment, his release
from the hospital, or plans for the future?
Cues: Content to stay. Willing to "leave
it to the doctor." Sees no need for treat¬
ment. Seems to have no goals and no ex¬
pectations.
H. DISORIENTATION (DIS). The syndrome
measures varying degrees of disorientation. As
represented here, it probably is not due to brain
injury but is indicative of autism or intense self-
directed attention.
DOES HE KNOW
70. That he is in a hospital?
71. In what state the hospital is located or the
nearest large city?
I. MOTOR DISTURBANCES (MTR). Rigid,
bizarre postures; grimacing, and repetitive move¬
ments are the principal behaviors defining this syn¬
drome.
COMPARED TO THE NORMAL PERSON
TO WHAT DEGREE DOES HE
6. Exhibit postures that are peculiar, un¬
natural, rigid, or bizarre?
Cues: Head twisted to one side, or arm and
hand feeld oddly. Judge the degree of
peculiarity of the posture.
10. Manifest overt signs of tension?
Cues: Moves or shifts restlessly; body
musculature appears taut, strained or
tense; fingers clothing, scratches, drums
or fiddles with objects, face or neck
muscles twitch; exhibits startle reactions,
palms sweaty.
J. CONCEPTUAL DISORGANIZATION
(CNP). Disturbances in the stream of thought
evidenced in irrelevant answers and incoherent or
rambling speech characterize this syndrome. These
suggest disorganization of thinking processes.
COMPARED TO THE NORMAL PERSON
TO WHAT DEGREE DOES HE
2. Give answers that are irrelevant or un¬
related in any immediately conceivable
way to the question asked or topic dis¬
cussed?
Cues: Do not rate here wandering or
rambling conversation which veers away
from the topic at issue. Also, do not rate
the coherence of the answer.
3. Give answers that are grammatically dis¬
connected, incoherent, or scattered, i.e.,
not sensible or not understandable? I
Cues: Judge the grammatical structure of
his speech, not the content, which may or
may not be bizarre.
Scoring.—The dichotomous items are given
values of 0 and 1; the five-point scales, values from
0 to 4; the nine-point scales values from 0 to 8.
Differences in scale range are adjusted when the
scales are combined into a syndrome score by as¬
signing weights of 8, 2 and 1 for the two-point, five-
point, and nine-point scales, respectively, to equal¬
ize approximately the contribution of each item to
the syndrome score. The syndrome scores for one
rater are obtained as follows:
A. For scores other than DIS and INP find the
sum of weighted ratings on the scales defining
the syndrome.
B. The score for DIS is the sum of the ratings
defining DIS multiplied by —1 plus a con¬
stant of 6.
| '
C. The INP score is the sum of the weighted
ratings defining INP plus a constant of 8
which is needed to avoid negative values
introduced by one scale with a negative weight.
The syndrome scores when ratings are available
from two raters are computed separately, then
added together. The materials used in scoring arc
the score sheet and the centile norms. The scale
value of each rating is recorded on the score sheet
and then the weighted ratings are added. For DIS
and INP the necessary constant is added. The
centile rank corresponding to the weighted score for
each syndrome is provided by tables that show how
a given patient stands with respect to the patients
in the norm, population. For example, the centile
rank of 70 on the Excited syndrome means that the
patient is as much or more excited than 70 per cent
of the norm population.
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The morbidity scores.—In addition to these
syndrome measures, three "morbidity scores" were
derived from an analysis of the correlations among
the 10 syndrome scores.
The first measure is bipolar and defines an
Excitement versus Retardation pattern. The
score is the sum of EXC and HOS minus RTD.
The second pattern is one of tendency toward
distortion of thinking and perception. To score,
add the syndrome scores of the patient on PAR,
PCP and GRN.
The third pattern is one of schizophrenic dis¬
organization. To obtain the raw score, add syn¬
drome scores on MTR, DIS, CNP and RTD.
Reliability.—Degree of inter-rater agreement
was determined by obtaining two independent rat¬
ings on 508 patients in the norm sample and com¬
puting the intraclass coefficients for each scale.
These reliabilities ranged from .82 for MTR to .91
for GRN. The authors point out that somewhat
lower reliabilities are to be expected when only one
rater is used.
Reliabilities of individual items were computed
and found to range between .61 and .92.
Validity.—In one study reported in the Manual
all scores except INP, RTD, and DIS were found
to discriminate significantly between open ward
patients and closed ward patients in the expected
directions, i.e., those on closed wards showing a
greater degree of disturbance as indicated by
higher scores for seven syndromes.
If the IMPS scores are to be useful in diagnosis,
one would expect them to have some relation with
the usual psychiatric classifications. For 190
patients assigned to six standard diagnostic cate¬
gories, those groups designated paranoid schizo¬
phrenia, depression, and manic-excitement are well
described by appropriate scores. The remaining
groups, schizophrenia (mixed), hebephrenia, and
catatonia are not clearly delineated.
In one of the projects of the VA Cooperative
Studies of Chemotherapy in Psychiatry (1960) the
IMPS, along with other measures, was used in an
attempt to identify differential changes in schizo¬
phrenic patients treated with several drugs. The
major findings have greater relevance to the ques¬
tion of the efficacy of the treatments than to that
of the validity of the IMPS. It is interesting to
note, however, that several scores, HOS, PAR,
PCP, and CNP, were significantly related to
patients' scores on a scale of attitudes toward medi¬
cation. The more paranoid patients have less faith
that medication will help them. Similar results
were obtained with the Psychotic Reaction Profile
(PRP) for these same patients.
The four variables that make up the Schizo¬
phrenic Disorganization morbidity score, RTD,
DIS, MTR, and CNP, were found to be significantly
related to duration of hospitalization, suggesting a
usefulness for this score in predicting hospital stay.
The Abbreviated IMPS.—The authors have
selected from the complete set a group of 20 items,
two for each syndrome, which can be used for a
rapid assessment if necessary. Although scores on
the brief form agree closely with those on the com¬
plete form (the median correlation is about .88),
the authors warn that they are necessarily less
reliable and contain less information. Norms for
the syndromes and the morbidity scores are pro¬
vided.
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General description.—A behavior rating scale
to measure ward behavior factors by means of 85
statements rated True or Not True by a nurse or
attendant on the basis of a few days observation
of ambulatory functional psychotic patients. The
scales are labeled Withdrawal, Thinking Disorgan¬
ization, Paranoid Belligerence and Agitated De¬
pression. Centile norms by sex and age are avail¬
able for each scale and also norms for 16 unique
patterns.
Type of patient.—Functional psychotics, hos¬
pitalized, ambulatory.
Type of rater.—Ward personnel: nurse, nursing
assistant or hospital aide. The rater should be
trained in the use of the scale.
Basis for rating.—The patient is to be rated
solely on observations of hospital behavior for the
three days preceding the rating.
Source of items.—Four hundred behavior state¬
ments were constructed by scrutinizing published
inventories, rating scales, reports of factor studies
and psychiatric texts. A group of clinical psychol¬
ogists familiar with psychotic behavior allocated
the statements to one of nine areas of behavior dis¬
turbance, all of which have been repeatedly iden¬
tified in multiple-factor studies of interview and
ward behavior. The hypothesized primary con¬
structs were Resistiveness and Motor Disturbances
(catatonic-like behavior), Withdrawal versus So¬
ciability, Perceptual Distortions, Conceptual Dis¬
organization, Melancholy Agitation, Paranoid Pro¬
jection, Hostile Belligerence and Lack of Interest
in Self or Others. In addition an interpersonal
parameter of Dominance versus Submissiveness was
postulated. A final list of 172 items distributed
among the nine subscales was retained.
Data for approximately 1000 functional psy¬
chotic cases in 47 hospitals were analyzed and four
essentially homogeneous and independent groups
of items were identified and labeled Withdrawal,
Thinking Disorganization, Paranoid Belligerence,
and Agitated Depression. Intercorrelations among
the four are low (ranging from .05 to .40), indicat¬
ing a satisfactory degree of independence.
Type of item.—The Withdrawal Scale consists
of 38 statements, appears to be bipolar and is de¬
fined by three discernible elements: activity level,
manifest interest in the environment, and interper¬
sonal responsiveness. One pole of the scale defines
a withdrawal reaction consisting of a lack of inter¬
est or apathy, a failure to respond to others and a
reduced activity level. The opposite pole describes
an excessive busyness, overactivity, and a high
level of interpersonal reactivity. Examples of items
are: 1. Usually stays by himself; 5. Ignores the
activities around him; 13. Seems concerned about
what others think of him; 24. Nearly always chat¬
ting with someone.
The Thinking Disorganization Scale of 18 items
defines a broad parameter, probably central to
schizophrenia. Disorientation, irrelevant and in¬
coherent speech, hallucinations and peculiar move¬
ments are characteristic of this pattern. Examples
of items are: 4. Occasionally talks to himself; 8.
Answers sensibly when talked to; 12. Sees and
hears things that are not there; 20. Spends a lot of
i time talking to himself.
■ The Paranoid Belligerence Scale of 24 items de¬
scribes patients who are hostile, irritable, resistive,
i bossy and paranoid. To some clinicians this pattern
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would represent a hostile acting out. Examples of
items are: 2. Tells the other patients what to do;
6. Sometimes does the opposite of what he is asked
to do; 10. Acts as though the ward attendants are
against him; 25. Is likely to hit someone for no
apparent reason.
The Agitated Depression Scale consists of five
items which appear to suggest anxiety and obvious
depressive elements. The items are: 3. Shows real
sadness; 7. Seems to be unhappy; 11. Usually looks
tired and all worn out; 15. Seems scared all the
time.
Scoring.—The rater is asked to mark statements
as True or Not True. Items are arranged in random
order so that scale groupings are not apparent.
Centile norms by sex and age are available for each
scale. Norms are also available for 16 unique pat¬
terns.
Reliability.—Internal consistency reliability esti¬
mates were computed. All coefficients except that
for Agitated Depression are at least .90. To ascer¬
tain inter-rater reliabilities, data were obtained
from a state hospital on a group of 54 male and 52
female psychotics, each rated by two attendants.
The correlations indicate that all scales except the
Agitated Depression scale have a satisfactory re¬
liability. The Withdrawal scale is the most reliable
of the scales developed. The authors consider that
the reliabilities compare favorably with those re¬
ported for typical achievement and aptitude tests.
Validity.—One aspect of validity was investi¬
gated by determining whether the scales could
differentiate between open and closed ward patients,
since the former are likely to be less severely ill.
Two independent samples of 55 male open and 110
male closed ward patients were compared on each
of the four subscales. Thinking Disorganization
scores were significantly higher for closed ward
patients in bo£h samples. Withdrawal scores were
significantly higher for the closed ward patients at
the .10 level in sample A and at the .025 level in
sample B. Agitated Depression separates the two
groups in expected directions at the .10 level in both
samples. Paranoid Belligerence fails to differentiate
the two groups in either sample. To test whether
unique patterns on the four scales could differentiate
open from closed ward patients, each scale was
dichotomized and sixteen unique patterns con¬
structed, with each patient allocated to one pattern.
The utility of the patterns was tested on a sample
of 110 open ward patients and 220 closed ward
patients. Correct identification was made of 80
per cent of the closed ward patients, but open ward
patients could not be identified on a better than
chance basis.
When the initial keying procedure was applied
separately to the data based on the descriptions of
male and female patients, they failed to reveal any
differentiating items. The order of inclusion of
items in a cluster was not always the same, but the
final keys were essentially identical for both sexes.
The norm data also tended to support the conclu¬
sion that the psychotic reaction patterns do not
differ greatly for men and women. When each of
the four scale score distributions was examined for
sex differences, only Paranoid Belligerence differed
significantly. It is possible that this type of be¬
havior is tolerated more by ward personnel in
women and is likely suppressed or penalized in men.
Factor analysis.—An attempt to confirm that
PRP measured certain ward behavior factors was
made by Lorr and O'Connor (1962), using 500 male
psychotic patients. The ten postulated dimensions
were Manic Excitement, Withdrawal with Psycho¬
motor Retardation, Paranoid Projection, Perceptual
Distortion (Hallucinations), Conceptual Disorgani¬
zation (Incoherent and Disordered Speech), Re-
sistiveness, Depressive Agitation, Motor Dis¬
turbances (Manneristic Postures), and Hostile
Belligerence. A personality variable of Dominance
versus Submission was also introduced as potentially
useful in discriminating between patients. Analysis
revealed the following factors:
Factor TP—Thinking Disorganization (Ward)
Spends a lot of time talking to himself .75
Talks to himself about imaginary or real faults .65
Sees and hears things that are not there .59
Occasionally talks to himself .58
Smiles a lot to himself without sensible reason .58
Repeats words and phrases in a meaningless way .56
This factor includes diverse elements previously
considered to be distinct, such as motor disturb¬
ances, hallucinations and thinking disturbances.
The underlying disorder seems to be broadly indi¬
cative of schizophrenic disorganization and disinte¬
gration as conceived by Kraepelin and Bleuler.
Factor PR—Paranoid Projection (Ward)
Blames hospital for lack of attention and care .65
Complains about the food and care he receives .61
Acts as though the ward attendants are
against him .59
Acts as though the hospital is persecuting him .52
Often irritable, grouchy or complaining .47
The Paranoid Projection (Ward) factor describes
a tendency in a patient to feel that people are
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against him, to attribute hostile motives to others,
and to grouse or complain in dissatisfaction.
Factor HB—Hostile Belligerence (Ward)
Often swears and uses obscene language .53
Sometimes threatens to assault others .50
Often shouts and yells .48
Loses temper when dealing with other patients .48
Becomes noisy and hilarious at times .41
The factor labeled Hostile Belligerence has been
identified a number of times in other studies and in
most cases this syndrome is positively associated
with morbid suspicion as exemplified by the Para¬
noid Projection factor.
Factor It—Resistiveness (Ward)
Resists suggestions and requests from aides .41
Sometimes does the opposite of what he is
asked to do .38
Has to be pushed to follow routine .38
Resistiveness represents a tendency, high in
catatonics and paranoid patients, to resist helping,
working or complying with instructions, as well as
a tendency to do the opposite of what is asked.
Factor D—Dominance (Ward)
Bosses the other patients .74
Tells the other patients what to do .65
Acts superior to other patients .47
Upsets other patients by the way he talks to
them .38
The factor of Dominance'has not been found in
ward or interview data previously. The authors
believe it is more likely a personality characteristic
than a psychotic reaction.
Factor 0—Overactivity (Ward)
Is always doing something .84
Seems always busy with plans and projects .66
Starts conversations with aides to become
better acquainted .38
Will do anything for recreation that comes up .37
The factor tentatively labeled Overactivity
(Ward) is characterized by overactivity and busy¬
ness.
Factor AD—Agitated Depression (Ward)
Shows real sadness .57
Usually worried and nervous .52
Seems to be unhappy .44
Seems scared all the time .43
Usually looks tired and all worn out .36
The Agitated Depression (Ward) factor implies a
reaction, of fear, anxiety and psychomotor retarda¬
tion. It is strongly suggestive of depression with
agitation.
Factor W—Withdrawal (Ward)
Never says more than three or four words at
a time .54
Laughs or smiles at funny comments or events —.48
Doesn't take part in back and forth
conversation .45
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Usually stays by himself t .45
Never volunteers information about himself .39
Shows occasional interest in news and current
events —.34
Never asks for anything; waits for things to
be given him .36
Likes to go for exercise —.33
Ignores the activities around him .32
Shows no response to entertainment .32
Shows real friendliness towards at least one
other patient —.31
Interested in nothing .31
The Withdrawal factor (Ward) is well repre¬
sented in the inventory. The parameter is defined
by statements indicative of taciturnity or failure
to respond in conversation, avoidance of interactions
with others, and lack of interest in the surround¬
ing environment.
At the present time the Psychotic Reaction Profile
is being used in a number of studies, notably those in
the "Veterans Administration cooperative series. An
example is a study of the relations of attitude to¬
ward medication to treatment outcomes in psy¬
chotherapy (Gorham and Sherman, 1961) by ad¬
ministering a short scale measuring attitude toward
medication before and after 20 weeks of treatment
of 369 chronic schizophrenic patients assigned to
five drug groups. Also used were the PRP and
IMPS (Inpatient Multidimensional Psychiatric
Scale), with the PRP keyed to yield seven measures,
and the IMPS, 10 measures. The PRP measures
were Thinking Disorganization, Withdrawal, Para¬
noid Belligerence, Agitated Depression, Resistive¬
ness, Dominance and Activity Level.
The hypothesis that the attitude of patients to¬
ward their treatment is related to treatment re¬
sponse as measured by the 17 criteria was tested
for 80 per cent of the patients studied. It was found
that changes in symptom areas were not related to
patient belief in the efficacy of medication. The
relationship between attitude toward medication
and pretreatment symptom measures were found to
be statistically significant for six of the criteria;
IMPS—Paranoid Projection, five drug groups were
analyzed separately, several relationships were
found, suggesting that symptom relief was related to
positive ;attitude toward medication.
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